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PROPOSITIONS ACCOMPANYING THE THESIS
Hypofractionated radiotherapy for prostate cancer: How far can we go?
1.	 Applying	 moderately	 hypofractionated	 radiotherapy	 for	 prostate	 cancer	 enhances	 the	
incidence	 of	 acute	 gastrointestinal	 toxicity,	 even	when	 only	 three	 fractions	 per	 week	 are	
delivered.	(Chapter	2)
2.	 Using	 only	 physician	 scoring	 toxicity	 reports	 after	 prostate	 cancer	 radiotherapy	 can	
substantially	underestimate	acute	and	late	toxicity.	(Chapters	2	and	3)
3.	 Inter-fraction	 correction	 of	 catheter	 displacements	 in	 HDR-BT	 monotherapy	 for	 prostate	
cancer	is	feasible	and	may	contribute	to	avoidance	of	excessive	toxicity.	(Chapters	5	and	6)
4.	 The	use	of	a	HDR-BT	boost	to	escalate	the	prostate	dose	without	increasing	rectum	toxicity	is	
desirable.	(Chapter	4)
5.	 Prostate	cancer	patients	treated	with	hypofractionated	radiotherapy	may	possibly	be	selected	
based	on	baseline	symptoms.	(Chapters	2,	3,	7	and	9)
6.	 Future	 radiotherapy	 trials	 on	 prostate	 cancer	 should	 pay	more	 attention	 to	 quality	 of	 life	
endpoints	as	these	are	more	important	than	local	control.
7.	 The	availability	of	proton	therapy	centers	will	increase	the	expense	of	our	health	care	system	
with	only	a	limited	benefit	for	a	limited	group	of	patients.
8.	 Androgen	deprivation	therapy	has	a	severe	impact	on	relatively	young	patients	and	needs	to	
be	better	investigated.	
9.	 Women	cannot	suffer	from	prostate	cancer	but	from	a	partner	with	prostate	cancer.
10.	 	Sex	performance	enhancers	can	only	increase	life	expectancy	in	men	and	therefore	create	
more	equality	in	the	life	expectations	of	men	and	women.
11.	 The	sound	of	your	own	Porsche	911	GT3	RS	is	more	beautiful	and	joyful	than	that	of	Adele	in	
her	best	performance.
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STELLINGEN BEHORENDE BIJ HET PROEFSCHRIFT 
Hypogefractioneerde radiotherapie voor prostaatkanker: Hoe ver kunnen we gaan?
1.	 Het	 toepassen	 van	 gematigd	 hypogefractioneerde	 radiotherapie	 voor	 prostaatkanker	
verhoogt	 de	 incidentie	 van	 acute	 gastro-intestinale	 toxiciteit,	 zelfs	 wanneer	 slechts	 drie	
fracties	per	week	worden	gegeven.	(Hoofdstuk	2)
2.	 Het	gebruik	van	alleen	de	scores	van	de	behandelende	artsen	voor	het	bepalen	van	de	toxiciteit	
na	radiotherapie	voor	prostaatkanker	kan	resulteren	in	aanzienlijke	onderschattingen	van	de	
incidenties	van	de	acute	en	late	schade.	(Hoofdstukken	2	en	3)
3.	 Correctie	van	katheterverschuivingen	tussen	opeenvolgende	fracties	bij	HDR	brachytherapie	
als	monotherapie	voor	prostaatkanker	is	haalbaar	en	draagt	mogelijk	bij	aan	het	vermijden	
van	overmatige	toxiciteit.	(Hoofdstukken	5	en	6)
4.	 Het	gebruik	van	een	HDR	brachytherapie	boost	voor	het	verhogen	van	de	totale	dosis	in	de	
prostaat	zonder	verhoging	van	rectum	toxiciteit	is	wenselijk.	(Hoofdstuk	4)
5.	 Prostaatkanker	 patiënten	 die	 worden	 behandeld	 met	 hypogefractioneerde	 radiotherapie	
kunnen	mogelijk	geselecteerd	worden	op	basis	van	baseline	symptomen.	(Hoofdstukken	2,	
3,	7	en	9)
6.	 Toekomstige	 radiotherapie	 studies	 over	 prostaatkanker	 zouden	 meer	 aandacht	 moeten	
besteden	aan	kwaliteit	van	leven	als	eindpunt,	aangezien	dit	belangrijker	is	dan	lokale	controle.
7.	 De beschikbaarheid van protonentherapiecentra zal de kosten in ons gezondheidszorgstelsel 
laten	toenemen	met	een	beperkt	voordeel	voor	slechts	een	beperkte	groep	patiënten.
8.	 Androgeen	deprivatie	therapie	heeft	een	ernstige	impact	op	de	kwaliteit	van	leven	van	relatief	
jonge	patiënten	en	moet	verder	worden	onderzocht.	
9.	 Vrouwen	 kunnen	 geen	 last	 hebben	 van	 prostaatkanker,	 maar	 wel	 van	 een	 partner	 met	
prostaatkanker.
10.	 De	lustpil	kan	de	levensverwachting	alleen	bij	mannen	vergroten	en	brengt	meer	gelijkheid	in	
de	levensverwachting	van	mannen	en	vrouwen.
11.	 Het	geluid	van	je	eigen	Porsche	911	GT3	RS	is	mooier	en	plezieriger	dan	dat	van	Adele	in	haar	
beste	optreden.
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Chapter 1: Introduction
GENERAL INTRODUCTION
Prostate	cancer	(PCa)	 is	the	second	most	common	cause	of	cancer	and	the	sixth	leading	cause	of	
cancer	death	among	men	worldwide	with	an	estimated	899.000	new	cases,	and	258.000	new	deaths	
in 20081.	According	to	the	Dutch	Cancer	registry,	PCa	is	the	first	most	diagnosed	cancer	in	men,	with	
around	11.000	new	cases,	and	2535	deaths	 in	20132,	which	 is	a	substantial	burden	for	the	Dutch	
healthcare	 system.	 The	 number	 of	 patients	with	 PCa	 is	 expected	 to	 increase	 due	 to	 the	 growth	
and	aging	of	the	global	population	and	screening.	Since	the	introduction	of	serum	prostate	specific	
antigen	(PSA)	based	screening,	the	majority	of	PCa	cases	is	diagnosed	with	organ-confined	disease,	
which	is	often	asymptomatic.	Almost	60%	of	new	PCa	cases	involves	men	over	the	age	of	70	years1-3.
There	 are	 several	 treatment	 options	 for	 organ-confined	 PCa.	 Next	 to	 surgery,	 external-beam	
radiotherapy	 (EBRT),	High-Dose-Rate	 (HDR)	 and	 Low-Dose-Rate	 (LDR)	 brachytherapy	 (BT),	 and	 for	
selected	 patients,	 active	 surveillance	 are	 all	 considered	 effective	 treatment	 methods.	 Choice	 of	
treatment	 is	mainly	 based	 on	 risk	 profile4,	 age,	 symptoms,	 co-morbidity	 and	 available	 treatment	
facilities.
Several	large	randomized	studies	have	shown	the	importance	of	EBRT	dose	escalation	to	improve	
relapse	free	survival	(RFS)5-7.	An	improvement	of	RFS	was	often	achieved	with	increased	toxicity.	In	
addition,	conventional,	high	dose,	fractionated	EBRT	treatments	are	protracted	over	7-9	weeks,	
which	impacts	the	patient’s	quality	of	life	and	utilization	of	hospital	resources.
According	 to	 the	 linear-quadratic	 model	 for	 cell-killing,	 the	 surviving	 fraction	 of	 cells	 has	 a	
component	linear	in	delivered	dose,	αD,	and	another	component	quadratic	with	delivered	dose,	
βD2.	 For	most	 cancers,	 the	 α/β	 ratio	 is	 high	 (~10	Gy),	 indicating	 that	 these	 tissues	 are	more	
sensitive	 to	 the	 total	 radiation	dose,	 rather	 than	 the	 dose	 per	 fraction.	 For	 the	 late-reacting	
normal	tissues	 surrounding	 the	prostate	 such	as	 rectum	and	bladder,	 the	α/β	 is	 low	 (around	
4-6	Gy)8,9,	indicating	a	higher	sensitivity	to	fraction	size.	There	is	now	growing	evidence	that	the	
α/β	for	PCa	cells8,10-16	may	be	lower	than	that	of	surrounding	normal	tissues,	perhaps	as	low	as	
1.5	Gy11,13,17-21.	This	means	that	increasing	fraction	dose	and	reducing	total	dose	could	enhance	
the	therapeutic	ratio,	as	demonstrated	in	modeling	studies19.	In	a	recent	systematic	analysis18, 
the	clinical	outcome	of	various	hypofractionated	schedules,	involving	over	2.800	patients,	was	
compared	to	conventional	fractionated	regimens,	delivered	to	11.000	patients.	This	study	(with	
other	smaller	studies)	confirmed	that	PCa	has	a	very	high	sensitivity	to	the	dose	per	fraction,	
with	an	α/β	of	1.0	to	1.7	Gy18,22,	 indicating	a	potential	clinical	advantage	of	hypofractionation	
for	the	treatment	of	PCa.	Apart	from	the	potential	therapeutic	gain,	hypofractionated	schedules	
also	have	economic	and	 logistic	advantages	due	to	the	reduction	in	the	number	of	treatment	
fractions	and	the	related	hospital	visits.
In	 the	 last	 decade,	 many	 efforts	 have	 been	 made	 to	 improve	 the	 dose	 delivery	 accuracy	 in	
EBRT,	such	as	 the	 introduction	of	 intensity-modulated	radiotherapy	 (IMRT)	and	 image-guided	
radiotherapy	 (IGRT),	 the	 use	 of	 implanted	 (gold)	 fiducials,	 and	 in-room	 imaging	 with	 Cone	
Beam	Computed	Tomography	(CBCT).	These	sophisticated	techniques	have	in	general	resulted	
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in	 decreased	 toxicity17,23-25.	 The	 availability	 of	 these	 techniques	 to	 prevent	 excessive	 toxicity	
favored	the	development	of	studies	on	hypofractionated	EBRT	regimens.
For	hypofractionation	in	PCa,	several	strategies	are	being	explored.	Moderate	hypofractionation,	
using	fraction	doses	<	4	Gy,	is	generally	delivered	with	EBRT	using	conventional	linear	accelerators.	
For	extreme	hypofractionation	(fraction	dose	≥	6	Gy),	both	HDR-BT	and	Stereotactic	Body	Radiation	
Therapy	(SBRT)	delivered	with	a	conventional	linear	accelerator	or	a	robotic	Cyberknife	are	applied.
SCOPE OF THE THESIS
The	 general	 purpose	 of	 this	 thesis	was	 to	 investigate	 the	 feasibility	 of	moderate	 and	 extreme	
hypofractionated	 radiotherapy	 for	 prostate	 cancer,	 with	 emphasis	 on	 treatment	 induced	 side	
effects.	In	this	context,	in	all	clinical	studies	toxicity	was	scored	by	both	physicians	and	patients,	
using	patient	self-assessment	questionnaires	(PSAQ).	
OUTLINE OF THIS THESIS
Part 1: Moderate hypofractionation with EBRT
In	2006	only	few,	small	randomized	trials	had	been	published	for	moderate	hypofractionation10-12, 
which	were	mostly	performed	with	low	treatment	doses	(66-72	Gy).	In	2007	we	started	with	the	
multicenter,	randomized	phase	III	HYPRO	trial,	comparing	a	conventional	schedule	of	39x2	Gy	with	
a	schedule	of	19x3.4	Gy,	with	410	patients	in	each	arm.	The	primary	aim	of	the	HYPRO	trial	was	to	
detect	an	absolute	10%	increase	in	the	5-year	RFS	with	hypofractionation,	with	non-inferiority	in	
cumulative	grade	≥	2	acute	and	late	genitourinary	(GU)	and	gastrointestinal	(GI)	toxicities26.	This	
thesis	contains	the	final	reports	on	acute	and	late	toxicity	(Chapters 2 and 3).	
Part 2: Extreme hypofractionation with HDR brachytherapy
The	use	of	HDR-BT	as	a	boost	combined	with	EBRT	has	been	advocated	for	organ-confined	PCa	in	
several	publications	27,28,29.	In	these	studies	toxicity	was	only	scored	by	treating	physicians.	In	Chapter 
4	we	report	on	our	long-term	outcome	and	toxicity	of	EBRT	(25	fractions	of	1.8	Gy)	with	an	HDR-BT	
boost	consisting	of	3	 fractions	of	6	Gy	for	hormone-naive	patients	with	 low-	or	 intermediate-risk	
PCa30.	Long	term	toxicity	results	were	derived	from	physicians’	reports	and	PSAQ.		
The	excellent	 results	of	 this	 combined	 regimen	gave	a	motivation	 to	 investigate	 the	 feasibility	 and	
effectiveness	of	HDR-BT	as	monotherapy	(4	fractions	of	9.5	Gy)	for	organ-confined	PCa.	The	aim	was	
a	treatment	time	reduction	from	6	weeks	to	2	days,	without	compromising	oncological	outcome	and	
keeping	toxicity	rates	acceptable.	As	HDR-BT	as	monotherapy	was	delivered	in	4	fractions	in	a	short	
period	of	time	 (36	hours)31,35,	 the	overall	 dosimetric	 accuracy	and	 reproducibility	depended	on	 the	
stability	 of	 catheter	 positions	 in	 the	 prostate.	 Displacement	 of	 catheters	 in	 between	 fractions	 can	
occur,	which,	if	not	corrected,	can	influence	the	dose	distribution	drastically39,40.	Only	few	papers	have	
addressed	catheter	displacement35,41.	In Chapter 5,	the	effect	of	catheter	displacement	is	analyzed	in	
a	systematic	simulation	study,	both	for	target	coverage	and	organs	at	risk	(OAR)	exposure.	In	Chapter 
6,	 the	clinical	 impact	of	catheter	displacements	and	corrections	of	displacements	on	acute	and	late	
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Chapter 1: Introduction
toxicity	in	HDR-BT	monotherapy	is	investigated.	Chapter 7	presents	oncological	outcome	in	terms	of	
biochemical	RFS,	disease	specific	survival	(DSS),	and	overall	survival	(OS),	and	acute	and	late	toxicity	for	
HDR-BT	as	monotherapy.	Furthermore	the	quality	of	life	using	the	PR-2542	questionnaires	was	evaluated.
Part 3: Extreme hypofractionation with SBRT using the Cyberknife
Although	HDR-BT	as	monotherapy	is	an	excellent	treatment	option	for	organ-confined	PCa,	the	
limited	 surgery	 capacity	 and	 the	 increased	 number	 of	 (older)	 patients	 with	 co-morbidities	 or	
contra-indications	 for	 anesthesia	 raise	 the	need	 to	 offer	 those	patients	 also	 a	 short	 treatment	
course	with	results	comparable	to	HDR-BT	monotherapy.	For	this	purpose,	a	treatment	protocol	
for	the	robotic	Cyberknife,	mimicking	HDR-BT,	was	developed	to	accurately	deliver	4	fractions	of	
9.5	Gy	in	a	single	week.	Chapter 8	reports	on	the	clinical	feasibility	for	low	and	intermediate-risk	
PCa	patients.	
Studies	on	patterns	of	failure	following	conventionally	fractionated	EBRT	show	that	the	dominant	
intra-prostatic	nodule	is	responsible	for	local	recurrence	in	89%	43	–	100%	44,45	of	cases.	Possibly,	
higher	doses	to	the	dominant	lesion	could	enhance	the	biochemical	control	rate	while	avoiding	the	
increase	in	side	effects	seen	with	whole	gland	dose	escalation46,47.	A	protocol	for	Cyberknife	SBRT	
was	developed	for	 low-	and	 intermediate-risk	PCa	to	deliver	4	 fractions	of	9.5	Gy	to	the	whole	
gland,	with	a	2.5-3	Gy	boost	to	the	MRI-visible	tumor.	In	Chapter 9,	toxicity,	biochemical	control	
rate,	and	quality	of	life	results	are	reported	for	the	first	50	patients	treated	with	this	protocol.	
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Chapter 2: Acute toxicity HYPRO trial
SUMMARY
Background   
In	2007,	we	began	the	randomised	phase	3	multicentre	HYPRO	trial	 to	 investigate	the	effect	of	
hypofractionated	 radiotherapy	 compared	 with	 conventionally	 fractionated	 radiotherapy	 on	
relapse-free	 survival	 in	 patients	 with	 prostate	 cancer.	 Here,	 we	 examine	 whether	 patients	
experience	differences	in	acute	gastrointestinal	and	genitourinary	adverse	effects.
Methods   
In	 this	 randomised	 non-inferiority	 phase	 3	 trial,	 done	 in	 seven	 radiotherapy	 centres	 in	 the	
Netherlands,	we	enrolled	intermediate-risk	or	high-risk	patients	aged	between	44	and	85	years	with	
histologically	confirmed	stage	T1b–T4	NX-0	MX-0	prostate	cancer,	a	PSA	concentration	of	60	ng/
mL	or	lower,	and	WHO	performance	status	of	0–2.	A	web-based	application	was	used	to	randomly	
assign	(1:1)	patients	to	receive	either	standard	fractionation	with	39	fractions	of	2	Gy	in	8	weeks	(five	
fractions	per	week)	or	hypofractionation	with	19	fractions	of	3·4	Gy	in	6·5	weeks	(three	fractions	per	
week).	Randomisation	was	done	with	minimisation	procedure,	stratified	by	treatment	centre	and	
risk	group.	The	primary	endpoint	is	5-year	relapse-free	survival.	Here	we	report	data	for	the	acute	
toxicity	outcomes:	the	cumulative	incidence	of	grade	2	or	worse	acute	and	late	genitourinary	and	
gastrointestinal	toxicity.	Non-inferiority	of	hypofractionation	was	tested	separately	for	genitourinary	
and	gastrointestinal	acute	toxic	effects,	with	a	null	hypothesis	that	cumulative	incidences	of	each	type	
of	adverse	event	were	not	more	than	8%	higher	in	the	hypofractionation	group	than	in	the	standard	
fractionation	group.	We	scored	acute	genitourinary	and	gastrointestinal	toxic	effects	according	to	
RTOG-EORTC	criteria	from	both	case	report	forms	and	patients’	self-assessment	questionnaires,	at	
baseline,	twice	during	radiotherapy,	and	3	months	after	completion	of	radiotherapy.	Analyses	were	
done	 in	 the	 intention-to-treat	population.	Patient	 recruitment	has	been	completed.	This	 study	 is	
registered	with	www.controlled-trials.com,	number	ISRCTN85138529.
Findings   
Between	March	19,	2007,	and	Dec	3,	2010,	820	patients	were	 randomly	assigned	 to	 treatment	
with	standard	fractionation	(n=410)	or	hypofractionation	(n=410).	3	months	after	radiotherapy,	73	
(22%)	patients	in	the	standard	fractionation	group	and	75	(23%)	patients	in	the	hypofractionation	
group	 reported	 grade	 2	 or	 worse	 genitourinary	 toxicity;	 grade	 2	 or	 worse	 gastrointestinal	
toxicity	was	noted	in	43	(13%)	patients	in	the	standard	fractionation	group	and	in	42	(13%)	in	the	
hypofractionation	group.	Grade	4	acute	genitourinary	toxicity	was	reported	for	two	patients,	one	
(<1%)	in	each	group.	No	grade	4	acute	gastrointestinal	toxicities	were	observed.	
We	noted	no	significant	difference	in	cumulative	incidence	by	120	days	after	radiotherapy	of	grade	
2	or	worse	acute	genitourinary	 toxicity	 (57·8%	 [95%	CI	52·9–62·7]	 in	 the	standard	 fractionation	
group	 vs	 60·5%	 (55·8–65·3)	 in	 the	 hypofractionation	 group;	 difference	 2·7%,	 90%	 CI	 –2·99	 to	
8·48;	 odds	 ratio	 [OR]	 1·12,	 95%	 CI	 0·84–1·49;	 p=0·43).	 The	 cumulative	 incidence	 of	 grade	 2	 or	
worse	 acute	 gastrointestinal	 toxicity	 by	 120	 days	 after	 radiotherapy	 was	 higher	 in	 patients	
given	hypofractionation	(31·2%	[95%	CI	26·6–35·8]	 in	the	standard	fractionation	group	vs	42·0%	
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[37·2–46·9]	in	the	hypofractionation	group;	difference	10·8%,	90%	CI	5·25–16·43;	OR	1·6;	p=0·0015;	
non-inferiority	not	confirmed).
Interpretation   
Hypofractionated	 radiotherapy	 was	 not	 non-inferior	 to	 standard	 fractionated	 radiotherapy	 in	
terms	of	acute	genitourinary	and	gastrointestinal	toxicity	for	men	with	intermediate-risk	and	high-
risk	prostate	cancer.	In	fact,	the	cumulative	incidence	of	grade	2	or	worse	acute	gastrointestinal	
toxicity	was	significantly	higher	in	patients	given	hypofractionation	than	in	those	given	standard	
fractionated	radiotherapy.	Patients	remain	in	follow-up	for	efficacy	endpoints.
Funding   
The	Dutch	Cancer	Society.
INTRODUCTION
Prostate	cancer	is	the	second	most	common	cancer	and	the	sixth	leading	cause	of	cancer	death	
in	men	worldwide.1	External	beam	radiotherapy	is	the	treatment	of	choice	for	a	large	proportion	
of	patients.	Findings	of	several	trials	have	shown	significant	improvements	in	relapse-free	survival	
after	external	beam	radiotherapy	for	patients	with	prostate	cancer	because	of	dose	escalation.2–4 
However,	this	improvement	in	relapse-free	survival	was	associated	with	a	significant	increase	in	toxic	
effects,2,4,5	which	makes	further	dose	escalation	not	preferable.	Several	investigators	have	reported	a	
low	α/β	ratio	for	prostate	cancer,6–8 suggesting	that	hypofractionation	could	be	used	to	enhance	the	
biological	tumour	dose	without	increasing	toxic	effects.8	Additionally,	the	reduction	in	the	number	
of	treatment	fractions	has	economic	and	logistical	advantages.	Small	studies	reported	encouraging	
results	 for	 hypofractionation.8–12 In	 2007,	 the	 randomized	 phase	 3	multi	 centre	 HYPRO	 trial	 was	
initiated	in	the	Netherlands	to	investigate	the	effect	of	hypofractionation	on	relapse-free	survival	in	
patients	with	prostate	cancer.	Here	we	report	data	for	acute	toxic	effects.
METHODS
Study design and participants
In	this	open-label,	randomised,	phase	3	study,	we	recruited	intermediate-risk	and	high-risk	patients13 
aged	 between	 44	 and	 85	 years	 with	 histologically	 confirmed	 stage	 T1b–T4	 NX-0	MX-0	 prostate	
cancer,	a	prostate-specific	antigen	concentration	of	60	ng/mL	or	 lower,	and	a	WHO	performance	
status	of	0–2.	We	excluded	patients	with	previous	pelvis	irradiation,	radical	prostatectomy,	evidence	
of	pelvic	nodal	disease	(by	CT	of	the	pelvis),	presence	of	distant	metastases	(by	bone	scintigraphy),	
and	low-risk	patients	(stage	T1b–T2a,	Gleason	score	of	≤6,	PSA	concentration	of	10	ng/mL).3 This trial 
was	approved	by	the	medical	ethics	committee	of	the	Erasmus	MC	Cancer	Institute,	Rotterdam,	the	
Netherlands	(06-045).	All	patients	provided	written	informed	consent.	The	trial	was	coordinated	and	
managed	by	the	departments	of	Radiation	Oncology	and	the	Clinical	Trials	Center	of	the	Erasmus	MC	
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Cancer	Institute.	Each	participating	centre	used	its	own	protocol	for	adjuvant	hormonal	therapy	in	
both	groups.	The	rate	of	use	of	adjuvant	hormonal	therapy	in	the	seven	institutions	ranged	between	
51%	and	87%	and	the	duration	of	hormonal	therapy	varied	from	6	months	to	3	years.
Randomisation and masking
We	 randomly	 assigned	 (1:1)	 patients	 to	 receive	 standard	 fractionation	 or	 hypofractionation,	
applying	 a	 minimization	 procedure,	 ensuring	 balance	 overall	 and	 within	 each	 stratum	 of	 the	
stratification	factors	(treatment	centre	and	risk	group).	Patients	were	assigned	via	a	web-based	
application	(done	by	the	Clinical	Trials	Center,	Erasmus	MC	Cancer	Institute,	Rotterdam)	and	the	
assigned	treatment	group	was	sent	immediately	via	fax	or	email	to	local	investigators.	The	local	
investigators	were	treating	physicians,	so	they	were	not	masked	to	treatment.	Randomization	took	
place	at	least	4	weeks	before	the	start	of	treatment.
Procedures
Patients	randomly	assigned	to	receive	standard	fractionation	were	treated	with	39	fractions	of	2	Gy,	
while	those	randomly	assigned	to	receive	hypofractionation	were	treated	with	19	fractions	of	3·4	Gy.	
Assuming	the	α/β	ratio	was	1·5 Gy for prostate cancer,8	the	tumour	equivalent	dose	in	2	Gy	fractions	
(EQD2Gy)	 for	 hypofractionation	 was	 90·4	 Gy	 compared	 with	 78	 Gy	 with	 standard	 fractionation.	
Considering	an	α/β	ratio	in	the	range	of	4–6	Gy	for	late	toxic	effects,7	the	rectum	and	bladder	EQD2Gy 
for	the	prescribed	hypofractionation	dose	would	be	77·5–79·7	Gy	(ie,	close	to	standard	fractionation	
of	78	Gy).	To	avoid	potential	excessive	acute	toxic	effects	in	the	hypofractionation	group,	only	three	
fractions	per	week	were	given	to	this	group,	resulting	in	an	overall	treatment	time	of	about	6·5	weeks.	
In	 the	standard	 fractionation	group,	patients	 received	five	daily	 fractions	of	2	Gy	a	week	 (overall	
treatment	time	about	8	weeks).	Assuming	an	α/β	ratio	of	10	Gy	for	acute	toxicity,	this	would	result	in	
weekly	and	total	acute	toxicity	EQD2Gy values of 11·4	Gy	for	the	hypofractionation	regimen	and	72·1 
Gy	for	standard	fractionation	compared	with	10	Gy	for	the	hypofractionation	regimen	and	78	Gy	for	
standard	fractionation.	
Three	treatment	groups	were	defined	on	the	basis	of	the	risk	of	seminal	vesicle	involvement:	14 group 
1	had	a	risk	of	10%	or	less;	group	2	had	a	risk	of	10–25%;	group	3	had	a	risk	of	higher	than	25%.	For	
group	1,	the	clinical	target	volume	consisted	of	the	prostate	only,	to	be	treated	to	the	prescribed	
dose.	For	group	2,	the	prostate	was	treated	to	the	prescribed	dose,	whereas	the	seminal	vesicle	was	
treated	to	a	dose	of	35	 fractions	of	2	Gy	or	39	 fractions	of	1·85	Gy	 (standard	 fractionation),	or	a	
dose	of	16	fractions	of	3·4	or	19	fractions	of	3·04	Gy	(hypofractionation	group).	For	group	3,	both	
the	prostate	and	the	seminal	vesicle	were	treated	up	to	the	prescribed	dose.	 In	the	Netherlands,	
elective	lymph	node	irradiation	is	not	applied	because	of	inconclusive	evidence.15 Depending on the 
set-up	verification	and	correction	strategy	used	in	each	participating	institute,	margins	of	3–10	mm	
were	added	to	the	clinical	target	volume	equal	in	both	groups,	yielding	the	planning	target	volume.	
For	the	boost,	these	margins	could	be	reduced	to	0	mm	towards	the	rectum,	and	3–5	mm	in	other	
directions.	This	boost	could	either	be	delivered	sequentially	or	simultaneously	integrated	depending	
on	the	institute’s	preference.	The	planning	CT	or	MRI	was	done	2	weeks	before	start	of	radiotherapy.	
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After	the	end	of	the	radiation	treatment,	patients	were	seen	every	3	months	for	the	first	2	years,	
every	6	months	 in	years	2–5,	and	once	a	year	up	to	10	years.	Acute	toxicity	was	scored	before	
treatment	 to	give	baseline	values,	 twice	during	 the	 radiotherapy	 course	and	at	3	months	after	
the	radiation	therapy.	Late	toxicity	was	scored	at	6	months,	and	at	1,	2,	3,	4,	and	5	years	after	
completion	of	radiation	therapy.	Quality	of	life	was	assessed	at	6	months,	and	1,2,	3,	4,	and	5	years	
after	treatment.16,17	Assessment	of	tumour	response	was	done	by	PSA	testing	every	3	months	the	
first	2	years	after	treatment,	every	6	months	the	third,	fourth,	and	fifth	year,	and	from	then	once	
a	year	till	5–10	years.	Transrectal	ultrasound	of	the	prostate,	a	CT	scan	of	the	pelvis,	and	a	bone	
scintigraphy	were	done	in	case	of	suspicion	of	tumour	recurrence	or	metastases.	
We	scored	acute	genitourinary	and	gastrointestinal	toxicities	by	case	report	form	with	the	Radiation	
Therapy	Oncology	Group	and	European	Organisation	for	Research	and	Treatment	of	Cancer	(RTOG-
EORTC)	scoring	criteria,18	and	patients’	self-assessment	questionnaires	at	baseline,	as	previously	
used	in	the	CKVO	96-10	trial.5	Acute	toxicity	scores	from	both	sources	were	determined	at	four	
points—ie,	pre	radiotherapy	(before	start	of	radiotherapy	until	6	days	after	start	of	radiotherapy);	
4	weeks	(between	7	and	34	days	after	start	of	radiotherapy);	6	weeks	(between	35	days	after	start	
of	 radiotherapy	 to	59	days	after	completion	of	 radiotherapy);	and	3	months	after	 radiotherapy	
(between	60	days	till	120	days	after	completion	of	 radiotherapy).	We	also	 recorded	 incidences	
Figure 2.1 | Trial	profile 
ITT=intention-to-treat
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standard fractionation group (n=391) hypofractionation group (n=403)
Age	(years) 	71	(67-75) 70	(66-74)
Transurethral	prostate	resection 	42	(11%) 35	(9%)
Abdominal	surgery 106	(27%) 	93	(23%)
Gastrointestinal	comorbidity 	41	(10%) 36	(9%)
Adjuvant	hormonal	therapy	 261	(67%) 265	(66%)
T-stage
 T1a
 T1b
 T1c
 T2a
 T2b
 T2c
 T3a
 T3b
 T4
	1	(0%)	
	3	(1%)
	55	(14%)
	45	(12%)
	38	(10%)
	48	(12%)
	160	(41%)	
	38	(10%)
	3	(1%)
 0 
	3	(1%)
	55	(14%)
	50	(12%)
	35	(9%)
	49	(12%)
	157	(39%)
	47	(12%)
	7	(2%)
PSA	concentration	(ng/ml)*
	<	10
 10 – 20
 >20
	103	(26%)
	157	(40%)
	131	(34%)
	124	(31%)
	159	(39%)
	120	(30%)
Gleason score
	≤6
 7
 8
 9
 10
	119	(31%)
	178	(46%)
	57	(15%)
	33	(8%)
	4	(1%)
	122	(30%)
	181	(45%)
	60	(15%)
	37	(9%)
	3	(1%)
Treatment	group
 1
 2
 3 
	78	(20%)
190	(49%)
123	(31%)
	79	(20%)
198	(49%)
126	(31%)
Risk	group	
	Intermediate
 High
	106	(27%)
285	(73%)
	104	(26%)
299	(74%)
Prostate	volume	(cm3)
	≤50
>50
Unknown
186	(48%)
196	(50%)
	9	(2%)
	182	(45%)
	207	(51%)
	14	(3%)
Duration	of	HT	use	before	RT
	≤2	months
	>2	months
	Unknown
120	(31%)
136	(35%)
	6	(2%)
	117	(29%)
	145	(36%)
	4	(1%)
Data	are	n	 (%)	or	median	 (IQR).	*PSA	concentration	median	 in	 the	standard	Fractionation	group	14.8	  
(IQR	9.8–24.0)	and	13.9	(9.2–21.3)	in	the	hypofractionation	group.
Table 2.1 | Patient	characteristics	at	baseline
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of	a	number	of	symptoms,	including	nocturia,	frequency,	pain,	haematuria	and	incontinence	for	
genitourinary	effects,	and	pain	with	urge	and	discomfort,	frequencies,	use	of	pads,	bleeding,	and	
diarrhoea	 for	gastrointestinal	effects	 (part	of	 toxicity	 scores	derived	 from	both	 the	case	 report	
form	and	the	RTOG	questionnaires).19
Outcomes
The	primary	endpoint	 is	5-year	relapse-free	survival.	Relapse	was	defined	as	biochemical	relapse,	
clinical	relapse,	locoregional	or	distant	relapse,	or	start	with	hormonal	therapy,	whichever	happened	
first.	Biochemical	relapse	was	defined	as	PSA	concentration	greater	than	the	present	nadir	plus	2	ng/
ml,	without	backdating.	Patients	who	died	without	evidence	of	previous	relapse	and	not	because	of	
toxic	effects	of	treatment	were	censored	at	date	of	death.	Additional	key	endpoints	were	acute	and	
late	gastrointestinal	and	genitourinary	toxicity,	defined	as	 the	cumulative	 incidence	of	grade	2	or	
worse	acute	and	late	genitourinary	toxic	effects.	Secondary	endpoints	were	quality	of	life	and	erectile	
functioning.
Statistical analysis
The	 primary	 hypothesis	 of	 the	 HYPRO	 trial	 was	 to	 detect	 a	 10%	 improvement	 in	 relapse-free	
survival	improvement	with	the	hypofractionation	regimen	compared	with	standard	fractionation,	
with	non-inferiority	of	hypofractionation	with	respect	to	the	cumulative	incidence	of	grade	2	or	
worse	acute	and	late	genitourinary	and	gastrointestinal	toxic	effects.	The	power	for	the	relapse-
free	survival	endpoint	was	92%,	for	late	genitourinary	effects	84%,	for	late	gastrointestinal	effects	
86%,	 and	 for	 acute	 toxic	 effects	 71%,	 and	 so	we	 calculated	 that	we	would	 need	 to	 enroll	 820	
patients,	including	allowance	for	a	dropout	of	20	patients.	Analyses	were	intention-to-treat.	
The	 analyses	 presented	here	 are	 for	 the	 comparison	 of	 the	 cumulative	 incidences	 of	 grade	 2	 or	
worse	acute	toxic	effects;	for	each	patient,	we	included	the	highest	grade	recorded	until	120	days	
after	 completion	 of	 radiotherapy.	 Non-inferiority	 of	 hypofractionation	 was	 tested	 separately	
for	 genitourinary	 and	 gastrointestinal	 acute	 toxic	 effects,	with	 a	 null	 hypothesis	 that	 cumulative	
incidences	 in	 the	 hypofractionation	 group	 were	 not	more	 than	 8%	 higher	 than	 in	 the	 standard	
fractionation	group.	Non-inferiority	of	the	hypofractionation	group	was	tested	at	a	significance	level	
of	5%	with	a	two-sided	90%	CI	that	correspondingly	gives	the	upper	limit	of	the	one-sided	95%	CI.	
An	upper	limit	of	the	CI	for	the	recorded	difference	in	cumulative	incidence	less	than	8%	suggested	
non-inferiority	of	the	hypofractionation	group.	The	sample	size	of	the	HYPRO	trial	was	based	mainly	
on	power	considerations	for	the	relapse-free	survival	endpoint.	With	400	patients	per	group	and	
proportions	of	grade	2	or	worse	acute	toxicity	of	about	50%	in	both	groups,5 the standard error of the 
difference	between	the	two	proportions	would	be	3·5%	and	the	90%	two-sided	CI	would	be	between	
–5·8 and 5·8	from	the	recorded	difference	between	the	proportions.	Thus,	an	upper	limit	of	8%	as	pre	
specified	in	the	study	protocol	would	imply	a	difference	between	the	two	proportions	of	2·2%,	which	
was	deemed	small	and	not	suggestive	of	a	clear	increase	in	acute	toxicity.	
We	applied	logistic	regression	analysis	to	compare	the	incidences	of	acute	toxicity	in	the	two	groups	
with	calculation	of	odds	ratios	and	95%	CI.	We	did	univariate	and	multivariate	logistic	regression	
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Table 2.2 | Cumulative	incidences	of	acute	genitourinary	and	gastrointestinal	toxicity	by	grade
Genitourinary Gastrointestinal
standard  
fractionation  
group
hypo- 
fractionation 
group
P value* standard  
fractionation  
group
Hypo- 
fractionation 
group
P value*
Before radiotherapy
n 391 403 391 402
1 115	(29%) 124	(31%) 0·45 30	(8%) 43	(11%) 0·044
≥2 85	(22%) 93	(23%) 0·65 9	(2%) 16	(4%) 0·18
2 73	(19%) 70	(17%)  - 7	(2%) 14	(3%)  -
3 12	(3%) 23	(6%) 0·068 2	(1%) 2	(<1%) 0·98 
4 - - - - - -
4 weeks
n 385 401 385 400
1 118	(31%) 120	(30%) 0·41 117	(30%) 104	(26%) 0·22
≥2 171	(44%) 191	(48%) 0·37 70	(18%) 108	(27%) 0·0031
2 131	(34%) 144	(36%) - 62	(16%) 97	(24%)  -
3 40	(10%) 45	(11%) 0·55 8	(2%) 11	(3%)  0·54
4 - 2	(<1%) - - - -
6 weeks
n 376 376 378 376
1 100	(27%) 98	(26%) 0·46 98	(26%) 81	(22%) 0·27
≥2 178	(47%) 171	(45%) 0·61 86	(23%) 117	(31%) 0·01
2 144	(38%) 125	(33%) - 72	(19%) 104	(28%)  -
3 33	(9%) 45	(12%) 0·16 14	(4%) 13	(3%) 0·86
4 1	(<1%) 1	(<1%) - - - -
3	month	after	radiotherapy
n 325 327 326 327
1 56	(17%) 91	(28%) 0·0045 47	(14%) 56	(17%) 0·51
≥2 73	(22%) 75	(23%) 0·89 43	(13%) 42	(13%) 0·90
2 47	(14%) 51	(16%) - 39	(12%) 32	(10%)  -
3 25	(8%) 23	(7) 0·75 4	(1%) 10	(3%) 0·11 
4 1	(<1%) 1	(<1%) - - - -
Maximum	toxicity	score	after	radiotherapy
n 391 403 391 402
1 114	(29%) 120	(30%) 0·14 140	(36%) 129	(32%) 0·028
≥2 226	(58%) 244	(61%) 0·43 122	(31%) 169	(42%) 0·0015
2 155	(40%) 160	(40%)  104	(27%) 146	(36%)  
3 69	(18%) 82	(20%) 0·34 18	(5%) 23	(6%) 0·48 
4 2	(1%) 2	(<1%) - - - -
					*Reported	p	values	are	for	significance	test	of	the	difference	in	toxicity	of	the	respective	grade	or	higher.
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analyses	to	assess	the	effect	of	symptoms	of	baseline	grade	2	or	worse,	age,	PSA	concentration,	
Gleason	 score,	 T	 stage,	 previous	 transurethral	 prostate	 resection,	 use	 of	 hormonal	 therapy,	
previous	 abdominal	 morbidity	 and	 surgery,	 prostate	 volume,	 treatment	 group	 according	 to	
risk	of	seminal	vesicle	involvement,	and	treatment	group5,17	on	incidence	of	acute	toxic	effects.	
Differences	in	percentages	were	tested	applying	Pearson’s	χ2	or	Fisher’s	exact	tests.	Comparison	
of	the	correlated	proportions	of	patients	with	toxicities	according	to	the	case	report	form	and	
patients’	self-assessment	questionnaires	was	done	with	McNemar’s	test.	
According	 to	 the	 protocol,	 Cox	 regression	 modelling	 was	 used	 for	 late	 toxic	 effects	
but	 not	 for	 acute	 toxic	 effects.	 No	 corrections	 for	 multiple	 testing	 were	 applied	 and	 all	
reported	 p	 values	 were	 based	 on	 two-sided	 tests.	 We	 deemed	 a	 p	 value	 of	 less	 than	 0·05 
as	 significant.	 Analyses	 were	 done	 with	 STATA	 (version	 13.1).	 This	 study	 is	 registered	 with	 
www.controlled-trials.com,	number	ISRCTN85138529.
Figure 2.2 | Acute	toxicity	as	a	function	of	time
Cumulative	 incidence	 of	 grade	 2	 or	worse	 genitourinary	 toxic	 events	 (A),	 prevalence	 of	 grade	 2	 or	worse	
genitourinary	toxic	events	(B),	and	distribution	of	genitourinary	toxicity	scores	(C).	Cumulative	incidence	of	
grade	2	or	worse	 gastrointestinal	 toxic	 events	 (D),	 prevalence	of	 grade	2	or	worse	 gastrointestinal	 events	
(E),	and	distribution	of	gastrointestinal	toxicity	scores	(F).	HF=hypofractionation.	SF=standard	fractionation.	
RT=radiotherapy.	GU=genitourinary.	GI=gastrointestinal.
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Role of the funding source
The funder provided peer-reviewed approval for the trial, but had no other role in study design, 
collection,	 analysis	 or	 interpretation	 of	 data.	 The	 corresponding	 author	 and	 the	 principal	
investigators	of	the	study	(LI	and	FP)	had	full	access	to	all	data	and	had	final	responsibility	for	the	
decision	to	submit	for	publication.
RESULTS
Between	March	19,	 2007,	 and	Dec	3,	 2010,	 820	patients	 from	seven	Dutch	 radiotherapy	 centres	
(appendix)	were	randomly	assigned	to	treatment	with	standard	fractionation	or	hypofractionation	
(410	patients	in	each	group).	25	patients	(18	in	the	standard	fractionation	group	and	seven	in	the	
hypofractionation	group)	were	excluded	because	of	non-eligibility	 (n=14),	double	entry	 (n=1),	not	
being	treated	or	they	died	before	start	of	 treatment	 (n=10),	or	non-evaluability	 for	acute	toxicity	
(n=1),	resulting	in	794	assessable	patients	(391	in	the	standard	fractionation	group	and	403	in	the	
hypofractionation	group;	figure	1).	 Table	1	 shows	baseline	 characteristics.	 There	were	 treatment	 
delivery	 deviations	 in	 14	 patients	 (six	 in	 the	 standard	 fractionation	 group,	 eight	 in	 the	 
Table 2.3 | Specific	symptoms	according	to	treatment	group
Standard fractionation  
group (n=390)
Hypofractionation  
group (n=402)
p value
Genitourinary
Pain	needing	drugs	(grade	2) 14	(4%) 21	(5%) 0·26
Macroscopic	haematuria	(grade	3) 9	(2%) 15	(4%) 0·24
Increased	frequency	at	day	(grade	2) 96	(25%) 100/401	(25%)* 0·92
Increased	frequency	at	night	five	
to	seven	times	(grade	2)
107	(27%) 125/401	(31%)* 0·25
Increased frequency at night 
>seven	times	(grade	3)
26	(7%) 46/401	(12%)* 0·019
Incontinence	(grade	3) 39/364	(11%)* 49/372	(13%)* 0·30
Gastrointestinal
Pain	needing	drugs	(grade	2) 18	(5%) 35	(9%) 0·021
Diarrhoea	with	drugs	(grade	2) 19	(5%) 21	(5%) 0·82
Increased	frequency	≥	six	(grade	2) 31	(8%) 58	(15%) 0·0035
Use	of	pads	(grade	3) 22	(6%) 32	(8%) 0·19
Blood	or	mucous	loss	(grade	3)	 15	(4%) 22	(6%) 0·28
*	The	number	of	assessable	patients	per	specific	symptom	can	vary	and	the	denominator	is	indicated	
when	that	happens.	
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hypofractionation	 group)	 that	 included	 temporary	 interruption	 for	 three	 patients	 (two	 in	 the	
standard	 fractionation	 group,	 one	 in	 the	 hypofractionation	 group),	 discontinuation	 of	 irradiation	
in	 three	 patients	 because	 of	 toxic	 effects	 (one	 in	 the	 standard	 fractionation	 group,	 two	 in	 the	
hypofractionation	group),	 technical	 failure	 (two	 in	the	standard	fractionation	group),	on	patients’	
requests	(two	in	the	hypofractionation	group),	and	other	(three	in	the	standard	fractionation	group,	
one	in	the	hypofractionation	group).	
Hormonal	therapy	was	given	to	around	two-thirds	of	patients	 in	each	group	(table	1).	Intensity-
modulated	 radiation	 therapy	and	 set-up	 verification	and	 correction	based	on	 implanted	fiducials	
were	used	 in	 370	 (95%)	of	 391	patients	 in	 the	 standard	 fractionation	group	and	 in	 380	 (94%)	of	
403	patients	in	the	hyprofractionation	group.	Median	time	from	onset	of	hormonal	therapy	to	the	
date	of	planning	CT	or	MRI	was	1·7	months	(IQR	0·8–2·8)	in	the	standard	fractionation	group	and	
1·8	months	 (0·9–3·3)	 in	 the	hyprofractionation	group.	At	closure	of	 the	database	 (Sept	12,	2014),	
716	patients	 (354	 in	standard	fractionation	group	and	362	 in	hyprofractionation	group)	were	still	
alive	with	a	median	follow	up	of	49·2	months	(IQR	9·2–58·2).	We	noted	no	significant	difference	in	
cumulative	 incidence	up	 to	120	days	after	 radiotherapy	of	 grade	2	or	worse	acute	genitourinary	
toxicity	(57·8%	[95%	CI	52·9–62·7]	in	the	standard	fractionation	group	vs 60·5%	[55·8–65·3]	in	the	
hypofractionation	group;	difference	2·7%,	90%	CI	–2·99 to 8·48;	OR	1·12,	95%	CI	0·84–1·49;	p=0·43; 
table	2).	Thus	hypofractionation	was	not	non-inferior	 to	standard	 fractionation	 in	 terms	of	acute	
genitourinary	toxicity.20	Figure	2	and	table	2	show	differences	between	standard	fractionation	and	
hypofractionation	in	incidence	of	grade	2	or	worse	acute	genitourinary	toxicity	as	a	function	of	time.	
The	cumulative	incidence	of	grade	3	genitourinary	toxicity	was	17·6%	(95%	CI	13·9–21·4)	for	standard	
fractionation	and	20·3%	(16·4–24·3)	for	hypofractionation	(p=0·34).	In	each	group,	two	patients	had	
grade	4	acute	genitourinary	toxicity.	Table	3	shows	the	comparison	between	standard	fractionation	
and	hypofractionation	for	specific	symptoms.	Nocturia	seven	times	or	more	per	night	was	reported	
more	in	the	hypofractionation	group	than	in	the	standard	fractionation	group	(OR	1·81,	95%	CI	1·10–
3·00;	p=0·019;	table	3).	The	cumulative	incidence	of	grade	2	or	worse	acute	gastrointestinal	toxicity	
up	to	120	days	after	radiotherapy	was	higher	in	patients	given	hypofractionation	than	those	treated	
with	standard	fractionation	(31·2%	[95%	CI	26·6–35·8]	in	the	standard	fractionation	group	vs 42·0%	
[37·2–46·9]	 in	 the	hypofractionation	group;	difference	10·8%,	90%	CI	 5·25–16·43;	OR	1·6;	95%	CI	
1·19–2·14;	p=0·0015;	table	4).	Thus	hypofractionation	was	not	non-inferior	to	standard	fractionation	
in	terms	of	acute	gastrointestinal	toxicity.	Figure	2	and	table	2	show	differences	between	standard	
fractionation	and	hypofractionation	groups	in	incidence	of	grade	2	or	worse	acute	gastrointestinal	
toxicity	at	 the	various	time	points.	The	difference	 in	 toxicity	between	standard	 fractionation	and	
hypofractionation	had	dissipated	by	3	months	after	radiotherapy	(p=0·90;	figure	2	and	table	2).	In	the	
standard	fractionation	group,	the	cumulative	incidence	of	grade	3	gastrointestinal	toxicity	was	4·6%	
(95%	CI	2·5–6·7)	versus	5·7%	(3·4–8·0)	in	the	hypofractionation	group	(p=0·48).	We	did	not	record	
any	grade	4	gastrointestinal	toxicity	(table	2).	Pain	with	urge	and	discomfort	was	frequently	noted	in	
the	hypofractionation	group	(OR	1·98,	95%	CI	1·10–3·55;	p=0·021;	table	3).	Stool	frequency	greater	
than	 six	per	day	was	also	 significantly	 increased	with	hypofractionation	compared	with	 standard	
fractionation	(OR	1·96,	95%	CI	1·24–3·10;	p=0·0035;	table	3).	
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Table 2.4 | Univariate	and	multivariate	 logistic	 regression	analyses	exploring	 the	association	of	baseline	
factors	with	the	observed	cumulative	incidence	of	grade	2	or	worse	acute	gastrointestinal	and	genitourinary	
toxic	effects
Univariate Multivariate
p value OR	(95%	CI) p value OR	(95%	CI)
Genitourinary
Genitourinary	complications	(equal	
to	grade	2	or	worse	RTOG	toxicity	
score)	at	baseline
15·7(8·4-29·5) <0·001 14·5(7·7-27·3) <0·001
Age	(>70	years) 1·45(1·09-1·92) 0·011 1·38(1·00-1·90) 0·051
PSA	(<20) 0·90(0·66-1·22) 0·49 -
Gleason(<7) 0·68(0·49-0·96) 0·026 -  
T-stage(T3-T4	vs	T1-T2) 1·24(0·93-1·64) 0·14 -  
Transurethral	prostate	resection 0·86(0·53-1·38) 0·53 0·88(0·52-1·49) 0·63
Adjuvant	hormonal	therapy 1·11(0·82-1·50) 0·49 -
Months	hormonal	therapy	before	RT
 <2 vs none
 >2 vs none
1·07(0·75-1·52)
1·11(0·79-1·57)
0·53*
0·72
0·53
 
0·99(0·65-1·51)
1·10(0·73-1·65)
0·61*
0·96
0·65
Abdominal	surgery 1·19(0·86-1·65) 0·30   
Gastrointestinal	comorbidity 1·03(	0·64-1·66) 0·92 0·97(0·57-1·65) 0·90
Prostate	volume	(>50	vs	<50	cm3) 1·28(0·96-1·71) 0·088 1·36(0·98-1·89) 0·064
Treatment	group	
2 vs 1
3 vs 1
 
1·07(0·74-1·56)
1·36(0·91-2·05)
0·11*
0·72
0·14
 
1·01(0·67-1·53)
1·29(0·80-2·07)
0·75*
0·97
0·29
Treatment	group	(hypofractionation	
vs	standard	fractionation)
1·12(0·84-1·49) 0·43 1·07(0·78-1·46) 0·68	†
Gastrointestinal
Gastrointestinal	complications	
(equal	to	grade	2	or	worse	RTOG
toxicity	score)	at	baseline
5·8(2·3-14·6) <0·0001 5·5(2·1-14·3) 0·0010
Age	(>70	years) 1·23(0·92-1·64) 0·17 1·23(0·91-1·68) 0·18
PSA	(<20) 0·86(0·63-1·18) 0·35 -
Gleason	(<7) 0·84(0·60-1·17) 0·29 -
T	stage	(T3-T4	vs	T1-T2) 0·98(0·74-1·31) 0·90 -
Transurethral	prostate	resection 0·81(0·49-1·34) 0·41 0·75(0·45-1·27) 0·29
Adjuvant	hormonal	therapy 0·74(0·55-1·00) 0·052 -
Months	of	hormonal	therapy	
before radiotherapy
 <2 vs none
 >2 vs none
0·91(0·63-1·30)
0·63(0·44-0·89)
0·009*
0·59
0·009
0·88(0·59-1·31)
0·58(0·39-0·87)
0·007*
0·52
0·008
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Figure 2.3 | Acute	 toxicity	 reported	 by	 case	 report	 forms,	 patient	 self-assessment,	 and	 combined. 
Cumulative	incidence	of	grade	2	or	worse	genitourinary	toxic	events,	(A)	prevalence	of	grade	2	or	worse	
genitourinary	toxicity,	(B)	cumulative	incidence	of	grade	2	or	worse	gastrointestinal	toxicity,	(C)	prevalence	
of	grade	2	or	worse	gastrointestinal	toxicity	(D).
Abdominal	surgery 0·93(0·66-1·29) 0·65  1·0
GI	comorbidity 1·25(0·78-2·02) 0·36 1·24(0·74-2·06) 0·41
prostate	volume	(>50	vs	<50	cm3) 1·49(1·11-2·00) 0·008 1·33(0·97-1·82) 0·079
Treatment	group	
 2 vs 1
 3 vs 1
1·24(0·84-1·84)
1·41(0·93-2·15)
0·11*
0·28
0·11
 
1·37(0·90-2·08)
1·79(1·12-2·86)
0·009*
0·14
0·015
Treatment	group	(hypofractionation	
vs	standard	fractionation)
1·60(1·19-2·14) 0·0015† 1·57(1·16-2·13) 0·0034†
RTOG=Radiation	Therapy	Oncology	Group.	PSA=prostate-specific	antigen.	*p	values	for	linear	trend	tests	
across	the	categories.	†p	value	based	on	likelihood	ratio	test.		
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The	 presence	 of	 baseline	 grade	 2	 or	 worse	 genitourinary	 symptoms	 was	 the	 only	 significant	
prognostic	factor	for	increased	cumulative	incidence	of	grade	2	or	worse	acute	genitourinary	toxicity	
in	multivariate	analyses	 (OR	14·5,	95%	CI	7·7–27·3;	p<0·0001;	 table	4).	Baseline	grade	2	or	worse	
gastrointestinal	symptoms	were	associated	with	an	increased	incidence	of	gastrointestinal	toxicity	
(OR	5·5,	95%	CI	2·1–14·3;	p=0·0010).	Hormonal	therapy	use	for	2	months	or	longer	before	start	of	
radiotherapy	compared	with	no	hormonal	therapy	was	associated	with	a	reduction	in	incidence	of	
gastrointestinal	toxicity	(OR	0·58,	95%	CI	0·39–0·87;	p=0·0085).	Additionally,	we	noted	a	significant	
trend	in	increasing	gastrointestinal	toxicity	when	going	from	treatment	group	1	to	2	to	3	(trend	test	
p=0·0089).	For	group	1,	the	clinical	target	volume	consisted	of	the	prostate	only,	to	be	treated	to	
prescribed	dose.	For	group	2,	the	prostate	received	the	prescribed	dose,	while	the	seminal	vesicle	
were	treated	to	a	dose	of	35	fractions	of	2	Gy	or	39	fractions	of	1·85	Gy	(standard	fractionation),	or	a	
dose	of	16	fractions	of	3·4	Gy	or	19	fractions	of	3·04	Gy	in	the	hypofractionation	group.	For	group	3,	
RESEARCH IN CONTEXT 
Systematic review  
We	 searched	 Medline	 without	 language	
restriction	 between	 February,	 2005,	 and	
May,	2006,	with	the	search	terms	“prostate	
cancer”,	“radiotherapy”,	“hypofractionation”,	
“alpha	 beta	 ratio”,	 “toxicity”.6–8,10–12,21 The 
scientific	 literature	 shows	 evidence	 for	 a	
low	 α/β	 ratio	 for	 prostate	 cancer6–8 with a 
potential	for	an	enhanced	therapeutic	ratio	
for	 hypofractionated	 radiotherapy.	 In	 the	
development	phase	of	the	HYPRO	trial,	only	
a	 few,	 small	 randomised	 hypofractionation	
trials had been published,10–12 which 
were	 mostly	 done	 with	 lower	 treatment	
doses	 (66–72	 Gy).	 The	 use	 of	 intensity-
modulated	 radiation	 therapy	 and	 image-
guided radiotherapy are associated with low 
toxicity	 rates.22–25 The availability of these 
techniques	 to	 prevent	 excessive	 toxicity	
favoured	 launching	 of	 a	 hypofractionation	
trial.	 The	 aim	 of	 the	 HYPRO	 trial	 is	 to	
show superior relapse-free survival for 
hypofractionation	 compared	with	 standard	
fractionation,	with	non-inferiority	for	toxicity,	
prescribing	 an	 enhanced	 tumour	 EQD2Gy.	 
To our knowledge, only one other trial 
aimed	at	relapse-free	survival	enhancement	
with	hypofractionation	with	a	small	patient	
sample,26 whereas other trials11,27 addressed 
toxicity	 or	 non-inferiority	 by	 use	 of	 a	 low	
tumour	EQD2Gy.
Interpretation  
Hypofractionation	 was	 not	 non-inferior	
to	 standard	 fractionation	 for	 acute	
genitourinary	 and	 gastrointestinal	 toxicity;	
indeed,	the	cumulative	incidence	of	grade	2	
or	worse	acute	gastrointestinal	toxicity	was	
significantly	 higher	 for	 hypofractionation.	
However,	 by	 3	months	 after	 completion	of	
radiotherapy,	 differences	 in	 genitourinary	
and	 gastrointestinal	 toxicities	 were	 not	
significant.	 Presence	of	 baseline	 symptoms	
was	 the	 most	 important	 predictive	 factor	
for	acute	 toxicity.	The	use	of	patients’	 self-
assessment	 questionnaires	 complementary	
to	 case	 report	 forms	 can	 prevent	 serious	
under-reporting	 of	 toxic	 effects	 and	 is	
recommended.	These	finding	are	useful	for	
patients	 and	 physicians	 when	 considering	
treatment	with	a	hypofractionated	regimen	
with	a	fraction	dose	higher	than	3	Gy.
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both	the	prostate	and	the	seminal	vesicle	were	treated	up	to	prescribed	dose,	group	3	patients	had	
a	higher	risk	of	gastrointestinal	toxicity	than	patients	in	group	1	(table	4).	In	the	multivariate	analysis,	
when	 adjusting	 for	 all	 those	 factors,	 hypofractionation	 remained	 associated	 with	 a	 significantly	
higher	cumulative	incidence	of	grade	2	or	worse	acute	gastrointestinal	toxicity	than	with	standard	
fractionation	(OR	1·57, CI 1·16–2·13;	p=0·0034).	
For	both	genitourinary	and	gastrointestinal	adverse	events,	 the	total	 reported	 incidences	derived	
from	 the	 combined	 use	 of	 case	 report	 form	 and	 patients’	 self-assessment	 questionnaires	 were	
substantially	higher	than	for	case	report	form	only	(figure	3).
DISCUSSION
On	 the	 basis	 of	 our	 findings,	 hypofractionation	 is	 not	 non-inferior	 to	 standard	 fractionation	 in	
terms	of	acute	grade	2	or	worse	genitourinary	and	gastrointestinal	toxicity	(panel).	There	was	no	
significant	difference	in	the	cumulative	incidence	of	grade	2	or	worse	acute	genitourinary	toxicity	
between	the	groups;	however,	grade	2	or	worse	acute	gastrointestinal	toxicity	was	significantly	
more	common	in	the	hypofractionation	group	than	in	the	standard	fractionation	group.	Although	
3	months	after	completion	of	radiotherapy	this	difference	had	dissipated,	it	 is	possible	that	late	
gastrointestinal	 toxicity	 will	 be	 worse,	 due	 to	 the	 known	 association	 between	 acute	 and	 late	
toxicity;5	patients	remain	in	follow-up	and	we	will	investigate	this	association	in	the	future.	
It	is	possible	that	our	trial	was	underpowered	to	conclude	non-inferiority	for	acute	toxic	effects.	
The	trial’s	sample	size	was	mainly	based	on	power	considerations	for	relapse-free	survival.	When	
designing	 the	trial,	a	power	of	71%	for	 the	acute	 toxicity	comparisons	was	accepted	to	avoid	a	
substantial	increase	in	the	number	of	patients,	resulting	in	an	unfavourable	time	for	completion	
of	the	trial.	Further,	 the	per-protocol	defined	margin	for	non-inferiority	of	8%	might	have	been	
stringent	with	only	800	patients	included.	
Several	 investigators	 have	 reported	 increased	 acute	 toxicity	 with	 hypofractionation.	 In	 these	
studies,	the	overall	treatment	time	was	shorter	for	the	hypofractionation	group	than	the	standard	
fractionation	group	 (5·0–5·5 weeks vs 7–8	weeks).9,11,28	 In	our	 trial,	 the	overall	 treatment	times	
of	hypofractionation	and	standard	 fractionation	differed	only	by	1·5	weeks.	We	chose	a	 longer	
schedule	for	our	hypofractionation	regimen	to	eliminate	overall	treatment	time	as	a	study	variable	
and	to	avoid	excessive	acute	toxicity.	Because	of	this	protracted	dose	delivery,	the	time	saving	of	
hypofractionation	was	reduced	compared	with	the	other	studies,	but	still	the	reduction	from	39	to	
19	fractions	benefited	patients	in	terms	of	convenience.	
The	α/β	ratio	for	acute	side-effects	with	radiotherapy	is	often	assumed	to	be	about	10	Gy.	For	an	
α/β	ratio	of	10	Gy,	the	EQD2Gy	for	hypofractionation	would	be	almost	6	Gy	lower	than	for	standard	
fractionation.	The	recorded	increase	in	acute	gastrointestinal	toxicity	with	hypofractionation	in	this	
trial	could	indicate	that	the	α/β	ratio	is	actually	around	4	Gy.	However,	notwithstanding	the	similarity	
of	overall	treatment	time	in	the	standard	fractionation	and	hypofractionation	groups	in	our	trial,	the	
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predicted	weekly	EQD2Gy	for	acute	toxicity	was	1·4	Gy	higher	in	the	hypofractionation	group	than	in	
the	standard	fractionation	group,	which	could	possibly	have	contributed	to	the	higher	rate	of	acute	
gastrointestinal	 toxicity.	More	research	 is	needed	to	better	understand	the	radiobiology	of	acute	
toxicity	in	hypofractionated	radiotherapy	in	relation	to	the	α/β	ratio	and	overall	treatment	time.	
Findings	of	the	CHHiP	trial27	showed	a	peak	in	acute	toxicity	at	7–8	weeks	from	the	start	of	standard	
fractionated	 radiotherapy;	 for	 hypofractionation	 there	was	 a	 peak	 at	 4–5	weeks	 (the	 duration	
of	 the	hypofractionation	course	was	4	weeks).	 Investigators	of	 the	CKVO	96-10	 trial29 reported 
a	steady	 increase	 in	acute	 toxic	effects	during	 the	first	7	weeks	 for	 standard	 fractionation.	We	
recorded	toxicity	during	treatment	at	only	two	time	points.	Thus	we	may	have	missed	the	peak	
toxicity	in	the	standard	fractionation	group.	More	measurements	during	the	acute	phase	would	
have	provided	us	with	a	better	resolution	of	data.	However,	from	earlier	experiences,	more	than	
three	assessments	during	radiotherapy	is	a	heavy	burden	for	patients.	
We	 stratified	 patients	 according	 to	 treatment	 centre,	 and	 in	 each	 centre	 the	 same	 treatment	
technique	was	used	in	both	groups.	This	method	ensured	balance	between	the	groups	within	each	
stratum	and	thus	avoided	bias	in	the	overall	results,	despite	inter-institutional	technique	variations.	
The	cumulative	incidence	of	grade	2	or	worse	acute	genitourinary	toxicity	in	this	trial	was	similar	
to	that	recorded	in	the	high-dose	group	(39	fractions	of	2	Gy)	in	the	CKVO	96-10	trial.5 However, 
the	cumulative	incidence	of	grade	2	or	worse	acute	gastrointestinal	toxicity	in	the	high-dose	group	
of	the	CKVO	96-10	trial	was	much	higher	than	we	noted.	In	the	CKVO	96-10	study,	most	patients	
were	given	three-dimensional	conformal	radiotherapy.	Almost	all	patients	in	our	trial	were	given	
intensity-modulated	radiation	therapy	with	daily	online	set-up	verification	and	correction	on	the	
basis	of	implanted	fiducials.	These	differences	in	treatment	technique	might	have	contributed	to	
the	lower	gastrointestinal	toxicity	in	our	trial.	
Our	reported	acute	toxicity	is	higher	than	in	other	published	studies	of	hypofractionation.9,11,12,21,27,28 
Often,	acute	toxicity	scoring	 is	based	on	case	report	 forms	only.	 In	our	 trial,	 scoring	was	based	
on	both	case	report	forms	and	patients’	self-assessment	questionnaires.	The	addition	of	patients’	
self-assessment	questionnaires	 to	 the	analyses	 resulted	 in	 significant	 increases	 in	 the	 reported	
incidence	 of	 acute	 toxicity	 (figure	 3).	 Underestimation	 of	 toxicity	 by	 use	 of	 case	 report	 forms	
has	 been	 reported	 previously.30	 Addition	 of	 patients’	 self-assessment	 questionnaires	 results	
in	more	 robust	 toxicity	 scores	 and	might	 seriously	 affect	 conclusions	 drawn	 from	 studies.	 The	
means	of	toxicity	scoring	should	be	accurately	described	to	allow	comparison	with	other	studies.	
Preferentially,	both	case	report	form	and	patients’	self-assessment	questionnaires	should	be	used.	
Compared	with	 some	 other	 studies,12,27	 the	 HYPRO	 trial	 included	more	 high-risk	 patients	 (584	
[74%]	of	794),	and	for	249	(31%)	of	794	of	these	patients	the	whole	seminal	vesicle	was	given	the	
prescribed	dose.	The	inclusion	of	the	seminal	vesicle	in	the	target	volume	might	have	contributed	
to	an	enhanced	incidence	of	acute	toxicity	in	our	study.	Furthermore,	the	mean	age	of	the	patients	
in	our	trial	was	higher	than	in	other	series.5,26,27	In	our	trial,	being	older	than	70	years	was	a	negative	
prognostic	 factor	 for	 genitourinary	 toxicity	 (in	both	 groups)	only	 in	 the	univariate	 analysis,	 but	
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Pollack and colleagues26	reported	age	67	years	or	older	as	a	poor	prognostic	factor	for	genitourinary	
toxicity	in	their	hypofractionation	group.	
In	our	multivariate	analyses,	we	noted	a	decrease	in	risk	of	acute	gastrointestinal	toxicity	with	the	
use	of	neoadjuvant	hormonal	therapy;	this	has	also	been	reported	before.5,31	Hormonal	therapy	
could	have	resulted	in	a	decrease	in	prostate	volume,	and	consequently	reduced	organs	at	risk	dose	
delivery.	However,	hormonal	therapy	remained	significant	in	the	multivariate	analyses	including	
the	prostate	volume.	
The	incidence	of	grade	2	or	worse	genitourinary	toxicity	3	months	after	completion	of	radiotherapy	
was	 about	 23%	 in	 both	 groups,	 which	 is	 the	 same	 as	 the	 baseline	 level.	 This	 finding	 suggests	
that	most	acute	genitourinary	 symptoms	were	 reversible	 in	both	groups	within	3	months	after	
radiotherapy.	Presence	of	baseline	grade	2	or	worse	gastrointestinal	or	genitourinary	symptoms	
was	 strongly	 associated	 with	 enhanced	 incidence	 of	 acute	 gastrointestinal	 and	 genitourinary	
toxicity	in	both	groups,	which	was	also	reported	in	the	CKVO	96-10	trial.5 The high baseline rate of 
grade	2	or	worse	genitourinary	symptoms	(about	23%	of	patients),	compared	with	10%	in	the	CKVO	
96-10 trial,5,32	might	partly	explain	the	high	acute	genitourinary	toxicity	in	the	our	trial,	although	
most	patients	were	given	intensity-modulated	radiation	therapy	and	daily	online	set-up	correction.
In	 conclusion,	 hypofractionated	 radiotherapy	 for	men	with	 prostate	 cancer	 is	 not	 non-inferior	
in	 terms	of	 acute	grade	2	or	worse	genitourinary	and	gastrointestinal	 side	effects.	 Indeed,	 the	
cumulative	incidence	of	grade	2	or	worse	acute	gastrointestinal	toxicity	was	significantly	higher	
for	hypofractionation.	Patients	in	this	trial	remain	in	follow-up	for	the	main	efficacy	endpoint	of	
recurrence	free	survival.	
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SUMMARY 
Background  
Several	 studies	 have	 reported	 a	 low	 α	 to	 ß	 ratio	 for	 prostate	 cancer,	 suggesting	 that	
hypofractionation	could	enhance	the	biological	tumour	dose	without	 increasing	genitourinary	
and	gastrointestinal	toxicity.	We	tested	this	theory	in	the	phase	3	HYPRO	trial	for	patients	with	
intermediate-risk	and	high-risk	prostate	cancer.	We	have	previously	reported	acute	 incidence	
of	 genitourinary	 and	 gastrointestinal	 toxicity;	 here	we	 report	 data	 for	 late	 genitourinary	 and	
gastrointestinal	toxicity.	
Methods
In	 this	 randomised	 non-inferiority	 phase	 3	 trial,	 done	 in	 seven	 radiotherapy	 centres	 in	 the	
Netherlands,	we	enrolled	intermediate-risk	or	high-risk	patients	aged	between	44	and	85	years	
with	 histologically	 confirmed	 stage	 T1b–T4	Nx–0	Mx–0	 prostate	 cancer,	 a	 prostate-specific	
antigen	concentration	of	60	ng/mL	or	lower,	and	WHO	performance	status	of	0–2.	A	web-based	
application	was	used	to	randomly	assign	(1:1)	patients	to	receive	either	standard	fractionation	
with	39	 fractions	of	2	Gy	 in	8	weeks	 (five	 fractions	per	week)	or	hypofractionation	with	19	
fractions	of	3·4	Gy	in	6·5	weeks	(three	fractions	per	week).	Randomisation	was	done	with	the	
minimisation	procedure,	stratified	by	treatment	centre	and	risk	group.	The	primary	endpoint	
was	to	detect	a	10%	enhancement	 in	5-year	relapse-free	survival	with	hypofractionation.	A	
key	additional	endpoint	was	non-inferiority	of	hypofractionation	 in	cumulative	 incidence	of	
grade	2	or	worse	 acute	 and	 late	 genitourinary	 and	 gastrointestinal	 toxicity.	We	planned	 to	
reject	 inferiority	of	hypofractionation	for	 late	genitourinary	 toxicity	 if	 the	estimated	hazard	
ratio	 (HR)	was	 less	 than	1·11	and	 for	gastrointestinal	 toxicity	was	 less	 than	1·13.	We	scored	
toxicity	with	the	Radiation	Therapy	Oncology	Group	and	European	Organisation	for	Research	
and	Treatment	of	Cancer	(RTOG/EORTC)	criteria	from	both	physicians’	records	(clinical	record	
form)	and	patients’	self-assessment	questionnaires.	Analyses	were	done	in	the	intention-to-
treat	population.	Patient	recruitment	for	the	HYPRO	trial	was	completed	in	2010.	The	trial	was	
registered	with	www.controlled-trials.com,	number	ISRCTN85138529.	
Findings 
Between	March	19,	2007,	and	Dec	3,	2010,	820	patients	 (410	 in	both	groups)	were	 randomly	
assigned.	Analyses	for	late	toxicity	included	387	assessable	patients	in	the	standard	fractionation	
group	and	395	in	the	hypofractionation	group.	The	median	follow-up	was	60	months	(IQR	51·2–
67·3).	 The	database	 for	 all	 analyses	 (both	groups	and	both	genitourinary	and	gastrointestinal	
toxicities)	 was	 locked	 on	 March	 26,	 2015.	 The	 incidence	 of	 grade	 2	 or	 worse	 genitourinary	
toxicity	at	3	years	was	39·0%	(95%	CI	34·2–44·1)	in	the	standard	fractionation	group	and	41·3%	
(36·6–46·4)	 in	the	hypofractionation	group.	The	estimated	HR	for	the	cumulative	incidence	of	
grade	2	or	worse	late	genitourinary	toxicity	was	1·16	(90%	CI	0·98–1·38),	suggesting	that	non-
inferiority	could	not	be	shown.	The	incidence	of	grade	2	or	worse	gastrointestinal	toxicity	at	3	
years	was	17·7%	(14·1–21·9)	in	standard	fractionation	and	21·9%	(18·1–26·4)	hypofractionation.	
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RESEARCH IN CONTEXT 
Evidence before this study 
When	 the	 HYPRO	 trial	 was	 being	 planned	
and	developed,	only	a	few,	small	randomised	
hypofractionation	trials	had	been	published,	
which	 were	 done	 mostly	 with	 lower	
treatment	 doses	 (66–72	 Gy).	 Scientific	
literature	showed	 initial	evidence	for	a	 low	
α	 to	ß	 ratio	 for	prostate	cancer.	There	was	
a	 clear	 need	 for	 large	 randomised	 trials	 to	
test	 the	 predicted	 enhanced	 therapeutic	
ratio	 with	 hypofractionation.	 The	 use	 of	
intensity-modulated	 radiotherapy	 and	
image-guided	 radiation	 therapy	with	 lower	
published	 toxicity	 had	 become	 common.	
Availability of these techniques to prevent 
excessive	 toxicity	 favoured	 launching	 of	 a	
hypofractionation	 trial.	 The	 HYPRO	 trial	
aimed	to	show	superior	relapse-free	survival	
with	 hypofractionation,	 by	 prescribing	 an	
enhanced	 tumour	 equivalent	 dose	 in	 2	Gy	
fractions	 (EQD2Gy)	 compared	with	 standard	
fractionation,	without	increasing	toxicity.	To	
our	 knowledge,	only	one	other	 trial	 aimed	
at	 relapse-free	 survival	 enhancement	 with	
hypofractionation	 with	 a	 small	 patient	
sample,	 whereas	 other	 trials	 addressed	
toxicity	 or	 non-inferiority,	 using	 a	 lower	
tumour	EQD2Gy.	
Added value of this study 
Our	 findings	 could	 not	 confirm	 the	 per-
protocol hypothesized non-inferiority of 
hypofractionation	 for	 late	 genitourinary	
and	 gastrointestinal	 toxicity.	Moreover,	 the	
cumulative	 incidence	 of	 grade	 3	 or	 worse	
late	 genitourinary	 toxicity	 was	 significantly	
higher	 in	 the	 hypofractionation	 group.	
Because the hypothesized non-inferiority 
of	 hypofractionation	 for	 late	 toxicity	 was	
based	 on	 calculations	 with	 the	 linear-
quadratic	model	with	the	generally	applied	
α	 to	β	 ratio	of	4–6	Gy	 for	 late	 toxicity,	 this	
approach	might	be	questionable.	The	use	of	
patient	 self-assessment	 questionnaires	 on	
top	of	clinical	record	forms	did	significantly	
enhance	reported	late	toxicity.
Implication of all available evidence
Together	 with	 previous	 findings	 that	
were unable to show non-inferiority 
of	 hypofractionation	 for	 both	 acute	
gastrointestinal	 and	 genitourinary	 toxicity,	
and	 the	 recorded	 significant	 increase	 in	
incidence	 of	 acute	 gastrointestinal	 toxicity,	
the	 findings	 of	 late	 toxicity	 question	 the 
added	 value	 of	 hypofractionation	 with	
a	 fraction	 dose	 higher	 than	 3	 Gy	 for	
all	 patients,	 and	 the	 need	 for	 patient	
selection—eg,	based	on	baseline	symptoms,	
which can reduce both genitourinary 
and	 gastrointestinal	 toxicity.	 Before	
conclusions	 can	 be	 made	 about	 the	 value	
of	 hypofractionation,	 treatment	 outcomes	
need	 to	 be	 reported.	 The	 addition	 of	
patient	 self-assessment	 questionnaires	
to	 toxicity	 reporting	 with	 clinical	 record	
forms	 could	 avoid	 serious	 toxicity	 under-
reporting.	 The	 findings	 of	 reported	
genitourinary	 and	 gastrointestinal	 toxicity	
on	 the	 application	 of	 the	 linear-quadratic	
model	 should	 be	 considered	 in	 the	 design	
of	 new	 hypofractionation	 trials.	 Whether	
hypofractionation	can	be	incorporated	in	to	
routine	clinical	practice	will	depend	on	the	
toxicity	 and	 outcome	 results	 of	 continuing	
studies	with	long	follow-up.
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With	an	estimated	HR	of	1·19	 (90%	CI	0·93–1·52)	 for	 the	 cumulative	 incidence	of	 grade	2	or	
worse	late	gastrointestinal	toxicity,	we	could	not	confirm	non-inferiority	of	hypofractionation	
for	 cumulative	 late	 gastrointestinal	 toxicity.	 Cumulative	 grade	 3	 or	worse	 late	 genitourinary	
toxicity	was	significantly	higher	in	the	hypofractionation	group	than	in	the	standard	fractionation	
group	(19·0%	[95%	CI	15·2–23·2]	vs	12·9%	[9·7–16·7],	respectively;	p=0·021),	but	there	was	no	
significant	difference	between	cumulative	grade	3	or	worse	late	gastrointestinal	toxicity	(2·6%	
[95%	CI	1·2–4·7])	in	the	standard	fractionation	group	and	3·3%	[1·7–5·6]	in	the	hypofractionation	
group;	p=0·55).
Interpretation 
Our	 data	 could	 not	 confirm	 that	 hypofractionation	 was	 non-inferior	 for	 cumulative	 late	
genitourinary	and	gastrointestinal	toxicity	compared	with	standard	fractionation.	Before	final	
conclusions	can	be	made	about	the	utility	of	hypofractionation,	efficacy	outcomes	need	to	be	
reported.	
Funding   
The Dutch Cancer Society. 
INTRODUCTION 
Published	 data	 for	 the	 unique	 radiobiology	 of	 prostate	 cancer	 reported	 a	 low	 α	 to	 ß	 ratio,	
suggesting	a	therapeutic	advantage	of	hypofractionation	for	the	treatment	of	intermediate-risk	
and	high-risk	prostate	cancer.1,2	Findings	of	trials	3,4,5 in	which	fractions	of	3	Gy	or	less	were	used	
showed	acceptable	rectum	and	bladder	toxicity	after	hypofractionation	(these	trials	had	small	
numbers	of	patients	or	short	follow-up).	 In	2007,	the	randomised	phase	3	multicentre	HYPRO	
trial6	was	initiated	in	the	Netherlands	to	test	hypofractionated	treatment	with	a	fraction	dose	
of	3·4	Gy,	delivered	during	19	fractions,	three	fractions	per	week,	to	 investigate	the	potential	
benefit	 for	 relapse-free	survival	with	non-inferiority	 for	acute	and	 late	 toxicity.	As	previously	
reported,6	assuming	an	α	to	ß	ratio	of	1·5	Gy	for	prostate	cancer,	the	tumour	equivalent	dose	
in	2	Gy	fractions	(EQD2Gy)	for	19	×	3·4	Gy	would	be	90·4	Gy	(compared	with	78	Gy	for	standard	
fractionation)	with	an	expected	increase	in	relapse-free	survival	of	10%	compared	with	standard	
fractionation.	Considering	an	α	to	ß	ratio	of	4–6	Gy	for	late	genitourinary	and	gastrointestinal	
toxicity,7,8	 the	EQD2Gy	 for	19	×	3·4	Gy	would	be	77·5–79·7	Gy,	 close	 to	 the	78	Gy	 for	 standard	
fractionation.	 Therefore,	 we	 expected	 incidences	 of	 late	 genitourinary	 and	 gastrointestinal	
toxicities	 to	 be	 similar	 to	 late	 genitourinary	 and	 gastrointestinal	 toxicity	 in	 standard	 group.	
We	chose	three	fractions	per	week	 for	hypofractionation	to	make	the	overall	 treatment	time	
as	 similar	 as	possible	 in	both	 groups,	 avoiding	excessive	 acute	 toxicity	 for	hypofractionation.	
After	our	report	of	acute	toxicity,6	here	we	report	data	for	late	genitourinary	and	gastrointestinal	
toxicity,	as	primary	endpoints	of	the	HYPRO	trial.	
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METHODS 
Study design and participants 
In	this	open-label,	phase	3	study,	we	recruited	intermediate-risk	and	high-risk	patients	with	prostate	
cancer9	aged	between	44	and	85	years	who	had	histologically	confirmed	stage	T1b–T4	Nx–0	Mx–0,	
prostate-specific	antigen	of	60	ng/mL	or	less	and	a	WHO	performance	status	of	0–2.	In	cases	in	
which	patients	had	prostate-specific	antigen	less	than	20	ng/mL	or	a	Gleason	score	lower	than	8,	
patients	could	be	included	without	a	work-up	for	metastases.	We	excluded	patients	with	previous	
pelvis	 irradiation,	radical	prostatectomy,	evidence	of	pelvic	nodal	disease	 (determined	by	CT	of	
pelvis),	presence	of	distant	metastases	(determined	by	bone	scintigraphy),	and	low-risk	patients	
(stage	 T1b–T2a,	 Gleason	 score	 ≤6,	 prostate-specific	 antigen	 ≤10	 ng/mL).9,10	 Each	 participating	
centre	followed	its	own	protocol	for	adjuvant	hormonal	therapy,	which	had	to	be	applied	equally	
for	both	study	groups.	This	trial	was	approved	by	the	medical	ethics	committee	of	the	Erasmus	
Medical	Centre	 in	Rotterdam,	the	Netherlands	 (06-045).	All	patients	provided	written	 informed	
consent.	The	trial	was	coordinated	and	managed	by	the	Department	of	Radiation	Oncology	and	the	
Clinical	Trials	Center	of	the	Erasmus	MC	Cancer	Institute.	
Randomisation and masking 
Patients	were	randomly	assigned	(1:1)	to	open-label	treatment	groups	with	standard	fractionation	
or	hypofractionation,	applying	a	minimisation	procedure.	There	was	a	random	element	in	the	
randomisation	and	it	ensured	overall	balance	and	within	each	stratum	of	the	stratification	factors	
(i.e.,	treatment	centre	and	risk	group).	Patients	were	assigned	via	a	web-based	application	(done	
by	the	Clinical	Trials	Center,	Erasmus	MC	Cancer	Institute,	Rotterdam)	and	the	assigned	treatment	
group	 was	 sent	 immediately	 via	 fax,	 telephone,	 or	 email	 to	 the	 local	 investigator.6 The local 
investigators	were	treating	physicians,	so	they	were	not	masked	to	treatment.	Randomisation	took	
place	at	least	4	weeks	before	the	start	of	treatment.	
Procedures 
Patients	were	randomly	assigned	to	receive	either	standard	fractionation	(39	fractions	of	2	Gy,	five	
fractions	per	week)	or	hypofractionation	(19	fractions	of	3·4	Gy,	three	fractions	per	week).	Three	
treatment	groups	were	defined	based	on	the	risk	of	seminal	vesicle	involvement:11 group 1 with 
risk	of	10%	or	less,	group	2	with	risk	between	10%	and	25%,	and	group	3	with	a	risk	of	more	than	
25%	(current	pre-radiotherapy	MRI	staging	might	change	the	role	of	the	applied	Partin’s	table11 for 
assessment	of	the	risk	of	seminal	vesicle	invasion).	For	group	1,	the	clinical	target	volume	consisted	
of	the	prostate	only,	to	be	treated	to	the	prescribed	dose	i.e.,	39	×	2	Gy	for	standard	fractionation	
and	19	×	3·4	Gy	 for	hypofractionation.	For	group	2,	 the	prostate	 received	 the	prescribed	dose,	
whereas	the	seminal	vesicle	was	treated	to	a	dose	of	35	fractions	of	2	Gy	up	to	70	Gy	or	39	fractions	
of	1·85	Gy	(standard	fractionation	group),	or	a	dose	of	16	fractions	of	3·4	Gy	or	19	fractions	of	3·04	
Gy	(hypofractionation	group).	For	group	3,	both	the	prostate	and	the	seminal	vesicle	were	treated	
up	to	the	prescribed	dose.6 
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Depending	on	the	set-up	verification	and	correction	strategy	used	in	each	participating	institute,	
margins	 of	 3–10	mm	were	 added	 to	 the	 clinical	 target	 volume	 (equal	 in	 both	 groups),	 yielding	
the	planning	 target	 volume.6	 For	 the	boost,	 these	margins	 could	be	 reduced	 to	0	mm	 towards	
the	rectum,	and	3–5	mm	in	other	directions.	This	boost	could	either	be	delivered	sequentially	or	
simultaneously	 integrated	depending	on	the	institute’s	preference.	The	planning	CT	or	MRI	was	
done	2	weeks	before	start	of	radiotherapy.	
As	prescribed	by	the	study	protocol,	patients	were	assessable	for	late	toxicity	as	long	there	was	
no	evidence	of	relapse.	Genitourinary	and	gastrointestinal	toxicity	were	scored	by	clinical	record	
form,	 as	 reported	by	 the	 treating	physician,	 following	 the	Radiation	Therapy	Oncology	Group-
European	 Organisation	 for	 Research	 and	 Treatment	 of	 Cancer	 (RTOG-EORTC)	 scoring	 criteria,6 
and	by	patient	self-assessment	questionnaires.10,12 Both	for	late	genitourinary	and	gastrointestinal	
toxicity	overall	(cumulative)	toxicity	scores	were	taken	as	the	highest	of	the	two	scores.	The	earliest	
date	from	either	source	on	which	a	toxicity	score	of	grade	2	or	worse	was	reported	was	defined	
as	 the	date	of	 incidence	of	 grade	2	or	worse	 late	 toxicity.6,12 We	assessed	 late	 toxicity	 from	90	
days	after	treatment	 (at	6,	12,	24,	36,	48,	and	60	months).	We	recorded	 incidences	of	clinically	
relevant	symptoms,	 including	nocturia,	 frequency,	dysuria	needing	medication,	haematuria	and	
incontinency	for	genitourinary	toxicity,	and	pain	with	urge	and	discomfort,	frequency,	use	of	pads,	
Figure 3.1 | Trial	profile
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bleeding,	and	diarrhoea	needing	medication	for	gastrointestinal	toxicity.6,12,13	 Information	about	
smoking	was	collected	after	randomisation	and	before	treatment.	
Outcomes 
The	primary	endpoint	of	this	trial	is	5-year	relapse-free	survival.	Key	endpoints	are	3-year	cumulative	
grade	 2	 or	worse	 acute	 and	 late	 gastrointestinal	 and	 genitourinary	 toxicity,	with	 hypothesised	
non-inferiority	of	hypofractionation.	Secondary	endpoints	are	quality	of	life	and	erectile	function.	
The	protocol	defined	3-year	late	toxicity	for	the	non-inferiority	endpoint.	This	was	based	on	the	
results	of	our	dose	escalation	study12	in	which	most	toxicities	were	reported	in	the	first	3	years	after	
treatment.	We	waited	for	the	5	years	late	toxic	effect	results	to	report	on	in	this	paper.	
Statistical analysis 
The	HYPRO	trial	was	powered	to	show	a	reduction	from	30%10	(based	on	the	results	of	the	Dutch	
dose	escalation	study10)	 to	20%	 in	relapse-free	survival	 (the	primary	endpoint)	with	a	power	of	
92%	for	800	patients.	Non-inferiority	for	late	toxicity	was	tested	separately	for	late	genitourinary	
and	 gastrointestinal	 toxicities,	 with	 the	 null	 hypothesis	 that	 the	 cumulative	 incidence	 in	 the	
hypofractionation	group	was	8%	or	higher	than	in	the	other	group	against	the	alternative	hypothesis	
that	 the	cumulative	 incidence	 in	 the	hypofractionation	group	was	 less	 than	or	equal	 to	 that	of	
standard	fractionation.	For	the	non-inferiority	hypotheses,	one-sided	tests	with	an	α	of	0·05	were	
used	for	each	of	the	endpoints	without	adjustment	for	multiple	testing.	For	standard	fractionation,	
the	expected	cumulative	incidence	of	grade	2	or	worse	genitourinary	toxicity	at	3	years	was	31%.10 A 
difference	of	8%	corresponds	with	a	hazard	ratio	(HR)	of	1·33.	The	null	hypothesis	of	inferiority	was	
to	be	rejected	only	if	the	estimated	hazard	ratio	of	the	incidence	of	late	genitourinary	toxicity	in	the	
hypofractionation	group	compared	with	the	control	group	was	less	than	1·11,	which	corresponds	
with	 a	maximum	 absolute	 increase	 of	 2·8%.	 The	 expected	 cumulative	 incidence	 of	 grade	 2	 or	
worse	late	gastrointestinal	toxicity	at	3	years	for	standard	fractionation	was	26%.10	A	difference	
of	8%	corresponds	with	an	HR	of	1·38.	The	null	hypothesis	of	inferiority	was	to	be	rejected	only	if	
the	estimated	HR	of	the	incidence	of	late	gastrointestinal	toxicity	in	the	hypofractionation	group	
compared	with	the	control	group	was	less	than	1·13,	which	corresponds	with	a	maximum	absolute	
increase	of	2·8%.	For	late	genitourinary	and	gastrointestinal	toxicity,	the	power	for	showing	non-
inferiority	for	2	×	400	patients	was	84%	and	86%,	respectively.	This	power	was	decided	acceptable	
to	avoid	a	substantial	 increase	 in	 the	number	of	patients,	 resulting	 in	an	unfavourable	time	for	
completion	of	the	trial.	For	example,	if	we	had	powered	the	test	with	90%,	then	the	sample	size	
would	have	been	2	×	688	patients.	Incidence	probabilities	of	grade	2	or	worse	late	toxicity	were	
estimated	by	the	Kaplan-Meier	method	and	compared	between	the	standard	fractionation	and	
hypofractionation	groups	using	the	Cox	likelihood	ratio	(LR)	test.	Univariate	and	multivariate	Cox-
regression	analyses	were	done	to	assess	the	effect	of:	baseline	symptoms	equivalent	to	grade	2	
or	worse	toxicity,	acute	toxicity,	age,	prostate-specific	antigen,	Gleason	score,	T	stage,	previous	
transurethral	 resection	 of	 the	 prostate	 (TURP),	 use	 of	 hormonal	 therapy,	 previous	 abdominal	
morbidity	and	surgery,	prostate	volume,	 treatment	group	according	 to	 risk	of	 seminal	vesicle	
involvement,	and	treatment	group	on	late	toxicity	incidence.	Hazard	ratios	(HRs)	with	95%	CIs	
were	determined.	 The	 treatment	effects	 in	 subgroups	were	explored	 in	post-hoc	 analyses	by	
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comparing	the	subgroup	incidences	of	grade	2	or	worse	late	toxicity	by	estimating	the	HRs	with	
95%	CIs	and	testing	for	interaction	effect	of	the	risk	factors	with	treatment	group.	
We	tested	differences	in	percentages	by	applying	Pearson’s	χ2	test	(Fisher’s	exact	test	was	applied	
if	the	percentage	in	one	of	the	groups	was	very	small).	There	was	no	data	imputation	of	the	missing	
data	and	all	available	data	were	analysed.	We	compared	the	correlated	proportions	of	patients	
with	 toxicity	according	 to	 the	clinical	 record	 form	and	patients’	 self-assessment	questionnaires	
by	applying	the	McNemar’s	test.	No	corrections	for	multiple	testing	were	applied	and	all	reported	
p	values	were	based	on	two-sided	tests.	We	regarded	a	p	value	of	 less	than	0·05	as	significant.	
Analyses	were	intention	to	treat.	We	used	Stata	(version	13.1)	for	the	analyses.	
This	 trial	 was	 approved	 by	 the	 medical	 ethics	 committee	 of	 the	 Erasmus	Medical	 Center	 in	
Rotterdam,	 the	Netherlands	 (06-045),	and	 registered	with	www.controlledtrials.com,	number	
ISRCTN85138529.	
Role of the funding source 
The funder provided peer-reviewed approval for the trial, but had no other role in study design, 
collection,	 analyses	 or	 interpretation	 of	 data.	 The	 corresponding	 author	 and	 the	 principal	
investigators	of	the	study	(LI	and	FP)	had	full	access	to	all	data	and	had	final	responsibility	for	the	
decision	to	submit	for	publication.	
Standard fractionation group 
(n=387)
Hypofractionation group 
(n=395)
Age	(years) 71	(67-75) 70	(66-74)
T-stage
T1a
T1b
T1c
T2a
T2b
T2c
T3a
T3b
T4
	1	(0%)	
	3	(1%)
	54	(14%)
	44	(12%)
	38	(10%)
	48	(12%)
	159	(41%)	
	37	(10%)
	3	(1%)
0 
	3	(1%)
	52	(14%)
	49	(12%)
	35	(9%)
	49	(12%)
	155	(39%)
	46	(12%)
	6	(2%)
PSA	concentration	(ng/ml)
<	10
10 – 20
>20
	102	(26%)
	155	(40%)
	130	(34%)
	122	(31%)
	157	(40%)
	116	(29%)
Table 3.1 |	Baseline	characteristics
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Median	PSA	(range) 14·8	(1·1-59·6) 13·8	(1-59)
Q1 9·8 9·2
Q3 24 21·1
Gleason score
	≤6
 7
 8
 9
 10
118	(30%)
176	(45%)
56	(14%)
33	(9%)
4	(1%)
120	(30%)
179	(45%)
59	(15%)
34	(9%)
3	(1%)
Treatment	group
 1
 2
 3 
78	(20%)
188	(49%)
121	(31%)
78	(20%)
196	(50%)
121	(31%)
Risk	group 
Intermediate
High
105	(27%)
282	(73%)
103	(26%)
292	(74%)
Prostate	volume	(cm3)
	≤50
>50
Unknown
183	(47%)
195	(50%)
	9	(2%)
177	(45%)
205	(52%)
13	(3%)
Adjuvant	hormonal	therapy 260	(67%) 259(66%)
≤	6	months 38	(10%) 45	(11%)
6-12	months 37	(10%) 34	(9%)
>	12	months 112	(29) 114	(29%)
Unknown	duration 73	(19%) 67	(17%)
Duration	of	hormonal	therapy	
use before radiotherapy
	≤2	months
	>2	months
	Unknown
119	(31%)
136	(35%)
	6	(2%)
 
114	(29%)
142	(36%)
4	(1%)
Transurethral	resection	of	
prostate
42	(11%) 33	(8%)
Abdominal	surgery 106	(27%) 89	(23%)
Gastrointestinal	comorbidity 41(11%) 35(9%)
Data	are	median	(IQR)	or	n	(%).	PSA=prostate-specific	antigen.	Q1	and	Q3	are	the	lower	and	upper	
bounds	of	IQR,	respectively.	Number	of	assessable	patients	differs	from	the	report	of	acute	toxicity	
because	some	were	not	assessable.
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RESULTS 
Between	March	19,	2007,	and	Dec	3,	2010,	820	patients	from	seven	Dutch	centres	were	randomly	
assigned	 to	 treatment	with	 standard	 fractionation	 (n=410)	 or	 hypofractionation	 (n=410).	 Patient	
recruitment	 for	 the	HYPRO	 trial	was	 completed	 on	Dec	 3,	 2010.	 25	 patients	 (18	 in	 the	 standard	
fractionation	group,	and	seven	in	the	hypofractionation	group)	were	excluded	from	the	intention-
to-treat	analysis	(figure	1).	Of	the	remaining	795	patients,	13	were	not	included	in	the	late	toxicity	
analyses	because	of	missing	data,	resulting	in	782	evaluable	patients	(387	in	the	standard	fractionation	
group,	and	395	in	the	hypofractionation	group).	The	median	follow-up	was	60	months	(IQR	51·2–67·3).	
The	median	follow-up	for	standard	fractionation	was	59·7	months	(IQR	51·3–69·0)	and	60·4	months	
(50·8–66·9)	for	hypofractionation.	The	baseline	characteristics	were	equally	distributed	(table	1).	756	
(97%)	of	782	patients	were	given	intensity	modulated	radiotherapy	(370	[96%]	of	387	patients	in	the	
standard	fractionation	group	vs	376	[95%]	of	395	patients	in	the	hypofractionation	group),	and	739	
(95%)	of	782	patients	had	 implanted	gold	fiducials	for	 image	guidance	(366	[95%]	 in	the	standard	
fractionation	group	and	373	[94%]	in	the	hypofractionation	group).	
Of	the	782	patients,	the	response	rates	from	either	source	(clinical	record	form	and	patients’	
self-assessment	questionnaires)	was	96%	at	2	years,	93%	at	3	years,	86%	at	4	years,	and	69%	at	
5	years	(95%,	93%,	86%,	and	68%,	respectively	in	standard	fractionation,	and	97%,	93%,	86%,	
and	 70%,	 in	 hypofractionation).	 The	 database	 for	 both	 groups	 and	 both	 gastrointestinal	 and	
genitourinary	toxicities	was	locked	on	March	26,	2015.	
At	3	years	after	radiotherapy,	the	cumulative	incidence	of	grade	2	or	worse	toxicity	was	39·0%	
(95%	CI	34·2–44·1)	for	patients	in	the	standard	fractionation	group	compared	with	41·3%	(36·6–
46·4)	for	those	in	the	hypofractionation	group	(HR	1·16,	95%	CI	0·94–1·43;	Cox	LR	test	p=0·16).	
The	estimated	HR	for	cumulative	incidence	of	grade	2	or	worse	late	genitourinary	toxicity	was	
1·16	(90%	CI	0·98–1·38),	suggesting	that	non-inferiority	could	not	be	shown.	Figure	2A	shows	a	
comparison	of	 the	Kaplan-Meier	estimates	of	cumulative	 late	genitourinary	toxicity	 incidence	
for	 standard	 fractionation	 and	 hypofractionation.	 The	 cumulative	 incidence	 of	 grade	 3	 or	
worse	late	genitourinary	toxicity	was	significantly	higher	in	the	hypofractionation	group	(19·0%	
[95%	 CI	 15·2–23·2]	 vs	 12·9%	 [9·7–16·7]	 for	 standard	 fractionation;	 p=0·021).	 In	 the	 standard	
fractionation	group,	three	patients	had	grade	4	late	genitourinary	toxicity	compared	with	two	in	
the	hypofractionation	group.	
3-year	cumulative	incidences	of	grade	2	or	worse	late	gastrointestinal	toxicity	were	17·7%	(95%	CI	
14·1–21·9)	in	the	standard	fractionation	group	versus	21·9%	(18·1–26·4)	for	the	hypofractionation	
group	(HR	1·19,	95%	CI	0·88–1·59;	Cox	LR	test	p=0·26).	With	an	estimated	HR	of	1·19	(90%	CI	0·93–
1·52)	for	the	cumulative	incidence	of	grade	2	or	worse	late	gastrointestinal	toxicity,	we	could	not	
confirm	non-inferiority	of	hypofractionation	for	cumulative	late	gastrointestinal	toxicity.	Figure	
2B	 shows	Kaplan-Meier	estimates	of	 cumulative	 incidence.	Cumulative	grade	3	or	worse	 late	
gastrointestinal	toxicity	was	2·6%	(95%	CI	1·2–4·7)	in	the	standard	fractionation	group	and	3·3%	
(1·7–5·6)	in	the	hypofractionation	group	(p=0·55).	
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Figure 3.2 | (A)	Cumulative	grade	≥2	late	genitourinary	toxicity,	(B)	cumulative	grade	≥2	late	gastrointestinal	
toxicity
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Table	 2	 presents	 specific	 symptoms	 of	 late	 genitourinary	 and	 gastrointestinal	 toxicity	 in	 the	
hypofractionation	 and	 standard	 fractionation	 groups.	 Incidences	 of	 nocturia	 (≥6	 times	 per	
night;	OR	4·94,	95%	CI	1·87–13·09;	p=0·0005)	and	incontinence	(1·52;	1·03–2·24;	p=0·04)	were	
significantly	 higher	 in	 the	 hypofractionation	 group	 than	 in	 the	 standard	 fractionation	 group.	
Stool	frequency	of	more	than	six	per	day	was	significantly	increased	with	hypofractionation	(7%)	
compared	with	standard	fractionation	(3%;	OR	2·11,	95%	CI	1·07–4·15;	p=0·034;	table	2).	
Table	 3	 presents	 the	 results	 of	 the	 univariate	 and	 multivariate	 Cox	 proportional	 hazards	 
regression	 analyses.	 Data	 for	 smoking	 was	 missing	 for	 20%	 of	 patients	 and	 there	 was	 no	
information	about	the	duration	of	smoking,	hence	smoking	was	not	included	in	the	univariate	
analyses.	In	a	multivariate	analysis	including	prognostic	factors	and	treatment	group,	cumulative	
grade	2	or	worse	acute	genitourinary	toxicity	(HR	2·51,	95%	CI	1·98–3·17;	p<0·0001),	age	older	
than	70	years	(1·56,	1·26–1·93;	p<0·0001),	and	the	use	of	adjuvant	hormonal	therapy	(1·36,	1·07–
1·74;	p=0·012)	were	independently	significantly	associated	with	increased	cumulative	incidence	
of	grade	2	or	worse	late	genitourinary	toxicity.	In	a	multivariate	analysis	for	late	gastrointestinal	
toxicity,	cumulative	grade	2	or	worse	acute	gastrointestinal	toxicity	(HR	2·75,	95%	CI	2·02–3·73;	
p<0·0001)	 and	 treatment	 group	 3	 (seminal	 vesicles	 treated	 to	 the	 prescribed	 dose)	 versus	 1	
(=10%	risk	of	seminal	vesicle	involvement;	1·65,	1·02–2·67;	p=0·042)	were	significantly	associated	
with	 increased	cumulative	 incidence	of	grade	2	or	worse	 late	gastrointestinal	toxicity.	Table	4	
shows	all	 symptoms	 that	are	 significantly	 associated	with	prognostic	 factors	 identified	 in	 the	
multivariate	analyses	for	both	late	genitourinary	and	gastrointestinal	toxicity.	
Figure	 3	 shows	 the	 results	 of	 post-hoc	 analyses	 to	 assess	 the	 heterogeneity	 of	 the	 effect	 of	
hypofractionation	across	subgroups	of	the	risk	factors	(figure	3A	for	genitourinary	toxicity	and	figure	
3B	for	gastrointestinal	toxicity).	We	noted	a	significant	interaction	effect	of	the	treatment	group	and	
prostate	volume	on	late	genitourinary	toxicity;	the	risk	was	significantly	higher	for	prostate	volume	
greater	than	50	cm³	but	not	for	prostate	volume	50	cm³	or	less	group.	For	late	gastrointestinal	toxicity	
there	were	significant	interactions	of	treatment	group	with	age	and	treatment	group.	
For	362	(46%)	of	782	assessable	patients,	172	(44%)	of	387	patient	in	the	standard	fractionation	
group	versus	190	(48%)	of	395	patients	in	the	hypofractionation	group,	a	cumulative	incidence	
of	grade	2	or	worse	late	genitourinary	toxicity	was	registered	in	clinical	record	form,	patients’	
self-assessment	questionnaires,	or	both.	For	240	(31%)	of	these	patients	(118	[31%]	in	standard	
fractionation	 vs	 122	 [31%]	 in	 hypofractionation),	 this	 toxic	 effect	 was	 reported	 in	 the	 clinical	
record	 form.	 Consequently,	 the	 addition	 of	 toxic	 effect	 scoring	 with	 patients’	 self-assessment	
questionnaires	to	clinical	record	form	scoring	resulted	in	an	overall	increased	reporting	of	toxicity	
by	16%	(14%	in	the	standard	fractionation	group	and	17%	in	the	hypofractionation	group).	For	250	
(32%)	of	patients	(109	[38%]	given	standard	fractionation	vs	141	[36%]	given	hypofractionation),	
cumulative	incidence	of	grade	2	or	worse	late	genitourinary	toxicity	was	reported	in	the	patients’	
self-assessment	 questionnaires.	 The	 difference	 in	 reported	 cumulative	 grade	 2	 or	 worse	 late	
genitourinary	toxicity	incidence	between	scoring	with	clinical	record	form	only	and	patients’	self-
assessment	questionnaires	only	was	not	significant	(McNemar’s	p	value	0·21).	For	178	(23%)	of	782	
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Standard fractionation 
group (n=387)
Hypofractionation
group (n=395)
OR (95% CI) p-value*
Late genitourinary toxicity
Drugs for pain 56	(15%) 68	(17%) 1·23	(0·84–1·81) 0·33
Interventional	
treatment	with	
proctoscopy/
colonoscopy needed 
by	mean	of	local	
anticoagulant	
treatment
9	(2%) 12	(3%) 1·32	(0·55–3·16) 0·66
Frequency	at	day	≥16	
urination/voiding
30	(8%) 40	(10%) 1·34	(0·82–2·20) 0·26
Frequency	at	day	≥	32	
urination/voiding
5	(1%) 8	(2%) 1·58	(0·51–4·87) 0·58
Frequency	at	night	4-6	
urination/voiding
75	(19%) 92	(23%) 1·26	(0·90–1·78) 0·19
Frequency	at	night	≥6	
urination/voiding
5	9	(1%) 24	(6%) 4·94	(1·87–13·09) <0·0005
Incontinency 52	(14%) 75	(20%) 1·52	(1·03–2·23) 0·04
 Late gastrointestinal toxicity
Drugs for pain 31	(8%) 32	(8%) 1·01	(0·60–1·69) 1·00
Drugs for diarrhoea 9	(2%) 6	(2%) 0·65	(0·23–1·84) 0·44
Frequency	≥	6 13	(3%) 27	(7%) 2·11	(1·07–4·15) 0·034
Use	of	pads 45	(12%) 63	(16%) 1·44	(0·96–2·18) 0·097
Incontinence	 46	(12%) 58	(15%) 1·28	(0·84–1·93) 0·29
Bleeding needing 
Argon	Plasma	
Coagulation
9	(2%) 18	(5%) 2·01	(0·89–4·52) 0·11
 
					*p	values	are	based	on	Fisher’s	exact	test.
Table 3.2 | Specific	symptoms	according	to	treatment	group
assessable	patients	(82	[21%]	given	standard	fractionation	vs	96	[24%]	given	hypofractionation),	
a	cumulative	incidence	of	grade	2	or	worse	late	gastrointestinal	toxicity	was	registered	in	clinical	
record	 form,	patients’	 self-assessment	questionnaires,	or	both.	For	141	 (18%)	of	 these	patients	
(64	 [17%]	standard	 fractionation	vs	77	 [20%]	hypofractionation),	 these	 toxicities	were	reported	
in	 the	 clinical	 record	 form.	 Therefore,	 the	 addition	 of	 patients’	 self-assessment	 questionnaires	
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Table 3.3 | Univariate	 and	 multivariate	 Cox	 proportional	 hazards	 regression	 analyses	 exploring	 the	
association	of	baseline	and	treatment-related	factors	with	the	recorded	cumulative	incidence	of	grade	2	or	
worse	late	gastrointestinal	and	genitourinary	toxicity
 Univariate*  Multivariate
HR(95% CI) P value  HR(95% CI) P value
Genitourinary toxicity
Genitourinary	toxicity	at	baseline,†	
equivalent	to	grade	≥	2
2·27(1·81-2·83) <0·001
Acute	genitourinary	toxicity,	 
grade	≥	2
2·57(2·03-3·25) <0·001 2·51(1·98-3·17) <0·0001
Age	(>70	years) 1·54(1·25-190) <0·001 1·56(2·26-1·93) <0·0001
PSA	(<20) 1·11(0·88-1·39) 0·369
Gleason	(<7) 0·69(0·55-0·87) 0·002
Tumour	stage	(T3-T4	vs	T1-T2) 1·13(0·92-1·39) 0·246
TURP 1·3(0·93-1·81) 0·145
Adjuvant	hormonal	therapy 1·24(0·99-1·55) 0·054 1·36(1·07-1·74) 0·012
Months	hormonal	therapy	use	 
before radiotherapy 
	≤2	vs	0
 >2 vs 0
1·34(1·04-1·74)
1·16(0·90-1·50)
0·260
0·026
0·248
Abdominal	surgery 1·15(0·91-1·45) 0·258
Gastrointestinal	comorbidity 1·29(	0·93-1·77) 0·138
Prostate	volume	(>50	vs	<50	cm3) 1·02(0·83-1·26) 0·842
Treatment	group	
 2 vs 1
 3 vs 1
1·27(0·96-1·69)
1·17(0·86-1·59)
0·424
0·091
0·313
1·27(0·96-1·69)
1·02(0·74-1·41)
0·868
0·099
0·897
Treatment	group	(hypofractionation	vs	
standard	fractionation)
1·16(0·94-1·43) 0·158 1·21(0·98-1·49) 0·073
Gastrointestinal toxicity
Gastrointestinal	toxicity	at	baseline,	†	
equivalent	to	grade	≥	2
3·43(1·98-6·04) <0·001
Acute	Gastrointestinal	toxicity, 
grade	≥	2
2·77(1·06-3·74) <0·001 2·75(2·02-3·	73) <0·0001
Age	(>70	years) 1·20(089-1·61) 0·224 1·16(0·86-1·56) 0·338
PSA	(<20) 0·83(0·61-1·13) 0·233
Gleason	(<7) 0·80(0·57-1·11) 0·184
Tumour	stage	(T3-T4	vs	T1-T2) 1·14(0·85-1·53) 0·387
TURP 1·03(0·62-1·69) 0·921
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Adjuvant	hormonal	therapy 1·07(078-1·46) 0·683 1·04(0·74-1·47) 0·809
Months	hormonal	therapy	use	before	
radiotherapy
	≤2	vs	0
 >2 vs 0
1·06(0·73-1·54)
1·05(0·73-1·50)
0·794
0·754
0·791
Abdominal	surgery 1·16(0·84-1·62) 0·377
Gastrointestinal	comorbidity 1·03(0·62-1·70) 0·913
Prostate	volume	(>50	vs	<50	cm3) 0·76(0·57-1·03) 0·077
Treatment	group	
 2 vs 1
 3 vs 1
1·38(0·89-2·13)
1·79(1·14-2·82)
0·008
0·155
0·012
1·31(0·84-2·04)
1·65(1·02-2·67)
0.036
0·239
0·042
Treatment	group	(hypofractionation	
vs	standard	fractionation)
1·19(0·88-1·59) 0·256 1·03(0·76-1·39) 0·860
HR=hazard	ratio.	PSA=prostate-specific	antigen.	TURP=transurethral	prostate	resection.	*Only	
significant	factors	from	the	univariate	analyses	were	included	in	the	multivariate	analyses.	†Because	
of	the	high	correlation	between	baseline	toxicity	and	acute	toxicity,	both	for	genitourinary	and	
gastrointestinal,	we	did	not	consider	baseline	toxicity	in	the	multivariate	analyses. 
for	toxic	effect	scoring	resulted	in	an	increase	of	toxicity	reporting	by	4·7	percentage	points	(5%	
in	both	groups)	compared	with	scoring	with	only	clinical	record	form	(overall	relative	increase	in	
reporting	26%).	For	73	(9%)	of	782	patients	(31	[8%]	given	standard	fractionation	and	42	[11%]	given	
hypofractionation),	the	cumulative	incidence	of	grade	2	or	worse	late	gastrointestinal	toxicity	was	
reported	by	patients’	self-assessment	questionnaires.	For	gastrointestinal	toxicity,	the	difference	
between	scoring	with	clinical	record	form	only	and	patients’	self-assessment	questionnaires	only	
was	significant	(McNemar’s	p	value	<0·0001).	
DISCUSSION 
The	 results	 of	 our	 randomised,	 phase	 3	 trial	 comparing	 hypofractionation	 with	 standard	
fractionation	 for	 patients	 with	 intermediate-risk	 and	 high-risk	 prostate	 cancer	 showed	 that	
non-inferiority	 of	 hypofractionation	 for	 late	 genitourinary	 and	 gastrointestinal	 toxicity	 could	
not	be	confirmed.	According	to	the	study	protocol,	the	included	820	patients	were	supposed	to	
prove	non-inferiority	of	hypofractionation	for	late	toxicity	with	a	power	of	84%	for	genitourinary	
and	86%	for	gastrointestinal,	considering	the	results	of	the	CKTO	dose	escalation	trial.10,12 Such 
power	percentages	are	generally	accepted	in	randomised	trials.	The	pre-defined	margin	for	non-
inferiority	in	HR	for	late	genitourinary	and	gastrointestinal	toxicity	of	8%	was	desirable	because	
of	the	importance	of	late	toxicity	for	patients.	
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Figure 3.3 | Forest	plots	of	hypofractionation	compared	to	standard	fractionation	for	grade	2	or	worse	late	
toxicities	for	(A)	genitourinary	and	(B)	gastrointestinal	in	prognostic	subgroups
HR=hazard	 ratio.	 GU=genitourinary.	 PSA=prostate-specific	 antigen.	 TURP=transurethral	 resection	 of	
prostate.	 HT=hormonal	 therapy.	 RT=radiotherapy.	 GI=gastrointestinal.	 p	 value	 is	 for	 the	 test	 of	 the	
interaction	between	the	treatment	and	a	subgroup	variable.
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In	 the	 HYPRO	 trial,	 the	 recorded	 5-year	 cumulative	 incidence	 of	 grade	 2	 or	 worse	 late	 
genitourinary	 toxicity	 was	 46%,	 which	 is	 higher	 than	 the	 5-year	 to	 7-year	 late	 genitourinary	
toxicity	reported	in	other	studies	using	a	conventional	three-dimensional	treatment	technique.12 
The	 effect	 of	 intensity	 modulated	 radiotherapy	 and	 image	 guidance	 (as	 applied	 for	 most	 
patients	 in	 the	HYPRO	study)	on	sparing	of	 the	urethra	and	 the	bladder	base	 is	probably	 low	
because	a	large	part	of	these	structures	will	unavoidably	get	high	doses,	resulting	in	a	low	effect	
on	the	incidence	of	genitourinary	toxicity.	This	is	especially	true	for	the	HYPRO	study	because	
there	were	no	planning	objectives	or	constraints	for	the	bladder	in	the	study	protocol.6 
Hormonal	 therapy	 was	 reported	 as	 significantly	 associated	 with	 higher	 incidences	 of	 late	
genitourinary	toxicity,12 which	was	confirmed	here.	66%	of	our	patients	had	hormonal	therapy,	
which	 could	 partly	 explain	 the	 higher	 late	 genitourinary	 toxicity	 incidence	 for	 standard	
fractionation	 in	 the	 HYPRO	 study.	 In	 the	 HYPRO	 trial,	 hormonal	 therapy	 was	 not	 stratified	
before	randomisation,	which	is	a	possible	limitation.	The	decision	to	use	hormonal	therapy	for	the	
patients	in	the	study	was	dependent	on	the	institutions’	policies,	but	the	same	hormonal	therapy	
protocol	had	to	be	used	 for	standard	 fractionation	and	hypofractionation.	The	median	age	of	71	
years	of	patients	 in	our	trial	 (399	patients	>70	years,	204	in	the	standard	fractionation	group	and	
195	 in	 the	 hypofractionation	 group)	 could	 also	 have	 contributed	 to	 the	 increased	 incidence	 of	
*OR (95% CI) p value
Late genitourinary toxicity
Acute	genitourinary	toxicity
		Nocturia	≥6	per	night 9·87	(2·33–41·80) <0·0001
		Day	frequency	≥12	per	day 6·04	(2·85–12·81) <0·0001
  Drugs for pain 3·41	(2·13–5·46) <0·0001
		Incontinence 2·39	(1·55–3·67) <0·0001
Age >70 years
		Nocturia	≥4	per	night 1·58	(1·11–2·23) 0·010
		Incontinence 2·16	(1·45–3·23) <0·001
Late gastrointestinal toxicity
Acute	gastrointestinal	toxicity
		Stool	frequency	≥6	per	day 3·82	(1·94–7·53) <0·0001
  Drugs for pain 4·76	(2·69–8·41) <0·0001
		Incontinence 2·55	(1·69–3·85) <0·0001
Treatment	group	(3	vs	2,	2	vs	1)
  Drugs for diarrhoea 2·23	(0·99–5·04) 0·042
	*OR=odds	ratio.
Table 3.4 | Symptoms	for	 late	gastrointestinal	and	genitourinary	toxicity	that	are	significantly	associated	
with	the	significant	prognostic	factors	identified	in	the	multivariate	analysis
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cumulative	grade	2	or	worse	late	genitourinary	toxicity,	because	being	aged	70	years	or	older	was	
found	to	be	significantly	associated	with	enhanced	incidence	of	late	genitourinary	toxicity	(table	3).	 
 
Another	contribution	to	the	high	incidence	of	late	genitourinary	toxicity	in	the	HYPRO	trial	is	the	high	
percentage	of	patients	with	baseline	genitourinary	symptoms	equivalent	to	2	or	worse	toxicity,	which	
we	found	was	significantly	associated	with	incidence	of	both	acute6	and	late	genitourinary	toxicity.	
Possibly,	patients	with	predisposing	factors	such	as	baseline	toxicity	are	less	tolerant	to	the	applied	
hypofractionation	treatment	regimen	and	need	to	be	excluded,	in	line	with	selection	criteria	for	high	
dose	rate	brachytherapy.14 
Finally,	the	use	of	patients’	self-assessment	questionnaires,	added	to	the	clinical	record	form	scoring,	
led	to	a	large	increase	in	registered	toxicity.	The	quite	low	reported	incidences	of	toxicity	in	previously	
published	series	using	only	clinical	record	form	could	be	an	underestimation	of	the	real	toxicity.6,12,15
In	multivariate	analyses,	there	was	no	significant	difference	in	grade	2	or	worse	late	genitourinary	
toxicity	 for	 hypofractionation	 (p=0·073),	 but	 the	 recorded	 cumulative	 incidence	 of	 grade	 3	 late	
genitourinary	toxicity	was	significantly	higher	 in	the	hypofractionation	group	(p=0·021).	 Incidence	
of	 grade	3	night	 frequency	of	 voiding	or	urination	 (≥six	per	night)	was	 significantly	higher	 in	 the	
hypofractionation	 group	 than	 the	 standard	 fractionation	 group	 (6%	 vs	 1%,	 respectively).	 This	
is	 considered	 a	 grade	 3	 toxicity	 and	 interferes	 negatively	 with	 quality	 of	 life	 in	 patients	 given	
radiotherapy	by	affecting	night	rest	and	daily	activities.	Incidence	of	daily	urine	incontinence	with	
use	of	pads	was	significantly	higher	in	the	hypofractionation	group	than	in	the	standard	fractionation	
group,	which	has	been	shown	previously.16–19	However,	in	these	previous	studies,	lower	fractionation	
doses	were	used.	
 
The	cumulative	incidence	of	grade	2	or	worse	late	gastrointestinal	toxicity	for	standard	fractionation	
in	this	report	(22%)	is	lower	than	the	reported	30%	for	the	39	×	2	Gy	group	of	the	previous	CKTO	
96-10	dose	escalation	trial12	which	applied	the	same	scoring	criteria.	The	majority	use	of	intensity	
modulated	 radiotherapy	 (95%)	 in	 the	 HYPRO	 trial,	 compared	 with	 12%	 in	 the	 CKTO	 study,	 the	
frequent	 use	 of	 implanted	 fiducials	 and	 daily	 set-up	 verification	 and	 correction,	 and	 the	 more	
restrictive	 constraints	 for	 rectum	 dose	 delivery	 could	 all	 have	 contributed	 to	 the	 lower	 rate	 of	
gastrointestinal	toxicity	 in	the	HYPRO	trial,	despite	the	higher	percentage	(31%	in	the	HYPRO	trial	
vs	15%	in	CKTO)	of	patients	treated	in	group	3	(treatment	of	seminal	vesicle	up	to	prescribed	dose). 
In	the	HYPRO	trial,	the	decision	to	treat	the	seminal	vesicle	to	the	prescribed	dose	was	dependent	on	the	
risk	of	seminal	vesicle	invasion	according	to	Partin’s	table,11	which	was	widely	used	in	general	practice	
at	the	time	of	designing	the	HYPRO	trial	(2006).	In	current	practice	with	the	increasing	use	of	MRI	
to	detect	invasion	of	the	seminal	vesicle,	the	use	of	Partin’s	table	can	be	avoided.	In	the	HYPRO	
trial,	stool	frequency	of	more	than	six	per	day	was	significantly	higher	in	the	hypofractionation	
group	than	in	the	standard	fractionation	group;	however,	it	was	lower	than	the	10%	for	the	39	×	2	
Gy	group	of	the	CKTO	96-10	study.12	On	the	other	hand,	the	use	of	faecal	incontinence	pads	more	
than	twice	per	week	for	patients	in	the	hypofractionation	group	is	16%	higher	than	published	
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data20	for	standard	fractionation	(12%	for	standard	group	vs	16%	for	the	hypofractionation	group). 
The	 reported	 incidences	 of	 grade	 2	 or	 worse	 late	 genitourinary	 and	 gastrointestinal	 toxicity	
for	 hypofractionated	 regimens	 show	 a	 wide	 range	 of	 variability.16–19,21,22 Although cross-trial 
compairsons	must	be	made	with	caution,	the	findings	of	the	phase	3	CHHiP	hypofractionation	
trial17	showed	much	lower	late	toxicity	after	a	follow-up	of	2	years	than	reported	here.	However,	
both	the	total	dose	and	fraction	dose	were	lower	(57–60	Gy	in	3	Gy	fractions)	than	in	the	HYPRO	
trial,	and	the	toxicity	was	derived	only	from	clinical	record	form	(physician-reported	toxicity).	
Recently,	 the	2-year	patient-reported	outcomes	 for	2100	patients	 included	 in	 the	CHHiP	 trial	
were published,23	reporting	no	differences	in	quality	of	life	between	the	applied	standard	and	
hypofractionated	 regimens.	 The	questionnaires	applied	 in	 the	CHHiP	 trial	were	quality-of-life	
measurement	instruments,	in	contrast	to	the	patients’	self-assessment	questionnaires	used	in	
the	HYPRO	trial	to	report	genitourinary	and	gastrointestinal	toxicity.6 However, these quality-of-
life	data	support	the	evidence	from	the	first	CHHiP	report17	on	toxicity	that	the	applied	fraction	
dose	and	total	dose,	in	combination	with	a	delivery	of	five	fractions	per	week,	did	not	lead	to	
increased	toxicity	in	the	hypofractionation	group	compared	with	standard	fractionation.	Long-
term	toxicity	reports	for	the	almost	3000	patients	included	in	the	CHHiP	trial	are	needed	to	fully	
assess	toxicity	for	the	applied	hypofractionation	schedule	and	the	efficacy	outcome	results	need	
to	be	available	before	final	conclusions	can	be	drawn.	The	latter	is	especially	important	because	
for	the	CHHiP	trial,	non-inferiority	in	outcome	was	planned	as	the	primary	endpoint,	whereas	
Pollack and colleagues19	 hypothesised	a	higher	 local	 control	 for	 their	hypofractionated	group	
because	of	a	presumed	higher	biological	tumour	dose,	which	could	not	be	shown.19	For	a	fraction	
dose	of	2·7	Gy	and	26	treatment	fractions,	Pollack	and	colleagues	reported	a	late	genitourinary	
toxicity	incidence	of	45%	similar	to	HYPRO	for	19	fractions	of	3·4	Gy,	and	a	slightly	lower	incidence	
for	late	gastrointestinal	late	toxicity.19	Investigators	reported	that	baseline	International	Prostate	
Symptom	 Score	 (IPSS)	 as	 correlated	 with	 higher	 incidence	 of	 late	 genitourinary	 toxicity	 (HR	
2·54).	The	IPSS	was	not	used	in	the	HYPRO	trial,	but	we	found	a	clear	correlation	between	late	
genitourinary	toxicity	and	the	presence	of	baseline	symptoms	equivalent	to	grade	2	or	worse	
genitourinary	late	toxicity	(HR	2·27	[1·81–2·83]).	Pollack	and	colleagues19 reported a higher rate 
of	late	genitourinary	toxicity	for	patients	older	than	67	years	over	5	years	(HR	1·91),	in	agreement	
with	the	increased	incidence	in	the	HYPRO	study	in	patients	older	than	70	years	(HR	1·56	[95%	CI	
1·26–1·93]).	Additionally,	in	the	high-risk	group	(treatment	of	seminal	vesicles	to	prescribed	dose,	
pelvic	nodes	to	50	Gy,	and	long-term	hormonal	therapy)	was	correlated	with	higher	rate	of	late	
genitourinary	toxicity.19	This	high-risk	group	corresponds	with	our	treatment	group	3,	which	was	
significantly	associated	with	higher	late	gastrointestinal	toxicity	(HR	1·65,	95%	CI	1·02–2·67),	but	
not	genitourinary	toxicity.	Pollack	and	colleagues	used	smaller	planning	target	volume	margins	
for	the	hypofractionation	group	and	dose	constraints	for	the	bladder	during	planning,	by	contrast	
with	the	HYPRO	trial.	In	the	HYPRO	study	we	used	the	same	margins	for	both	groups	and	did	not	
consider	dose	limiting	constraints	for	the	bladder.	
Previously	published	hypofractionation	series	used	different	fraction	and	total	doses,	different	
toxicity	scores,	generally	included	fewer	patients	than	HYPRO,	and	reported	different	length	of	
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follow-ups.16–19	All	these	factors	should	be	taken	into	consideration	when	comparing	results	of	
different	series.16,18,19	Moreover,	until	now,	patients’	self-assessment	questionnaires	had	not	been	
used	for	reporting	toxicity	in	most	published	trials.	In	this	report,	adding	patients’	self-assessment	
questionnaires	scoring	to	clinical	record	form	resulted	in	increases	in	reported	late	toxicity	of	51%	
and	26%	for	genitourinary	and	gastrointestinal,	respectively.	However,	the	use	of	only	clinical	record	
form	scoring	did	not	change	the	conclusions	regarding	non-inferiority	for	both	late	genitourinary	and	
gastrointestinal	toxicity.	
In	 the	HYPRO	trial,	 the	number	of	patients	filling	out	questionnaires	was	high,	contributing	to	an	
accurate	registration	of	(high)	toxicity	rates,	especially	because	there	was	no	imputation	of	missing	
data	used	and	all	available	data	was	analysed.	For	the	CHHiP	trial,	the	response	rate	at	2	years	was	
91%17	compared	with	96%	at	2	years	in	the	HYPRO	trial.	As	per	protocol,	we	will	continue	to	follow	up	
patients	for	10	years.	
In	this	study,	data	for	smoking	were	missing	for	20%	of	the	included	patients,	and	information	about	
the	duration	and	continuation	(pack-years)	of	smoking	was	not	collected.	In	the	univariate	analyses	
for	acute	toxicity	of	the	HYPRO	trial,6	no	significant	effect	was	found	between	smoking	and	acute	
toxicity.	Hence,	smoking	was	not	included	in	the	univariate	analyses	for	late	toxicity.	
In our previous study6	of	observed	acute	toxicity,	we	discussed	evidence	that	the	α	to	ß	ratio	for	
acute	toxicity	might	be	lower	than	the	generally	considered	value	of	10	Gy.6	The	late	toxicity	findings	
in	the	HYPRO	trial	might	also	raise	questions	about	the	validity	of	the	applied	α	to	ß	ratio	of	4–6	Gy	
for	late	toxicity7	(which	might	in	reality	be	lower)	for	comparing	conventional	with	hypofractionated	
treatment	because	the	suggested	4–6	Gy	ratio	gave	the	impression	that	the	delivered	dose	to	rectum	
and	bladder	should	be	the	same	around	the	78	Gy	in	both	groups;	the	results	of	higher	toxicity	in	
the	hypofraction	group	could	suggest	an	α	to	ß	ratio	lower	than	4	Gy.	Therefore,	researchers	should	
consider	the	possibilty	of	lower	α	to	ß	ratio	for	organ	at	risk.	
For	 both	 acute6	 and	 late	 genitourinary	 and	 gastrointestinal	 toxicity,	 non-inferiority	 of	
hypofractionation	could	not	be	confirmed.	Moreover,	the	cumulative	incidence	of	grade	3	or	worse	
late	genitourinary	toxicity	was	significantly	higher	in	the	hypofractionation	group	than	for	standard	
fractionation.	Furthermore,	we	noted	a	significant	 increase	 in	cumulative	 incidence	of	grade	2	or	
worse	acute	gastrointestinal	toxicity	in	the	hypofractionation	group.6	These	toxicity	findings	need	to	
be	considered	alongside	future	outcome	data	for	the	HYPRO	trial,	and	toxicity	and	outcome	data	for	
trials	in	progress	with	lower	fraction	doses.	In	view	of	the	strong	associations	recorded	between	late	
toxicity	and	baseline	symptoms,	age,	hormonal	therapy,	and	treatment	of	the	seminal	vesicles,	the	
hypofractionation	regimen	investigated	in	the	HYPRO	trial	might	be	best	for	a	selected	population	of	
patients.	
Toxicity	 data	 are	 not	 sufficient	 to	 influence	 routine	 clinical	 implementation	 of	 the	 tested	
hypofractionation	schedule;	the	efficacy	data	are	also	needed	before	such	adjustments	can	be	made.	
However,	 toxicity	 is	of	 increasing	 importance	when	considering	the	choice	of	 treatment	modality	
for	patients	with	prostate	cancer	because	of	the	large	variety	of	treatment	options,	which	was	why	
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both	acute	and	late	toxicity	were	considered	as	key	endpoints	in	the	HYPRO	trial.	Moreover,	because	
of	 the	 importance	 of	 toxicity	 for	 patients	 and	 clinicians,	we	 think	 that	 toxicity	 results	 should	 be	
published	as	soon	as	available	and	publication	should	not	wait	for	efficacy	results	that	have	not	yet	
been	completed.	The	toxicity	results	could	also	affect	the	design	of	new	studies	on	hypofractionated	
radiotherapy	for	prostate	cancer.	Both	for	acute6	and	late	toxicity	we	have	found	results	that	might	
question	the	validity	of	the	linear-quadratic	model	and	the	(generally)	applied	α	to	ß	ratios.	These	
findings	could	also	be	taken	into	consideration	in	the	design	of	new	trials.	
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ABSTRACT
Purpose:
To	report	clinical	outcome,	early	and	late	complications	in	264	hormone-naïve	patients	with	low	
and	 intermediate	risk	prostate	cancer	(PC)	treated	with	high-dose-rate	brachytherapy	(HDR-BT)	
and	external	beam	radiotherapy	(EBRT).	
Methods and materials:
Between	February	2000	and	July	2007,	264	patients	underwent	HDR-BT	in	combination	with	EBRT	
as	 a	 treatment	 for	 their	 low	 to	 intermediate	 risk	 PC.	HDR-BT	was	 performed	 using	 ultrasound	
based	implantation.	The	total	HDR-BT	dose	was	18	Gy	in	3	fractions	within	24	hours	with	a	6	hours	
minimum	interval.	EBRT	started	2	weeks	after	HDR-BT	and	was	delivered	in	25	fractions	of	1.8	Gy	
to	45	Gy	within	5	weeks.	
Results:
After	a	mean	follow-up	of	74.5	months,	four	patients	showed	a	PSA	progression	according	to	the	
ASTRO	definition	(1.5%)	and	eight	patients	according	to	the	Phoenix	definition	(3%).	A	biopsy	proven	
local	recurrence	was	registered	in	one	patient	(0.4%),	clinical	progression	(bone	metastases)	was	
documented	in	two	patients	(0.7%).	Seven	years	actuarial	freedom	from	biochemical	failure	(FFBF)	
was	97%,	seven	years	disease	specific	survival	(DSS)	and	overall	survival	(OS)	were	100%	and	91%,	
respectively.	Toxicities	were	comparable	to	other	series.	
Conclusions:
Treatment	with	interstitial	HDR-BT	plus	EBRT	treatment	shows	a	low	incidence	of	late	complications	
and	a	favourable	oncological	outcome	after	7	years	follow-up.
Key Words:
Prostate	cancer,	Radiotherapy,	Brachytherapy,	Toxicity.
SUMMARY
To	report	7	years	clinical	outcome	and	toxicity	
in	 264	 prostate	 cancer	 patients	 treated	
with	external-beam	radiotherapy	and	HDR-
brachytherapy	 boost.	 Brachytherapy	 dose	
was	18	Gy	in	3	fractions	followed	with
EBRT	in	25	fractions	to	45	Gy.	Eight	patients	
had	a	biochemical	 recurrence	according	 to	
Phoenix	 definition.	 Local	 recurrence	 in	 1	
patient	and	clinical	progression	in	2	patients.	
Freedom	from	biochemical	failure	was	97%.	
Toxicity	 was	 low	 and	 comparable	 to	 other	
series.
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INTRODUCTION 
External	beam	radiotherapy	(EBRT)	is	one	of	the	most	used	options	for	the	treatment	of	localized	
prostate	 cancer	 (PC).	 High	 doses	 >70	Gy	 have	 to	 be	 used	 to	 achieve	 a	 good	 local	 control,	 but	
may	 increase	 complications1,2.	 High	 dose	 conformal	 radiotherapy	 can	 also	 be	 achieved	 with	
brachytherapy.	The	use	of	HDR	brachytherapy	in	one	or	multiple	implants	as	a	boost	combined	
with	EBRT	is	advocated.	Martinez	et al.2	reported	good	results	using	two	to	three	implants	with	
fractions	of	5.5-11.5	Gy.	With	a	median	follow-up	of	8.2	years,	the	overall	survival	at	8	years	in	the	
series	of	Galalae	et	al.3	was	70%	after	40	Gy	EBRT	and	2x	15	Gy	HDR-BT	with	local	recurrence	rate	
of	6%	for	intermediate	and	high	risk	group	PC	patients.	This	combined	radiotherapy	approach	may	
enhance	the	local	control	and	decrease	complications	because	HDR-BT	creates	a	highly	conformal	
dose	of	radiation	within	the	prostate	with	a	rapid	dose	fall-off	outside.	The	HDR	boost	also	has	
a	radiobiological	advantage	gained	by	hypofractionation4.	Starting	in	2000	we	treated	hormone-
naïve	patients	with	a	low	and	intermediate	risk	PC	with	HDR-BT	as	a	boost	in	combination	with	
EBRT	to	shorten	the	overall	treatment	time	and	to	reduce	toxicity.	We	report	here	our	long	term	
results	and	toxicity.
METHODS AND MATERIALS
Patients:
Between	February	2000	and	July	2007,	264	patients	with	low	and	intermediate	risk	PC	were	treated	
with	EBRT	in	combination	with	a	HDR-BT	boost.	These	patients	had	a	stage	T1a-T2c	histologically	
proven	 PC,	 an	 initial	 Prostate	 Specific	 Antigen	 (iPSA)	 <15	 ng/ml,	 and	 a	 Gleason-score	 (GS)	 ≤7.	
Pre-treatment	evaluations	included	a	clinical	history,	physical	examination,	and	blood	laboratory	
findings.	A	bone	scan,	and	pelvic	computed	tomography	were	recommended	on	demand.	TNM	
scoring	was	according	to	the	AJCC	2003	guidelines.	Patients	with	T1b-T2a,	GS	6	and	PSA	≤10	ng/ml	
were	defined	to	have	a	low	risk	PC,	other	patients	with	one	of	more	of	the	following:	PSA	>10	ng/
ml,	GS	7,	T2b,	were	defined	to	have	an	intermediate	risk	PC.	Patients	with	a	previous	transurethral	
resection	of	the	prostate	(TURP),	lymph	nodes	metastases	or	hormonal	treatment	were	excluded.	
All	patients	were	seen	every	3	months	in	the	first	year,	and	yearly	afterwards	in	a	joined	out	clinic	
evaluation	 of	 the	 urologist	 and	 radiation-oncologist.	 A	 routine	 physical	 examination	 and	 PSA	
analysis	were	performed	(patient	characteristics	are	listed	in	table	1).
Toxicity:
All	patients	were	followed	prospectively;	they	were	asked	to	participate	in	the	collection	of	self-
administered	 European	 Organization	 for	 Research	 and	 Treatment	 of	 Cancer-Radiation	 Therapy	
Oncology	Group	prostate	toxicity	questionnaires.	Questionnaires	were	send	to	the	patients	at	time	
points;	baseline,	weekly	after	treatment	until	10	weeks,	at	3-6-12	months,	and	yearly	afterwards.
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Characteristics Value*
Patients(n) 264
Patient	factors
	Age	(y)
	Mean	 66.0	
	Pre-BT	prostate	volume(cm3)
	Mean 30
	Range 11-93
 Pre-BT IPSS 
	Mean 8.6
	Range 0-32
 T-stage
 T1a 4	(1.5)
 T1b 1(0.4)
 T1c 159(60.2)
 T2a 85(32.2)
 T2b 9	(3.4)
 T2c 3	(1.1)
	Unknown 3	(1.1)
GS 
 2+2 6	(3.2)
 2+3 9	(3.4)
 3+3 162	(83.5)
 3+4 17	(6.4)
 iPSA
	Median 6.8
 range 3-15
Abbreviations:	BT	=	brachytherapy;	IPSS	=	international	Prostate	Symptom	Score;	GS	=	Gleason	core;	
iPSA	=	initial	prostate-specific	antigen	value.
*	Data	in	parentheses	are	percentages.
Table 4.1 | Patient	characteristics
Radiation Therapy:
Treatment	consisted	of	HDR-BT	 followed	after	2	weeks	by	EBRT.	The	EBRT	 technique	consisted	
of	Computed	Tomography	(CT)	based	conformal	planning,	admitted	 in	a	5-field	technique	 in	47	
patients	(17.8%)	and	in	a	3-field	technique	in	217	(82.2%).	Total	EBRT	dose	was	45	Gy	in	25	fractions	
of	1.8	Gy	delivered	in	5	weeks.	The	planning	target	volume	(PTV)	was	the	prostate	expanded	with	
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7-10	mm	margins	to	all	directions.	HDR-BT	was	performed	using	ultrasound	guided	implantation	
and	CT	based	planning	using	the	PLATO	planning	system	and	a	192Ir-MicroSelectron	(Nucletron,	The	
Netherlands).	The	total	dose	was	18	Gy	in	3	fractions	within	24	hours	with	a	minimum	interval	of	6	
hours	between	2	fractions.	The	same	plan	was	used	to	deliver	the	consecutive	fractions.	Therefore	
a	 lateral	X-ray	was	made	before	each	fraction	to	check	the	position	of	the	catheters	relative	to	
the	implanted	markers.	Deviations	of	>3	mm	were	corrected	5.	The	PTV	was	the	prostate	without	
expanded	margins.
Oncological outcome:
The	biochemical	failure	(BF)	was	analysed	according	to	the	Phoenix	definition	(every	rise	of	PSA	≥2	
above	Nadir).	A	second	analysis	according	to	the	ASTRO	definition	has	been	done:	3	consecutive	
PSA	rises	after	Nadir	without	backdating.	Freedom	from	biochemical	failure	(FFBF)	was	defined	as	
the	percentage	of	patients	still	alive	without	evidence	of	BF.	Cause	Specific	Survival	(CSS)	registered	
mortality	due	to	PC.
STATISTICAL ANALYSIS
The	gastrointestinal	(GI)	and	genitourinary	(GU)	toxicities	were	evaluated	according	to	the	RTOG	
morbidity	 scales,	 using	 a	 combination	 of	 the	 patient	 EORTC-RTOG	 questionnaire	 information,	
and	the	RTOG	scores	from	the	physicians	notes	and	patient	charts.	Toxicities	within	90	days	after	
radiation	therapy	were	considered	acute	 toxicities,	and	considered	 late	 toxicities	after	90	days.	
Patients	with	a	BF	were	excluded	from	QoL	results	after	the	date	of	failure.	A	failure-free	survival	
(FFS)	is	defined	as	survival	from	biochemical	or	clinical	failures.	Disease	specific	survival	(DSS)	and	
overall	survival	 (OS)	were	also	measured.	The	non-parametric	variables	were	analysed	with	the	
Wilcoxon-Mann-Whitney	 test,	 and	 the	binairy	 variables	using	a	 logistic	 regression. The Kaplan-
Meier	(KM)	estimate	was	used	to	calculate	survival.	Two-tailed	tests	were	used	with	a	p	value	≤0.05	
considered	significant.	
RESULTS
The	median	 age	of	 patients	was	 66.0	 years	 (range,	 45-79).	Median	 follow-up	was	 74.5	months	
(range,	2.0-133.0	months).	Patients	contributed	with	a	median	of	13	 (range,	1-21)	EORTC-RTOG	
assessments	to	QoL	results.	All	but	13	patients	(95.1%)	contributed	with	minimal	1	QoL	assessment	
to	these	results,	and	all	but	2	patients	(99.3%)	contributed	with	a	minimum	of	1	PSA	analysis.	The	
T-stages	of	 the	patients	were:	T1a	 (1.5%),	T1b	 (0.4%),	T1c	 (60.2%),	T2a	 (32.2%),	T2c	 (1.1%),	T2b	
(3.4%),	T2c	(1.1%)	and	unknown	T	(1.1%).	The	GS	was	7	in	6%	of	the	patients	and	94%	had	a	GS	of	
6	or	less.	Median	iPSA	was	6.8	(range,	3-15	ng/ml).	The	median	number	of	needles	implanted	was	
19	(range,	12-29),	the	median	prostate	volume	was	30	cm3	(range,	11-93	cm3),	the	mean	PTV	V100	
(volume	PTV	receiving	100%	of	prescribed	dose)	was	93.4%	(range,	63.0-99.7%),	the	mean	urethra	
V120	(volume	urethra	receiving	120%	of	prescribed	dose)	was	0.0	cc	(range,	0.0-0.2	cc),	the	mean	
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rectum	V80	(volume	rectum	receiving	80%	of	prescribed	dose)	was	0.1cc	(range,	0.0-1.2	cc).	In	4	
patients	the	dose	of	the	EBRT	was	50	Gy	in	2	Gy	fractions	instead	of	the	protocol	dose	of	45Gy/1.8	
Gy,	2	patients	received	39.6	Gy	EBRT	because	of	urinary	retention.	
Survival
During	the	follow-up	30	(11.4%)	patients	died.	Cause	of	death	in	these	patients	was	in	13	patients	
(43.3%)	a	2nd	primary	tumor,	in	10	patients	(33.3%)	a	cardiovascular,	and	in	7	patients	(23.4%)	an	
intercurrent	 reason	or	natural	 cause.	 The	7	 years	OS	and	FFS	were	91%	 (C.I.	 89-93%)	and	96%	 
(92-97%),	respectively	(Fig	1).
Treatment sequelae:
Acute toxicity:
Peroperative	bladder	perforation	was	recorded	in	25	patients	(9%),	seven	patients	(2.5%)	needed	a	
Foley	catheter	during	the	first	4	weeks	after	treatment	for	at	least	4	weeks	(range,	4-27	weeks).	The	
incidence	of	grade	2	and	grade	3	acute	GU	toxicity	after	4	weeks	was	24%	and	13%,	and	decreased	
to	17%	and	3%	after	3	months,	respectively.	For	the	acute	GI	toxicity	the	percentage	of	grade	2	was	
16%,	and	4%	after	4	and	12	weeks,	respectively.	The	percentage	of	grade	3	GI	acute	toxicity	was	
3%	at	3	months.
Late toxicity:
Two	patients	underwent	a	TURP	after	HDR-BT	at	14	and	37	months	respectively	due	to	progressive	
obstructive	complaints	(0.75%).	Four	patients	needed	a	single	coagulation	therapy	because	of	a	
rectal	bleeding	 (1.5%);	all	4	were	 treated	after	 the	first	year	 following	HDR-BT.	For	 the	GU	 late	
toxicity	 registered	with	 the	RTOG-score,	 the	percentage	of	patients	with	grade	2	 toxicities	was	
6.3%	at	6	months,	and	remained	at	an	average	of	10%	afterwards.	Late	grade	3	GU	toxicities	were	
registered	 at	 an	 average	 incidence	 of	 3%.	Urinary	 retention	was	 reported	 in	 2.5%	 and	 urinary	
stricture	in	2.5%	with	a	cumulative	overall	incidence	of	grade	3	GU	toxicities	of	4.2%	(fig.	2).	The	
grade	2	GI	toxicity	was	registered	at	an	average	of	3%	during	FU;	the	percentage	of	grade	3	toxicity	
was	1.0%	(fig	3).
PSA Nadir and Bounce:
The	 PSA	 Nadir	 of	 the	 BF-free	 patients	 was	 reached	 after	 a	mean	 of	 43.5	months	 (range,	 5.5-
122.1	months)	with	a	mean	value	of	0.32	ng/ml	(range,	0.0-4.3	ng/ml).	A	Nadir	≤	1	was	reached	
after	a	mean	of	44.9	months	 (range,	5.5-122.0	months)	 in	95.0%	whilst	 in	4.9%	of	 the	patients	
the	Nadir	>	1	was	reached	 in	17.9	months	(range,	5.7-40.2	months).	Three	patients	had	a	Nadir	
above	2	without	progression	with	a	minimum	of	4	years	FU	after	treatment.		 	  
We	defined	a	PSA	bounce	as	an	increase	of	at	least	0.4	ng/ml	followed	by	any	decrease.	One	PSA	
bounce	was	recorded	in	87	patients	(33%),	20	(7.6%)	had	2	bounce	episodes,	and	6	(2.3%)	3	episodes.	
The	mean	interval	to	the	first	PSA	bounce	was	21.9	months	(range,	6.7-110.0	months),	while	the	
mean	time	to	the	second	PSA	bounce	episode	was	28.3	months	(range,	19.3-54.9	months),	and	the	
mean	time	to	the	third	bounce	was	45.0	months	(range,	32.1-64.9	months).	Of	the	patients	with	
a	BF	6	out	of	8	showed	a	PSA	bounce	at	a	median	of	23.1	months	(range,	10.8-57.4	months).	The	
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patients	with	a	bounce	reached	their	Nadir	in	a	shorter	period	of	21.0	months	than	the	non-bounce	
patients	(p=0.024).
Recurrence:
Eight	patients	met	the	condition	of	a	BF	according	to	the	Phoenix	definition,	out	of	them	4	met	the	
ASTRO	definition	as	well.	Mean	time	to	the	BF	was	48	months	(range,	21-83	months).	One	patient	
had	a	biopsy	proven	local	recurrence,	and	underwent	a	radical	prostatectomy	8	years	after	the	
treatment	with	EBRT+HDR-BT.	Bone	metastases	were	detected	in	2	patients	with	a	BF;	they	were	
treated	with	hormonal	therapy	(HT).	For	the	other	5	patients	with	BF	a	watchful	waiting	policy	was	
followed;	in	3	of	them	the	prostate	biopsies	are	still	negative	without	signs	of	distant	metastases.	
In	our	group	there	was	no	significant	difference	in	incidence	of	BF	or	FFS	between	the	low-	and	
intermediate-risk	groups.
DISCUSSION
High-dose-rate	 brachytherapy	 in	 combination	 with	 EBRT	 was	 given	 for	 localized	 low-	 and	
intermediate-risk	 PC.	 This	 group	 of	 patients	 can	 be	 treated	 with	 radical	 prostatectomy	 with	
a	 freedom	 from	 biochemical	 failure	 (FFBF)	 ranging	 from	 70-80%	 6;	 long-term	 results	 of	 the	
laparoscopic	prostatectomy	report	the	same	results	7.	EBRT	in	this	risk	group	has	a	good	oncological	
outcome	but	toxicity	is	a	major	concern	1,8.	The	majority	of	our	patients	were	low-risk	patients	with	
a	relatively	good	prognosis,	in	which	long-term	toxicity	is	a	very	important	concern.	This	is	especially	
true	with	the	new	perspectives	of	active	surveillance	policy	widely	followed	for	a	part	of	patients	
in	this	risk	group	showing	only	23-42%	of	patients	with	disease	progression	within	3-5	years	after	
diagnosis 9.	Debate	is	not	yet	settled	about	the	necessity	of	treatment	(with	its	risk	of	developing	
treatment-related	toxicity)	for	this	group.	HDR-BT	could	provide	better	sparing	of	organs	at	risk,	
while	delivering	a	higher	dose	to	the	prostate	comparable	to	a	seven-field	conformal	EBRT.	With	
the	use	of	high	dose	per	fraction	no	fraction	dose	limiting	toxicity	was	reported	using	HDR-BT	10,11.	
Because	of	the	need	for	dose	escalation	≥70	Gy	for	good	FFBF	which	increases	the	rectal	toxicities,	
the	use	of	HDR-BT	as	a	boost	could	keep	the	high	rate	of	 local	control	reached	with	EBRT	dose	
escalation,	but	decrease	rectal	toxicities.	HDR-BT	also	reduced	the	overall	treatment	time	and	is	
the	most	ultimate	conformal	therapy	without	setup	uncertainties	and	organ	motion	control	as	in	
3D-conformal	EBRT.	Furthermore	the	use	of	HDR-BT	reduced	the	irradiated	volume	because	the	
CTV	volume	equals	the	PTV	volume	without	extra	margins.	The	currently	accepted	idea	about	the	
low	α/β	ratio	of	PC, lower	than	5	for	tumor	control	probability,	makes	the	hypofractionated	HDR-BT	
more	powerful	12.
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Figure 4.2. | Radiation	Therapy	Oncology	Group	gastrourinary	(GU)	≥	grade	2	toxicity	(%).
Figure 4.1. | Overall	survival	(OS)	and	failure-free	survival	(FFS).
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Oncological outcome:  
Our	 results	 are	 similar	 to	 previous	 outcomes	 of	 HDR–BT	with	 EBRT	 in	 HT-naïve	 patients,	 showing	
excellent	FFBF	and	DSS	with	a	very	low	rate	of	urinary	and	bowel	toxicities	in	HT	naïve	patients.	Almost	
all	other	series	used	HT	in	part	of	their	patient’s	population.	Sato	et	al.4	reported	a	small	series	of	53	
hormone	naïve	patients	treated	with	EBRT	and	HDR-BT	with	a	five	year	OS	and	DSS	of	88%	and	100%,	
respectively.	Galalae	et	al.3	reported	5	year	biochemical	control	for	low	and	intermediate	risk	patients	 
of	 96%	 and	 88%,	 respectively.	 The	 cause	 specific	 survival	 (CSS)	 at	 5	 years	 was	 99%	 and	 100%,	
respectively	for	these	2	risk	groups.	About	30%	of	these	patients	received	a	short	course	of	neoadjuvant/ 
concurrent	androgen	deprivation	therapy	3.	Demanes	et	al.13	reported	a	10	year	OS	and	CSS	of	79%	
and	97%,	respectively.	Martinez	et	al.2	used	a	dose	escalation	regimen	in	intermediate	and	high	risk	 
patients	with	a	5	years	biochemical	control	of	87%	and	52%	for	low	and	high	risk	group	respectively.
Biochemical Failure:
In	patients	with	a	BF,	we	were	careful	not	to	initiate	HT	before	a	proven	clinical	recurrence.	The	
patient	with	a	proven	local	recurrence	in	the	prostate	was	successfully	treated	with	laparoscopic	
radical	 prostatectomy	 with	 an	 undetectable	 PSA	 afterwards.	 Two	 patients	 with	 proven	 bone	
metastases	started	HT	and	the	other	5	patients	with	BF	are	conservatively	followed	with	a	yearly	
biopsy	 and	 bone	 scintigram.	 In	 our	 group	 no	 differences	were	 found	 in	 oncological	 outcomes	
between	the	low	and	intermediate	risk	group.	This	may	be	because	of	the	low	incidence	of	BF	and	
the	excellent	DSS,	besides	the	 inclusion	of	 low-intermediate	risk	patients	only	where	the	doses	
have	been	given	may	be	high	enough	for	these	risk	groups.	However	we	used	the	clinical	staging	to	
Figure 4.3. | Radiation	Therapy	Oncology	Group	gastrointestinal	(GI)	grade	2	toxicity	(%).
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distinguish	low	from	intermediate	risk	group,	we	are	aware	about	the	difficulties	and	uncertainties	
of	this	staging	to	give	a	valuable	prognostic	system.	
PSA bounce:
We	defined	a	PSA	bounce	as	an	increase	of	at	least	0.4	ng/ml	followed	by	any	decrease	as	used	by	
Horwitz et al. 14	 in	his	multi-institutional	pooled	analysis.	From	the	4,839	patients	analysed,	978	
patients	(20%)	experienced	a	bounce	according	to	his	definition.	The	result	of	PSA	bounce	in	our	
group	corresponds	with	the	data	published.	Toledano	et al. 15	reported	a	rate	of	32%	of	patients	
with	a	bounce	of	at	least	0.4	ng/ml,	in	patients	treated	with	permanent	implant	brachytherapy.	In	
patients	treated	with	EBRT	and	HDR-BT	boost	the	bounce	is	not	well	defined.	Bachand	et al. 16 was 
the	first	to	report	a	rate	of	10%,	of	these	patients	with	a	bounce	using	a	high	PSA	threshold	of	2	ng/
ml.	The	majority	was	also	treated	with	HT.	We	are	the	first	reporting	the	bounce	in	this	treatment	
modality	according	to	the	currently	accepted	definition	 in	hormonal	naïve	patients.	We	did	not	
find	a	relation	between	bounce	and	age,	G-score,	T-stage,	and	PSA	level.	This	relation	was	also	not	
reported	in	the	published	literature.	Hinnen	et al. 17	reported	bounce	changes	in	patients	treated	
with 125I	implantation	monotherapy,	32%	of	the	975	analyzed	experienced	a	bounce	with	a	median	
time	to	bounce	of	18	months.	He	observed	a	better	FFBF,	DSS	and	OS	for	patients	experiencing	a	
bounce.	In	our	group	there	was	no	relation	between	bounce	and	BF,	DSS	or	OS	found.	It	is	very	
important	to	be	aware	of	this	phenomenon	before	initiating	any	HT,	especially	in	the	first	2	years	
after	radiotherapy.
Acute and late toxicities:
Compared	with	the	results	from	literature,	we	report	a	very	acceptable	and	low	rate	of	grade	≥	2	
GU	and	GI	toxicities.	Martinez	et	al.	2	reported	a	5-year	actuarial	rate	for	grade	3	and	4	toxicities	
of	8%	and	0%	for	GU	toxicities	and	0.5%	and	0.5%	for	GI	toxicities,	respectively.	Galalae	et al. 3 
reported	2%	in	terms	of	cystitis	and	4.1%	proctitis	and	6%	incontinence.	Sato	et al. 4 reported a very 
low	grade	2	GU	and	GI	toxicities	of	0%	and	3.8%,	respectively.
Demanes	et	al.18	report	results	with	long	FU	of	6.7%	and	1%	for	grade	3	and	4	for	late	GU	toxicities	
respectively.	Grade	 2	 rectal	 toxicity	 has	 been	 reported	 in	 2%,	 no	 grade	 3	 or	 4	 rectal	 toxicities	
developed18.	We	found	urinary	retention	in	2.5%	and	urinary	stricture	in	2.5%	after	7	years	with	
overall	grade	3	GU	toxicity	of	4.2%.	Late	rectal	grade	2	and	3	toxicity	after	7	years	was	registered	
in	3%	and	1%	respectively.
These	results	if	compared	to	the	results	of	EBRT	alone	and	low-dose-rate	could	indicate	a	benefit	of	
HDR-BT	boost	plus	EBRT	in	lowering	the	toxicity	depending	on	the	regimen,	dose,	and	fractionation	
used.	In	low-dose-rate	series	urinary	retention	is	reported	for	2-22%	of	the	patients.
In	general	late	GU	grade	3	toxicity	has	been	reported	in	3-9%	for	patients	treated	with	permanent-
seed	monotherapy	18,19.	Rectal	toxicity	has	been	reported	at	2-9.5%	for	grade	2,	0.5-2%	for	grade	3,	
and	0.4%	for	grade	4	at	5	year	follow-up.	Late	morbidity	for	conformal	EBRT	after	dose	escalation	
to 78 Gy has been reported by 2 trials; Peeters et al.1	 reported	 the	 toxicity	of	 the	Dutch	dose	
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escalation	trial	with	a	cumulative	incidence	of	grade	2	or	higher	GI	toxicity	of	26%	at	3	years	while	
the	incidence	of	grade	2	or	higher	GU	toxicity	was	29%	with	6%	rate	of	grade	3	GU	toxicities.	Pollack	
et al. 11	reported	the	results	of	a	randomised	dose	escalation	trial	comparing	70	Gy	versus	78	Gy	
with	an	incidence	of	grade	2	or	higher	GI	toxicity	at	6	years	of	26%	for	the	78	Gy	arm.	However	our	
good	results	for	low	and	intermediate	risk	patients	give	no	guarantee	that	the	HDR	monotherapy	
for	this	group	will	give	the	same	results,	the	increasing	evidence	that	the	HDR	monotherapy	is	safe	
and reasonable 19	gave	us	the	argument	to	stop	this	regimen	of	EBRT	plus	HDR-BT	in	2007	and	to	
start	a	monotherapy	HDR-BT	regimen	to	treat	low-	and	intermediate-risk	patients	giving	4	fractions	
of	9.5	Gy	within	36	hours.	We	have	previously	reported	our	early	experience20.	
Future
We	will	initiate	the	same	treatment	regimen	(EBRT	plus	HDR-BT)	for	a	(high)	intermediate-risk	group.
CONCLUSION:
We	reported	our	long-term	follow-up	results	of	EBRT	plus	HDR-BT	for	low-	and	intermediate-risk	
prostate	 cancer	 patients,	 in	 terms	 of	 oncological	 outcome	 and	 toxicity,	 and	we	 compared	 our	
results	with	available	 literature.	We	confirm	the	excellent	results	for	 low-	and	intermediate-risk	
PC	patients	using	EBRT	plus	HDR-BT.	We	suggest	the	use	of	less	intensive	treatment	for	this	group,	
using	monotherapy	HDR-BT.	We	also	suggest	the	treatment	of	a	higher	(intermediate)-risk	patient	
with	this	regimen	(EBRT	plus	HDR-BT)	to	decrease	the	percentage	of	late	toxicities.
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ABSTRACT
Purpose:
The	 aim	 of	 this	 study	was	 to	 systematically	 analyse	 the	 effect	 of	 catheter	 displacements	 both	
on	 target	 coverage	and	normal	tissue	 irradiation	 in	 fractionated	high	dose	 rate	 (HDR)	prostate	
brachytherapy,	 using	 a	 simulation	 study,	 and	 to	 define	 tolerances	 for	 catheter	 displacement	
ensuring	that	both	target	coverage	and	normal	tissue	doses	remain	clinically	acceptable.	Besides	
the	effect	of	 total	 implant	displacement,	also	displacements	of	 catheters	belonging	 to	selected	
template	rows	only	were	evaluated	in	terms	of	target	coverage	and	normal	tissue	dose,	in	order	
to	analyse	 the	 change	 in	dose	distribution	as	a	 function	of	 catheter	dwell	weight	and	catheter	
location.	
Material and methods:
Five	 representative	 implant	 geometries,	 with	 17	 catheters	 each,	 were	 selected.	 The	 clinical	
treatment	 plan	 was	 compared	 to	 treatment	 plans	 in	 which	 an	 entire	 implant	 displacement	 in	
caudal	direction	over	3,	5,	7	and	10	mm	was	simulated.	Besides,	treatment	plans	were	simulated	
considering	a	displacement	of	either	the	central,	most	ventral	or	most	dorsal	catheter	rows	only,	
over	5	mm	caudally.
Results:
Due	to	displacement	of	the	entire	implant	the	target	coverage	drops	below	the	tolerance	of	93%	
for	all	displacements	studied.	The	effect	of	displacement	of	the	entire	implant	on	organs	at	risk	
strongly	depended	on	 the	patient	anatomy;	e.g.	 for	80%	of	 the	 implant	geometries	 the	V80	of	
the	rectum	exceeded	its	tolerance	for	all	displacements.	The	effect	of	displacement	of	catheters	
belonging	to	selected	template	rows	depended	strongly	on	the	relative	weight	of	each	catheter	
row	when	considering	the	target	coverage	and	on	its	location	when	considering	the	dose	in	the	
organs	at	risk.
Conclusion:
This	 study	 supports	 the	 need	 for	 a	 check	 of	 the	 catheter	 locations	 before	 each	 fraction	 and	
correction	of	deviations	of	the	catheter	position	exceeding	3	mm.
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INTRODUCTION
The	use	of	high	dose	rate	 (HDR)	brachytherapy,	either	as	a	boost	after	external	beam	 irradiation	
or	 as	monotherapy	 for	 early	 stage	 prostate	 cancer	 patients	 is	 increasing	 worldwide	 1-6.	 General	
recommendations	 on	 how	 to	 perform	 HDR	 temporary	 brachytherapy	 for	 prostate	 cancer	 can	
be	 found	 in	Kovács	et	al.7.	HDR	 temporary	brachytherapy	offers	 several	advantages	over	 the	use	
of	permanent	low	dose	rate	seeds	from	a	practical,	physical	and	biological	point	of	view1,	e.g.	the	
reduced	radiation	hazard	because	of	the	use	of	remotely	controlled	afterloading,	the	ability	of	dose	
optimization	by	dwell	time	optimization	and	the	increased	effectiveness	of	a	high	dose	per	fraction	
due	 to	a	 low	α/β	 ratio.	HDR	brachytherapy	usually	 is	a	 fractionated	 treatment,	with	 the	number	
of	fractions	varying	between	two	and	five.	Therefore	needle	displacement	between	fractions	can	
occur,	which,	if	not	corrected,	can	influence	the	dose	distribution	drastically	3,8-13.	By	checking	(using	
ultrasound	(US),	computed	tomography	(CT)	or	fluoroscopy)	and	subsequently	adjusting	the	needle	
positions	before	each	fraction,	these	deviations	can	be	corrected.	
After	several	years	of	applying	HDR	brachytherapy	as	a	boost	 in	combination	with	external	beam	
irradiation	14,	we	embarked	on	HDR	monotherapy	recently.	 In	our	institute	HDR	brachytherapy	as	
monotherapy	is	performed	using	US	guided	implantation	and	CT	guided	treatment	planning,	which	
is	similar	to	the	procedure	used	for	the	boost	treatment,	as	described	earlier	15.	The	total	dose	is	38	
Gy	delivered	in	4	fractions	within	36	hours,	according	to	the	protocol	proposed	by	Martinez	et	al.3.	
Over	this	period	of	36	hours	a	displacement	of	the	implant	in	caudal	direction	is	sometimes	observed.	
Therefore,	a	lateral	X-ray	is	made	before	each	fraction	to	check	the	position	of	the	tip	of	the	catheters	
relative	to	 implanted	markers	using	a	set-up	protocol.	The	position	of	the	catheters	 is	adjusted	 if	
needed	by	 pushing	 the	 catheters	 to	 the	 planned	depth	 as	 indicated	 by	 their	 position	 relative	 to	
the	markers.	Analysis	of	the	first	45	patients	treated,	revealed	that	in	11	out	of	these	45	patients,	
a	catheter	displacement	before	one	or	more	fractions	was	detected	and	corrected.	However,	this	
procedure	is	time	consuming	and	we	decided	to	define	the	limits	for	implant	displacement	to	ensure	
that	target	coverage	and	normal	tissue	irradiation	would	remain	within	clinical	tolerances.
In	 the	 literature,	 clinically	 encountered	 displacements	 8,13	 and	 corresponding	 effects	 on	 dose	
distribution	are	discussed	3,9-12,16.	The	majority	of	these	papers	discuss	the	dose	degradation,	focusing	
on	the	decrease	in	target	coverage,	in	relation	to	the	clinically	encountered	implant	displacements.	
Simnor	et	al.	also	analysed	the	changes	in	dose	in	organs	at	risk,	i.e.	rectum	and	urethra12.	However,	
this	study	only	discussed	the	clinically	observed	implant	displacements	and	did	not	analyse	the	effect	
as	a	function	of	 increasing	implant	displacement.	Tiong	et	al.11	 is	the	only	one	who	systematically	
studied	the	effect	of	 implant	displacement	on	the	dose	distribution	by	simulating	the	decrease	in	
target	coverage	and	tumor	control	probability	(TCP)	as	a	function	of	implant	displacement.	However,	
the	effect	on	the	dose	in	organs	at	risk	was	not	evaluated.
The	aim	of	this	study	is	to	systematically	analyse	the	effect	of	catheter	displacements	both	on	
target	 coverage	 and	 normal	 tissue	 irradiation	 using	 a	 simulation	 study,	 in	 order	 to	 establish	
tolerances	for	catheter	displacement	ensuring	that	both	target	coverage	and	normal	tissue	doses	
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remain	clinically	acceptable.	Besides	the	effect	of	total	implant	displacement,	also	displacements	
of	catheters	belonging	to	selected	template	rows	are	evaluated	in	terms	of	target	coverage	and	
normal	tissue	dose.	
MATERIALS AND METHODS
Five	representative	implant	geometries,	with	17	catheters	each,	were	selected	because	presently	
most	 of	 our	 patients	 are	 treated	 with	 an	 implant	 consisting	 of	 17	 catheters,	 resembling	 the	
geometry	proposed	by	Mate	et	al.	17.	The	clinical	target	volume	(CTV)	was	defined	as	the	prostate	
without	margin;	no	planning	target	volume	(PTV)	to	CTV	margin	has	been	used.	The	mean	CTV,	
as	measured	on	postimplant	CT,	covered	by	the	implants	used	for	this	study	was	59.1	cc	(range	
48.5	–	69.9	cc).	The	mean	delineated	rectum	(delineated	from	the	lower	border	of	the	SI	joint	to	
the	anal	ring)	and	urethra	(as	delineated	from	the	outer	contour	of	the	inserted	Foley	catheter	from	
the	urethro-bladder	point	to	3	cm	under	the	prostate)	volumes	were	102.9	cc	(range	76.3	–	134.0	
cc)	and	2.7	cc	(range	2.3	–	3.2	cc),	respectively.	A	clinical	treatment	plan	was	calculated,	taking	into	
account	the	following	constraints	for	target	and	organs	at	risk:	prostate	D90	>	9.5	Gy,	V100	>	93%,	
rectum	V80	<	1	cc,	bladder	V80	<	1	cc,	urethra	V120	<	1%.	
The	clinical	treatment	plan	(Figure	1A)	was	compared	to	treatment	plans	in	which	an	entire	implant	
displacement	 in	caudal	direction	over	3,	5,	7	and	10	mm	was	simulated	(Figure	1B).	 In	this	case	
all	dwell	positions	were	translated	over	3,	5,	7	and	10	mm	in	caudal	direction	along	the	catheters	
relative	to	the	delineated	target	and	organs	at	risk.	The	dwell	times	were	kept	according	to	the	
clinical	treatment	plan	and	the	dose	distribution	was	evaluated	in	terms	of	target	coverage	and	
dose	to	organs	at	risk.
Besides,	treatment	plans	were	simulated	in	which	a	displacement	of	catheters	belonging	to	selected	
template	 rows	was	present,	 in	order	 to	 evaluate	 the	degradation	of	 the	dose	distribution	as	 a	
function	of	catheter	dwell	weight	and	catheter	location.	In	this	simulation	two	neighbouring	rows	
were	displaced	concurrently	in	order	to	predict	critical	factors.	In	the	case	of	the	most	ventral	or	
dorsal	catheters	this	situation	could	be	representative	for	a	tilt	of	the	template.	For	this	simulation	
a	 displacement	 of	 5	mm	was	 chosen,	 as	most	 of	 our	 clinically	 encountered	 displacements	 are	
on	the	order	of	5	mm.	In	this	case	only	dwell	positions	of	selected	catheters	were	translated	in	
caudal	direction	along	the	catheters	 relative	to	 the	delineated	target	and	organs	at	 risk.	Again,	
the	dwell	times	of	all	dwell	positions	were	kept	according	to	the	clinical	treatment	plan	and	the	
dose	distribution	was	evaluated	in	terms	of	target	coverage	and	dose	to	organs	at	risk,	taking	into	
account	the	dwell	weight	and	the	locations	of	the	selected	catheters.	This	situation	is	illustrated	in	
figure	1C	with	a	displacement	of	the	two	most	dorsal	catheter	rows.
All	 clinical	 treatment	 plans	 as	well	 as	 simulated	 treatment	 plans	were	 calculated	 on	 Plato	 BPS	
version	14.2.6	(Nucletron,	The	Netherlands)	and	assumed	a	situation	present	during	all	fractions.
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Figure 5.1 | Sagital	impression	of	the	implant	situation	during	simulations
A:	the	clinical	treatment	plan	with	all	catheters	inserted	until	the	base	of	the	prostate;
B:	virtual	displacement	of	the	entire	implant	over	3,	5,	7	and	10	mm;
C:	virtual	displacement	of	selected	catheter	rows	over	5	mm.
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RESULTS
The	tolerances	for	target	and	organs	at	risk	were	well	met	in	the	clinical	treatment	plans	(table	1).	
Only	for	one	patient	the	bladder	tolerance	was	not	met	(V80	=	1.35	cc).	The	change	in	target	coverage,	
rectum	V80	and	urethra	V120	is	summarized	in	table	1	and	shown	in	more	detail	for	each	patient	in	
figure	2.	The	effect	of	implant	displacement	on	the	rectum	V80	and	urethra	V120	strongly	depended	
on	the	patient	anatomy	(Figure	2B	and	2C):	the	individual	rectum	V80	increased	by	a	factor	ranging	
between	1.6	and	5.8,	the	individual	urethra	V120	by	a	factor	ranging	from	negligible	to	26.	As	expected	
the	dose	 in	 the	bladder	decreased	 rapidly	 as	 a	 function	of	 a	 caudal	 implant	displacement.	 For	 all	
patients	the	V80	bladder	became	negligible	for	an	implant	displacement	of	3	mm	or	more.	Therefore,	
the effects	of	catheter	displacements	on	the	bladder	dose	were	not	analysed	in	more	detail.
The	 effect	 of	 displacement	 of	 selected	 catheter	 rows	 is	 evaluated	 for	 the	 case	 in	 which	 two	
neighbouring	 rows	 are	 displaced	 concurrently	 in	 order	 to	 predict	 critical	 factors.	 In	 figures	 3	
and	4,	 the	 location	of	the	two	displaced	rows	 is	depicted	on	the	X-axis.	On	the	 left,	the	clinical	
treatment	plan	 is	 shown,	 i.e.	 the	case	without	displacement	of	any	catheter	 rows.	From	 left	 to	
right	more	dorsal	towards	more	ventral	neighbouring	rows	of	catheter	rows	are	selected.	In	figure	
3	the	dashed	 lines	present	the	target	coverage	(on	the	 left	Y-axis),	while	the	solid	 lines	present	
the	corresponding	total	dwell	weight	of	the	two	selected	catheter	rows	(on	the	right	Y-axis).	It	is	
clear	that	a	displacement	of	the	combination	of	rows	with	the	highest	weight,	i.e.	rows	1.5	and	2	
according	to	the	denomination	on	the	template	(see	sketch	in	figure	3),	results	in	the	lowest	target	
coverage.	However,	regarding	the	effect	on	the	organs	at	risk,	it	is	clear	that	the	location	of	the	two	
selected	catheter	rows	dictates	the	effect	of	a	displacement	more	than	the	weight,	i.e.	the	dorsal	
rows	for	the	rectum	(fig.	4A),	and	the	more	ventral	rows	for	the	urethra	(fig.	4B).
DISCUSSION
The	effect	of	catheter	displacements	both	on	target	coverage	and	normal	tissue	irradiation	in	HDR	
prostate	brachytherapy	was	systematically	analysed	using	a	simulation	study.	Our	results	show	that	
displacement	of	the	entire	implant	has	a	large	effect	on	the	dose	distribution.	The	target	coverage	
drops	below	the	tolerance	of	93%	for	all	displacements	studied,	i.e.	3	to	10	mm.	Therefore,	our	results	
confirm	the	conclusions	of	Tiong	et	al.	11	that	the	tolerance	of	implant	displacement	is	smaller	than	3	
mm,	in	order	to	achieve	adequate	target	coverage.	On	top	of	this	conclusion,	our	results	also	show	
that,	besides	target	coverage,	due	to	normal	tissue	tolerances	the	same	tolerance	of	3	mm	for	implant	
displacement	should	be	employed	as	for	4	of	the	5	implant	geometries	studied	the	V80	of	the	rectum	
exceeds	the	tolerance	of	1	cc.	From	this	latter	point	of	view	it	is	not	acceptable	to	employ	the	solution	
of	extension	of	the	target	volume	in	cranial	direction	by	adding	a	1	cm	margin,	as	suggested	by	Damore	
et	al.	8,	because	their	solution	does	not	solve	the	dose	increase	in	normal	tissues.	A	solution	which	
overcomes	Damore’s	shortcoming	is	suggested	by	Hoskin	et	al.9,	who	implant	catheters	1	cm	beyond	
the	base	of	the	prostate.	Both,	the	drop	in	target	coverage	and	the	overdosage	in	organs	at	risk	can	
be	corrected	simultaneously,	as	this	elegant	solution	enables	to	shift	active	dwell	positions	cranially	
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Figure 5.2 | Effect	of	total	implant	displacement	on:	(A)	target	coverage,	(B)	V80	rectum	and	(C)	V120	urethra.
Table 5.1 | The	 change	 in	 target	 coverage,	bladder	V80,	 rectum	V80	and	urethra	V120	as	 a	 function	of	
implant	displacement.
Implant 
displacement 
(mm)
Target coverage (%) V80 bladder (cc) V80 rectum (cc) V120 urethra (cc)
Mean Range Mean Range Mean Range Mean Range
0* 95.0 93.9	–	95.9 0.66 0.24	–	1.35 0.6 0.4	–	0.7 0.02 0.01	–	0.03
3 91.4 90.5	–	92.4 0.02 0.00	–	0.04 1.1 0.8	–	1.3 0.03 0.01	–	0.05
5 87.2 86.1	–	87.9 0.00 0.00	–	0.00 1.5 0.9	–	1.8 0.06 0.01	–	0.10
7 82.6 81.5	–	83.1 0.00 0.00	–	0.00 1.8 1.0	–	2.2 0.10 0.02	–	0.18
10 75.3 74.4	–	75.9 0.00 0.00	–	0.00 2.4 1.0	–	3.0 0.17 0.01	–	0.33
	*:	0	mm	implant	displacement	represents	the	clinical	treatment	plan.
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Figure 5.3 | The	target	coverage	(dashed	lines	relative	to	the	left	Y-axis)	as	a	function	of	a	5	mm	displacement	
of	 two	 selected	 catheter	 rows.	At	 the	 left	 side	of	 the	X-axis	 the	 clinical	 treatment	plan,	 i.e.	 no	 catheter	
displacements;	from	left	to	right	displacement	of	the	two	most	dorsal	towards	the	two	most	ventral	catheter	
rows.	The	solid	lines	depict	the	corresponding	dwell	weights	of	the	two	selected	catheter	rows	(on	the	right	
Y-axis).	The	marked	displacements	and	weights	correspond	to	the	marked	rows	in	the	template	diagram.
to	compensate	implant	displacement	without	the	necessity	to	manipulate	catheters.	A	drawback	of	
this	method	in	our	view	is	that	catheters	are	implanted	deeper	than	necessary,	although	the	authors	
state	that	this	can	be	done	without	additional	bladder	morbidity.
Several authors 8,11,12	use	a	margin,	e.g.	3	mm,	between	clinical	target	volume	(CTV)	and	planning	
target	volume	(PTV).	A	CTV	to	PTV	margin	is	an	appropriate	method	to	ensure	adequate	target	
coverage	in	presence	of	implant	displacement.	However,	it	is	not	a	solution	for	the	dose	increase	in	
surrounding	normal	tissues	due	to	implant	displacements.	In	case	implant	displacements	are	well	
controlled,	a	CTV	to	PTV	margin	is	not	necessary	to	achieve	adequate	target	coverage,	which	is	a	
clear	advantage	over	external	beam	radiotherapy	and	even	stereotactic	radiotherapy	18-20.	
The	range	of	displacements	studied	are	well	representative	for	the	ones	clinically	encountered.	In	
the	literature	mean	implant	displacements	up	to	10	mm	are	frequently	mentioned	3,8-13 depending 
on	 implantation	 technique	 but	 also	 varying	 along	 the	 treatment	 course.	 In	 general	 the	 largest	
displacements	occur	in	the	beginning	of	the	treatment	course.	Occasionally	a	single	patient	with	
an	 implant	 displacement	 up	 to	 30	mm	 is	 detected,	 necessitating	 corrective	 action.	 In	 general,	
displacements	encountered	in	our	institute	are	in	the	order	of	5	mm.
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Although	most	papers	concentrate	on	the	decrease	of	target	coverage	due	to	implant	displacement,	
Simnor	et	al.	also	included	a	discussion	on	the	dose	increase	in	surrounding	normal	tissues	as	rectum	
and	urethra	due	to	clinically	observed	implant	displacements	12.	They	conclude	that	the	rectum	and	
urethra	volume	receiving	the	tolerance	dose	increases	on	average	with	an	amount	of	0.4	to	0.7	cc	
with	a	large	interpatient	and	interfraction	variability.	In	their	study	a	CT	scan	was	made	before	each	
fraction.	A	limitation	was	that	target	and	organs	at	risk	were	delineated	retrospectively	on	each	of	
these	CT	scans.	This	introduced	an	unknown	variation	in	organ	definition	leading	to	inaccuracies	
in	their	results.	A	similar	interpatient	variability	is	also	seen	in	our	simulation	study.	However,	our	
current	study	concerns	a	more	systematic	analysis	of	the	dose	increase	in	organs	at	risk	using	a	
simulation,	including	a	varying	implant	displacement	and	a	single	delineation	of	target	and	organs	
at	risk.	On	top	of	the	interpatient	variability	we	also	demonstrated	the	increasing	dose	degradation	
due	to	an	increasing	implant	displacement.
 
Figure 5.4 | The	V80	rectum	(A)	and	V120	urethra	(B)	as	a	 function	of	a	5	mm	displacement	of	selected	
catheter	rows.	At	the	left	side	of	the	X-axis	the	clinical	treatment	plan,	i.e.	no	catheter	displacements;	from	
left	to	right	displacement	of	the	two	most	dorsal	towards	the	two	most	ventral	catheter	rows.	
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The	discussion	on	the	dosimetric	effects	due	to	implant	displacement	should	be	viewed	in	relation	
to	 other	 uncertainties	 in	HDR	brachytherapy,	 leading	 either	 to	 systematic	or	 random	errors	 in	
dose	delivery,	 as	 discussed	by	 Elfrink	 et	 al.21.	 A	 typical	 systematic	uncertainty	 in	HDR	prostate	
brachytherapy	is	discussed	by	Kim	et	al.22,	i.e.	the	dose	inaccuracy	due	to	the	uncertainty	in	needle	
tip	localisation	as	a	function	of	the	CT	slice	thickness.	This	simulation	study	including	both	random	
as	well	as	systematic	deviations	in	needle	tip	localisation	revealed	that	a	slice	thickness	of	3	mm	is	
a	good	compromise,	minimizing	the	needle	tip	localisation	error	without	increasing	the	number	of	
slices.	This	recommended	3	mm	slice	thickness	is	very	similar	to	the	proposed	3	mm	tolerance	for	
implant	displacement	as	both	introduce	a	discrepancy	or	inaccuracy	in	the	needle	position	relative	
to	target	and	normal	tissues.	Prostate	volume	changes,	frequently	discussed	in	permanent	seed	
implants	because	of	 its	effects	on	 the	dosimetry,	are	much	smaller	 in	 temporary	HDR	prostate	
brachytherapy	due	to	the	short	time	course	3,23.	Another	source	of	inaccuracy	in	dosimetry	is	due	
to	the	inaccuracy	in	prostate	delineation.	CT	based	treatment	planning	for	prostate	brachytherapy	
is	 known	 to	 have	 a	 larger	 contouring	 variability	 as	 compared	 to	 magnetic	 resonance	 imaging	
(MRI)-	or	transrectal	ultrasound	(TRUS)-based	planning24.	When	using	TRUS-	in	combination	with	
CT-based	treatment	planning	dosimetric	effects	because	of	implant	deformation	due	to	posture	
changes	were	observed	by	Seppenwoolde	et	al.25.	It	was	shown	that	the	dose	distribution	changed	
dramatically	when	shifting	from	a	TRUS	patient	set-up	to	a	CT	patient	set-up	influencing	both	target	
as	well	as	dose	in	organs	at	risk.
In	general,	most	displacements	concern	a	total	 implant	displacement.	Displacement	of	selected	
catheters	 due	 to	 sliding	 in	 the	 template	 is	 not	 likely	 to	 occur.	 However,	 due	 to	 tilting	 of	 the	
template	caused	by	tilting	of	the	pelvis,	it	is	possible	that	selected	pairs	of	catheter	rows	exhibit	
a	displacement	relative	to	the	target	and	organs	at	risk.	This	effect	of	displacement	of	selected	
catheters	has	not	been	evaluated	before.	We	have	analysed	the	effects	of	displacements	of	selected	
catheter	rows	in	order	to	predict	critical	factors.	As	expected,	displacement	of	catheter	rows	with	
a	higher	total	dwell	weight	has	the	largest	effect	on	target	coverage.	Usually,	these	are	the	2nd and 
3rd	row	dorsally.	With	the	most	dorsal	row	having	a	relatively	low	catheter	weight	one	can	expect	
that	a	tilt	with	a	caudal	displacement	of	dorsal	 rows	 is	expected	to	have	a	 large	effect.	Usually	
ventral	rows	have	a	low	catheter	weight,	thus	a	relatively	small	effect	on	target	coverage	due	to	
displacements,	and	a	negligible	effect	on	rectum	dose.	Therefore,	one	could	decide	not	to	correct	
displacement	of	these	ventrally	located	catheters	if	the	urethra	dose	is	not	too	critical.	However,	
due	to	target	coverage	degradation	and	overdosage	of	the	rectum	one	should	always	be	reluctant	
not	to	correct	more	dorsally	 located	catheters.	The	implant	method	that	has	demonstrated	the	
least	displacement	in	fractionated	therapy,	enabling	to	speed-up	the	procedure	by	avoiding	the	
necessity	 of	 a	 check	 of	 the	 implant	 position	 before	 each	 fraction,	 is	 the	 use	 of	 self-anchoring	
catheters16.	Pieters	et	al.	show	that	the	mean	implant	displacement	during	a	3	day	treatment	was	
limited	to	1.2	mm,	resulting	in	minor	alterations	in	the	dose	distribution	which	were	of	no	clinical	
importance.	We	have	the	intention	to	introduce	this	type	of	catheters	in	our	procedure	to	be	able	
to	skip	the	imaging	before	each	fraction	and	keep	doses	within	clinical	tolerances.
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CONCLUSION
This	 study	 supports	 the	 need	 for	 a	 check	 of	 catheter	 locations	 before	 each	 HDR	 prostate	
brachytherapy	fraction	and	correction	of	deviations	of	the	catheter	position	exceeding	3	mm,	not	
only	because	of	target	coverage	degradation,	but	also	to	avoid	an	overdosis	in	organs	at	risk.	The	
results	support	the	development	and	use	of	self-anchoring	catheters.
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Chapter 6: Clinical influence of displacement correction in HDR-brachytherapy for prostate cancer
ABSTRACT
Background and purpose:   
In	fractionated	high-dose-rate	brachytherapy	(HDR-BT)	for	prostate	cancer	(PCa)	with	one	implant	
for	several	fractions,	dose	delivery	relies	on	reproducibility	of	catheter	positions.	However,	caudal	
displacement	of	implanted	catheters	does	occur	between	fractions	and	needs	to	be	corrected.	Our	
protocol	prescribes	 correction	of	displacements	>3mm.	We	 investigated	whether	displacement	
and	its	corrections	influence	acute	and	late	toxicity	incidences.	
Methods and Materials:   
We	 analyzed	 162	 PCa	 patients	 treated	 with	 HDR-BT	 monotherapy	 between	 2007	 and	 2013.	
The	 implant	 remained	 in	 situ	 between	 the	 four	 fractions.	 Catheter	 displacement	was	 assessed	
before	each	fraction	using	lateral	X-ray	images	and	corrected	if	needed.	Genitourinary	(GU)	and	
gastrointestinal	(GI)	acute	and	late	toxicities	were	assessed	using	clinical	record	forms	and	patient	
self-assessment	questionnaires.
Results:   
Implant	 displacement	 corrections	 (DC)	 were	 needed	 in	 71	 patients	 (43.8%)	 whereas	 no	 
displacement	 corrections	 (NDC)	were	needed	 in	 91	patients	 (56.2%).	No	 statistically	 significant	
differences	were	seen	in	acute	and	late	grade	≥2	GU	and	GI	toxicity	incidences	between	DC	and	
NDC	 groups.	 The	maximum	displacement	 nor	 the	number	 of	 corrections	 had	 any	 influence	on	
toxicity.
Conclusions:   
The	 occurrence	 and	 subsequent	 correction	 of	 implant	 displacements	 exceeding	 3mm	 during	
fractionated	HDR-BT	monotherapy	for	PCa	did	not	lead	to	increased	incidences	of	acute	or	late	GU	
and	GI	toxicity.	This	indicates	that	our	clinical	protocol	to	correct	displacements	>3mm	results	in	
safe	treatment	regarding	organ	at	risk	toxicity.
SUMMARY
Catheter	 displacements	 in	 high-dose-rate	 
brachytherapy	 (HDR-BT)	 for	 prostate	
cancer	 need	 to	 be	 corrected	 if	 exceeding	
3mm	to	ensure	accurate	dose	delivery.	The	
clinical	 effect	 of	 displacement	 correction	
on	 genitourinary	 and	 gastrointestinal	
toxicity	 incidences	 was	 evaluated	 in	 162	
patients	treated	with	HDR-BT.	No	significant	
differences	 were	 seen	 in	 acute	 and	 late	
toxicity	incidences	between	patients	with	and	
without	the	need	for	displacement	correction.	
The	maximum	displacement	or	 the	number	
of	 corrections	 did	 not	 influence	 toxicity	 
either.
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INTRODUCTION
High-dose-rate	 brachytherapy	 (HDR-BT)	 is	 a	 safe	 and	 effective	 treatment	 option	 for	 low-	 and	
intermediate-risk	 prostate	 cancer	 (PCa)	 and	 has	 been	 increasingly	 used	 as	 monotherapy	 1-3.	
From	a	dosimetric	point	of	view,	HDR-BT	is	an	ideal	technique	enabling	intensity	modulation	and	
individual	 adaptation	 of	 the	 dose,	 resulting	 in	 a	 highly	 conformal	 treatment	 with	 an	 excellent	
dose	distribution	in	the	target	and	rapid	dose	fall-off	outside	 4.	 In	case	HDR-BT	monotherapy	 is	
delivered	in	several	fractions	(mainly	2-6	fractions)	in	a	short	period	of	time	using	one	implant	1,5, all 
dosimetric	advantages	rely	on	accuracy	and	reproducibility	of	the	position	of	the	catheters	before	
each	fraction.	Even	though	catheters	are	fixated	to	the	template	and	the	template	is	sutured	to	the	
patients	skin,	the	implant	can	displace	between	fractions.	Since	the	same	treatment	plan	is	used	
for	all	fractions,	displacements	can	result	in	changes	in	the	delivered	dose	to	the	target	and	organs	
at	 risk	 (OAR).	Several	papers	have	addressed	catheter	displacement6-12.	All	 these	series	 showed	
that	displacement	of	 catheters	 (usually	occurring	 in	 caudal	direction)	needs	 to	be	 corrected	 to	
ensure	 good	 target	 coverage	 and	 avoid	 overdosing	OAR.	 The	 clinical	 consequence	 of	 catheter	
displacement	and	its	correction,	however,	is	lacking	in	literature.	
Our	earlier	simulation	study	showed	that	catheter	displacements	of	more	than	3mm	resulted	in	
target	coverage	degradation	and	overdosing	OAR	10.	Based	on	these	findings,	we	implemented	a	
protocol	in	our	clinical	practice	to	check	catheter	positions	and	correct	displacements	exceeding	
3mm	before	delivering	each	fraction.	The	purpose	of	this	study	was	to	assess	our	hypothesis	that	
optimal	correction	of	catheter	displacement	will	keep	the	dosimetric	parameters	at	the	planned	
levels	and	that	no	effect	of	 the	corrected	displacements	on	toxicity	 incidences	 is	expected.	We	
analysed	 whether	 catheter	 displacement	 and	 its	 correction	 before	 each	 fraction	 in	 HDR-BT	
monotherapy	for	low-	and	intermediate-risk	PCa	influence	acute	and	late	toxicity	incidences.
METHODS AND MATERIALS
Patients
The	patient	population	of	the	present	study	is	a	subset	of	162	patients	from	the	population	in	our	
previous study3 for	which	data	on	implant	displacement	and	correction	before	each	fraction	was	
available.	Patients	with	histologically	confirmed	PCa,	clinical	stage	T1b-T2b,	Nx-0,	Mx-0,	Gleason	
score	≤7,	PSA	≤16	ng/ml	and	WHO	performance	status	of	0-2	were	eligible	for	HDR-BT	monotherapy	
and	were	treated	between	September	2007	and	December	2013.	From	2011	on,	patients	with	IPSS	
score	>18	were	no	longer	eligible.	Other	exclusion	criteria	were	prior	transurethral	resection	of	the	
prostate,	prostate	volume	>50ml	on	transrectal	ultrasound,	prior	radiotherapy	or	surgery	in	the	
pelvic	area	and	the	concomitant	use	of	androgen	deprivation	therapy.	TNM	scoring	was	according	
to	the	AJCC	2003	guidelines13.	Patient	characteristics	of	all	patients	 included	 in	the	analysis	are	
shown	in	Table	1.
Processed on: 28-9-2016
505259-L-bw-Aluwini
92
Chapter 6: Clinical influence of displacement correction in HDR-brachytherapy for prostate cancer
Radiotherapy
HDR-BT	monotherapy	with	a	total	dose	of	38	Gy	was	administered	in	four	fractions	of	9.5	Gy	with	
a	minimum	interval	of	six	hours	between	fractions.	All	fractions	were	delivered	within	36	hours	
according	to	one	treatment	plan	and	using	one	implant.	The	first	two	fractions	were	delivered	on	
the	day	of	the	implant,	the	last	two	the	next	day.	The	procedures	for	implantation	and	planning	
have	been	described	previously	in	more	detail	3,10,14.	In	short,	6F	plastic	needles	(ProGuide;	Elekta,	
Sweden)	were	 implanted	 template-based	using	 transrectal	ultrasound	 imaging	with	 the	patient	
under	 spinal	 anaesthesia	 and	 in	 lithotomy	 position.	 Treatment	 planning	 was	 performed	 with	
PLATO	 up	 to	 2009	 and	 Oncentra	 Brachy	 (Elekta,	 Sweden)	 afterwards	 based	 on	 CT	 imaging.	 A	
microSelectron	HDR	or	Flexitron	HDR	afterloader	(Elekta,	Sweden)	was	used	to	deliver	treatment.
Before	catheter	implantation,	four	markers	were	inserted:	two	at	the	base	and	two	at	the	apex	of	
the	prostate.	Immediately	after	catheter	implantation	and	the	planning	CT	scan,	a	reference	lateral	
X-ray	was	acquired	with	six	metal	dummy	sources	 inserted	 in	the	most	 lateral	placed	catheters	
in	three	rows,	 including	the	top	and	bottom	rows.	The	X-ray	tube	was	positioned	such	that	the	
catheter	tips	were	in	the	centre	of	the	image.	Before	each	fraction	a	new	lateral	X-ray	was	acquired	
using	the	same	localiser	configuration	and	patient	position	as	for	the	reference	image.
Both	the	reference	image	and	prefraction	image	were	imported	in	the	treatment	planning	system.	
Both	images	were	aligned	by	placing	a	coordinate	system	in	the	image	with	a	cranial	marker	as	centre	
point	and	the	y-axis	through	a	caudal	marker.	By	marking	the	catheter	tips	(with	dummies	inserted)	in	
both	images,	the	displacement	was	calculated.	Figure	1	shows	an	example	of	the	lateral	X-ray	images	as	
used	for	assessing	catheter	displacement.	Catheter	displacements	>3mm	were	corrected	by	manually	
adjusting	the	catheter	positions.	The	displaced	distance	was	marked	on	the	catheters,	which	were	
then	moved	until	the	marking	reached	the	template.	Subsequently,	a	second	X-ray	image	was	acquired	
to	confirm	the	correction	in	the	planning	system	(Figure	1C).	In	case	of	a	residual	displacement,	the	
above	mentioned	 procedure	was	 repeated	 until	 the	 remaining	 displacement	was	within	 1mm	 to	
ensure	a	conformal	dose	distribution10.	 In	this	method	of	checking	for	displacement,	 it	 is	assumed	
that	all	catheters	displace	the	same	distance	and	that	the	implanted	markers	do	not	migrate	through	
the	prostate.	All	patients	remained	in	bed	during	X-ray	imaging	and	dose	delivery.	The	transfer	tubes	
were	connected	just	before	the	first	fraction	and	disconnected	only	after	the	fourth	fraction.	This	way	
displacement	resulting	from	patient	transfer	and	connecting	the	transfer	tubes	was	minimized.
Data analysis  
All	patients	were	prospectively	followed	every	three	months	during	the	first	year,	and	twice	yearly	
thereafter.	Genitourinary	 (GU)	 and	 gastrointestinal	 (GI)	 toxicities	 grade	≥2	were	 assessed	using	
a	European	Organization	for	Research	and	Treatment	of	Cancer	 (EORTC)	and	Radiation	Therapy	
Oncology	Group	(RTOG)	toxicity	score	based	questionnaire	15,16.	This	self-assessment	questionnaire	
was	sent	to	all	patients	at	baseline	(before	treatment),	at	1,	2,	3,	6,	12,	18,	and	24	months	after	
treatment	and	yearly	thereafter.	Both	GU	and	GI	toxicity	were	evaluated	using	a	combination	of	
questionnaires	and	physicians	charts,	according	to	EORTC-RTOG	toxicity	scores	16,17.	The	highest	
score	of	toxicity	between	the	two	sources	was	registered.
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The	date	of	the	implantation	and	first	two	fractions	of	HDR-BT	was	considered	day	0.	Toxicity	within	
100	days	after	the	start	of	radiation therapy	(implantation	day)	was	considered	acute	toxicity,	and	
toxicity	after	100	days	as	late	toxicity.	
For	each	patient	and	each	fraction	was	recorded	whether	there	was	implant	displacement	that	needed	
correction	and,	if	applicable,	the	extend	of	the	displacement	correction.	To	determine	the	effect	of	
displacement	 correction	 on	 toxicity,	 several	 groups	were	 statistically	 compared.	 First,	 the	 group	
with	no	displacement	corrections	(NDC)	was	compared	to	the	group	with	displacement	corrections	
(DC).	The	NDC	group	consisted	of	patients	who	had	no	displacements	exceeding	3mm	during	all	four	
fractions.	The	DC	group	comprised	patients	in	whom	a	displacement	>3mm	occurred	that	needed	to	
be	corrected	before	one	or	more	fractions.	Within	the	DC	group,	the	total	number	of	displacement	
corrections	during	all	four	fractions	was	taken	into	account	and	a	comparison	was	made	between	
only	one	correction	before	one	fraction	and	corrections	before	more	than	one	fraction.	
The	 DC	 group	 was	 also	 stratified	 according	 to	 the	 maximum	 corrected	 displacement	 over	 all	
fractions	to	analyse	differences	in	toxicity.	Patients	with	maximum	displacement	corrections	up	to	
Table 6.1. | Patient	and	tumour	characteristics
n (%) Median (IQR)
Patients 162
Age	(yr) 68.9	(62.7-72.7)
Clinical T-stage T1c 110	(67.9%)
T2a 50	(30.9%)
T2b 2	(1.2%)
Gleason score 2+2 1	(0.6%)
2+3 1	(0.6%)
3+3 140	(86.4%)
3+4 19	(11.7%)
4+3 1	(0.6%)
PSA	(ng/ml) 7.9	(5.6-9.8)
IPSS baseline score 5	(3-10)
Urinary	flow	baseline	(Qmax;	ml/s) 14.5	(10.3-20.5)
Number	of	needles 17	(15-18)
PTV	volume	(cm3) 59.5	(48.8-68.2)
					Note:	IQR	=	interquartile	range
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5mm	were	compared	to	those	with	corrections	>5mm.	An	overview	of	all	analysed	groups	and	the	
number	of	patients	per	group	is	presented	in	Table	2.
Statistical	significance	of	differences	in	acute	toxicity	between	groups	was	tested	using	Pearson’s	
Chi-squared	test.	To	compare	the	incidence	rates	of	late	toxicity	the	log-rank	test	was	applied.	To	
analyse	the	effect	of	multiple	factors	on	late	toxicity	a	Cox	regression	analysis	was	performed.	Two-
tailed	tests	were	used	and	p-values	≤0.05	were	considered	significant.	Statistical	analyses	were	
performed	using	IBM	SPSS	Statistics	v21.0	(IBM	Corp).
RESULTS
In	91	patients	(56.2%)	no	catheter	displacement	corrections	(NDC)	were	needed,	whereas	 in	71	
patients	 (43.8%)	 one	 or	 more	 catheter	 displacement	 corrections	 (DC)	 were	 performed.	 In	 56	
(78.9%)	of	the	DC	patients	a	displacement	correction	before	one	of	the	four	fractions	was	done,	
whereas	15	patients	 (21.1%)	needed	corrections	before	more	than	one	 fraction.	Within	 the	DC	
group	a	maximum	displacement	correction	of	>3-5mm	was	observed	in	45	patients	(63.4%)	and	
>5mm	in	26	patients	(36.6%).	The	largest	displacement	correction	performed	was	18mm,	whereas	
the	median	correction	was	5mm.	
Of	 all	 displacement	 corrections,	 3	 (3.4%)	were	 performed	 before	 fraction	 1,	 42	 (47.2%)	 before	
fraction	2,	28	(31.4%)	before	fraction	3	and	16	(18.0%)	before	fraction	4.
Acute toxicity  
Median	follow-up	was	25	months,	with	a	mean	of	35	months	and	ranging	from	2	to	78	months.	Acute	
GU	grade	≥2	toxicity	was	reported	in	33.0%	and	31.0%	of	the	NDC	and	DC	groups,	respectively.	This	
difference	between	the	groups	was	not	statistically	significant	(p=0.866).	Within	the	DC	group,	the	
Table 6.2 | Number	of	patients	per	group
Number of patients (%)
Displacement	correction
No	correction 91	(56.2%)
Correction 71	(43.8%)
Maximum	displacement	correction
>3-5	mm 45	(63.4%)
>5	mm 26	(36.6%)
Number	of	displacement	corrections
1 56	(78.9%)
>1 15	(21.1%)
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maximum	displacement	correction	and	the	number	of	corrections	did	not	show	any	statistically	
significant	effect	on	acute	toxicity	incidences.	Acute	GU	toxicity	incidences	were	37.8%	and	19.2%	
for	 >3-5mm	 and	 >5mm	 corrections,	 respectively	 (p=0.119).	 In	 patients	 with	 one	 displacement	
correction	GU	toxicity	was	reported	 in	28.6%	compared	to	40.0%	 in	 the	group	with	more	than	
one	displacement	correction	(p=0.530).	Acute	GI	grade	≥2	toxicity	was	reported	in	26.4%	of	the	
NDC	group	and	in	28.2%	of	the	DC	group	(p=0.859).	In	the	DC	group,	acute	GI	grade	≥2	toxicity	
incidences	were	26.7%	and	30.8%	for	>3-5mm	and	>5mm	corrections,	respectively	(p=0.787).	GI	
toxicity	was	reported	by	25.0%	in	the	one	displacement	correction	group	compared	to	40.0%	in	
the	group	with	more	than	one	displacement	correction	(p=0.333).	None	of	these	differences	were	
statistically	significant.	An	overview	of	acute	toxicity	per	group	is	presented	in	Table	3.
Late toxicity  
Late	GU	grade	≥2	toxicity	was	reported	by	47.7%	of	patients	in	the	NDC	group,	whereas	this	was	
31.9%	in	the	DC	group.	The	difference	between	the	groups	appeared	to	be	statistically	significant	
with	a	p-value	of	0.043.	However,	in	a	multivariable	Cox	regression	analysis	including	risk	factors	
(age,	presence	of	acute	grade	≥2	toxicity,	baseline	IPSS	score,	baseline	urinary	flow,	comorbidity,	
number	of	needles	and	prostate	volume),	the	effect	of	displacement	correction	on	the	incidence	
of	 late	GU	toxicity	was	not	statistically	 significant	 (p=0.121)	with	a	 relative	hazard	 ratio	of	0.43	
(95%	confidence	interval	0.15-1.25).	None	of	the	other	factors	in	the	regression	analysis	showed	
significant	association	with	late	GU	toxicity.
Regarding	 the	maximum	displacement	correction	and	the	number	of	displacement	corrections,	
there	were	no	statistically	significant	differences	observed	in	GU	grade	≥2	toxicity	between	the	
groups.	Cumulative	 late	GU	 toxicity	 incidences	during	 the	 follow-up	were	34.1%	and	28.0%	 for	
the	groups	with	>3-5mm	and	>5mm	correction,	respectively	(p=0.834).	In	the	group	with	only	one	
correction,	late	GU	grade	≥2	toxicity	was	reported	in	35.2%,	versus	20.0%	in	the	>1	displacement	
corrections	group	(p=0.214).
Late	GI	grade	≥2	toxicity	was	observed	in	10.2%	of	NDC	and	8.7%	of	DC	patients,	which	difference	was	
not	statistically	significant	(p=0.888).	The	maximum	corrected	displacement	did	not	have	statistically	
significant	influence	on	GI	grade	≥2	toxicity	with	11.4%	and	4.0%	for	the	groups	with	>3-5mm	and	
>5mm	correction,	respectively	(p=0.520).	In	the	group	with	only	one	displacement	correction,	late	
GI	toxicity	was	reported	in	9.3%,	versus	6.7%	in	the	group	with	more	than	one	correction	(p=0.742).	
All	 late	 toxicity	 incidences	 are	 presented	 in	 Table	 3.	 Late	GU	 toxicity	 incidences	 over	 time	 are	
depicted	in	Figure	2	for	the	NDC	and	DC	group	separately.
Processed on: 28-9-2016
505259-L-bw-Aluwini
96
Chapter 6: Clinical influence of displacement correction in HDR-brachytherapy for prostate cancer
Fi
gu
re
 6
.1
 |
 L
at
er
al
	X
-r
ay
	im
ag
es
	fo
r	
as
se
ss
in
g	
ca
th
et
er
	d
is
pl
ac
em
en
t.
	(A
)	R
ef
er
en
ce
	im
ag
e	
aft
er
	im
pl
an
ta
ti
on
,	(
B)
	b
ef
or
e	
fr
ac
ti
on
	3
	w
it
h	
ca
th
et
er
	d
is
pl
ac
em
en
t	
of
	5
	
m
m
,	a
nd
	(C
)	b
ef
or
e	
fr
ac
ti
on
	3
	a
ft
er
	c
or
re
cti
on
	o
f	c
at
he
te
r	
di
sp
la
ce
m
en
t	
w
it
h	
re
si
du
al
	s
hi
ft
	<
1	
m
m
.
Ta
b
le
 6
.3
 |
 A
cu
te
	a
nd
	la
te
	t
ox
ic
it
y	
in
ci
de
nc
e	
in
	r
el
ati
on
	t
o	
di
sp
la
ce
m
en
t	
co
rr
ec
ti
on
D
is
pl
ac
em
en
t 
co
rr
ec
ti
on
M
ax
im
um
 d
is
pl
ac
em
en
t 
co
rr
ec
ti
on
N
um
be
r 
of
 d
is
pl
ac
em
en
t 
co
rr
ec
ti
on
s
N
o 
co
rr
ec
ti
on
  
(n
=9
1)
Co
rr
ec
ti
on
 
(n
=7
1)
p-
va
lu
e
>3
-5
 m
m
  
(n
=4
5)
>5
 m
m
  
(n
=2
6)
p-
va
lu
e
1 
 
(n
=5
6)
>1
  
(n
=1
5)
p-
va
lu
e
A
cu
te
	G
U
	g
ra
de
	≥
2	
(n
)
33
.0
%
	(3
0)
31
.0
%
	(2
2)
0.
86
6
37
.8
%
	(1
7)
19
.2
%
	(5
)
0.
11
9
28
.6
%
	(1
6)
40
.0
%
	(6
)
0.
53
0
A
cu
te
	G
I	g
ra
de
	≥
2	
(n
)
26
.4
%
	(2
4)
28
.2
%
	(1
2)
0.
85
9
26
.7
%
	(1
2)
30
.8
%
	(8
)
0.
78
7
25
.0
%
	(1
4)
40
.0
%
	(6
)
0.
33
3
La
te
	G
U
	g
ra
de
	≥
2	
(n
)
47
.7
%
	(4
2)
31
.9
%
	(2
2)
0.
04
3	
*
34
.1
%
	(1
5)
28
.0
%
	(7
)
0.
83
4
35
.2
%
	(1
9)
20
.0
%
	(3
)
0.
21
4
La
te
	G
I	g
ra
de
	≥
2	
(n
)
10
.2
%
	(9
)
8.
7%
	(6
)
0.
88
8
11
.4
%
	(5
)
4.
0%
	(1
)
0.
52
0
9.
3%
	(5
)
6.
7%
	(1
)
0.
74
2
	*
	p
-v
al
ue
	o
f	l
og
-r
an
k	
te
st
;	i
n	
m
ul
ti
va
ri
ab
le
	C
ox
	r
eg
re
ss
io
n	
p
=0
.1
21
Processed on: 28-9-2016
505259-L-bw-Aluwini
97
6
DISCUSSION
Correction	of	implant	displacements	exceeding	3mm	did	not	significantly	influence	GU	or	GI	toxicity	
incidences	in	both	the	acute	and	late	phase	compared	to	the	treatments	where	no	corrections	were	
needed.	There	were	no	significant	differences	in	toxicity	associated	with	the	number	of	corrected	
displacements	nor	with	the	maximum	amount	of	displacement	correction.	
HDR-BT	 allows	 for	 a	 conformal	 high	 dose	 to	 the	 prostate	 by	 optimizing	 the	 source	 dwell	 times	
and	positions	in	the	implanted	catheters4.	However,	the	accuracy	of	dose	delivery	relies	on	dwell	
positions	being	accurately	reproduced	for	all	fractions	during	treatment.	In	clinical	practice,	caudal	
migration	 is	 often	 observed	 between	 fractions	 6-9.	 Hoskin	 et	 al.	 identified	 potential	 sources	 of	
catheter	displacement:	external	migration	of	the	catheters	through	the	skin,	 internal	movement	
of	 the	prostate	gland	and	edema	build-up	between	the	prostate	apex	and	perineum8.	Since	the	
catheters	were	 locked	 in	 the	 template	 that	was	sutured	 to	 the	skin,	caudal	displacement	of	 the	
catheters	through	the	template	and	thus	the	skin	was	unlikely.	Edema	after	catheter	implantation	
has	been	described	by	several	authors.	Prostate	volume	change	in	the	two	days	after	implantation	
has	been	shown	to	be	largest	in	craniocaudal	direction6,7,9,18-20.	Analogue	to	these	authors,	we	expect	
edema	 to	be	 the	main	 cause	of	 catheter	 displacement	between	 fractions.	We	 found	 that	most	
displacements	occurred	before	fractions	2	(47.2%)	and	3	(31.4%),	suggesting	that	edema	build-up	is	
limited	in	the	time	between	implantation	and	the	first	fraction.
In	our	patients,	one	or	more	displacement	corrections	were	needed	in	43.8%	of	the	patients.	This	
shows	the	importance	of	a	check	and	subsequent	correction	of	catheter	displacement	in	HDR-BT.
To	our	 knowledge,	 this	 is	 the	first	 report	on	 the	 clinical	 effect	of	 catheter	displacement	and	 its	
correction	during	HDR-BT	as	monotherapy	for	PCa.	As	stated	by	Nuyen	and	Ciezki,	the	main	technical	
concern	on	HDR-BT	monotherapy	is	catheter	displacement	and	the	resulting	undercoverage	of	the	
prostate	base	and	overdosage	to	the	OAR	21.	Other	authors	have	previously	reported	on	catheter	
displacement	between	fractions	and	the	corrections	that	were	needed.	Based	on	simulations	of	
catheter	displacements	and	the	effects	on	target	coverage	and	OAR	dose,	both	Kolkman-Deurloo	
et	 al.	 and	 Tiong	 et	 al.	 suggested	 to	 correct	 displacements	 exceeding	 3mm10,22.	 Other	 authors	
have	shown	with	simulation	studies	that	correcting	catheter	displacements	resulted	 in	restoring	
the target coverage to the planned level8,9,23.	As	the	same	is	true	for	OAR	dose,	one	could	expect	
that	toxicity	incidences	would	be	similar	for	the	DC	group	compared	to	the	NDC	group.	We	have	
implemented	 the	3mm	 limit	 for	 correction	 in	 our	 clinical	 protocol	 and	our	 results	 indicate	 that	
correction	of	catheter	displacements	above	this	limit	resulted	in	similar	toxicity	incidences	in	clinical	
practice.	Therefore,	catheter	displacement	is	no	longer	a	concern	once	checked	and	corrected.
We	used	markers	 implanted	 in	 the	prostate	and	 lateral	X-rays	to	assess	catheter	displacements	and	
corrected	the	catheter	positions	by	manual	adjustments.	Instead	of	lateral	X-rays,	AP	X-rays	could	also	
be	used.	However,	Damore	et	al.	have	described	that	AP	images	tend	to	overestimate	the	amount	of	
catheter	displacement	with	an	average	of	13%	compared	to	lateral	images6.	This	is	described	to	be	due	to	
variations	in	the	amount	of	pelvic	flexion	between	the	different	images,	despite	the	use	of	skin	markers.
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There	 are	 some	 uncertainties	 in	 the	 used	 method	 for	 determining	 and	 correcting	 catheter	
displacement.	 First,	 we	 assume	 that	 the	markers	 do	 not	migrate	 through	 the	 prostate	 after	
implantation	and	that	there	is	only	limited	effect	of	prostate	volume	changes	due	to	prostatic	
edema.	These	assumptions	are	supported	by	literature.	Changes	in	prostate	volume	during	the	
time	interval	between	implantation	and	the	last	fraction	are	minimal,	as	mean	volume	changes	
of	2.7	to	6.2%	or	absolute	changes	of	1.2	to	3.9cm3 were described for this period 7,12,19.	Marker	
distance	changes	that	were	reported	are,	therefore,	also	small.	Mean	absolute	changes	of	0.6	
to	3mm	were	 reported	 for	 the	36	hour	period	of	our	HDR-BT	 scheme	 12,19,24.	As	both	marker	
migration	and	prostate	volume	changes	are	small,	the	uncertainties	related	to	these	factors	in	
displacement	measurement	are	expected	to	be	limited.
Another	 assumption	 is	 that	 all	 catheters	 displace	 the	 same	 amount	 and	 that	 the	 six	 checked	
catheters	are	representative	of	the	overall	displacement.	This	is	based	on	the	fact	that	all	catheters	
are	locked	in	the	template	and	are	therefore	unlikely	to	move	through	the	skin.	Damore	et	al.	have	
shown	before	that	all	catheters	displaced	the	same	amount	in	almost	all	of	their	96	patients	6.	
In	the	described	method	there	might	also	be	an	inaccuracy	in	displacement	measurement,	caused	
by	the	manual	identification	of	both	marker	points	and	catheter	tips	in	each	lateral	X-ray	separately.	
However,	this	inaccuracy	is	difficult	to	assess	and	quantify.
Even	though	there	are	several	assumptions	and	limitations	to	the	described	method	of	displacement	
measurement	 and	 correction,	 we	 can	 conclude	 that	 our	method	 of	 displacement	 correction	 is	
accurate	enough	to	avoid	dose	violations	in	organs	at	risk	based	on	the	toxicity	incidences	reported	
here.	
Other	authors	suggested	different	methods	to	assess	and	correct	displacements,	such	as	CT	imaging	
before	each	fraction	and/or	adjusting	dwell	positions	in	case	of	displacements	7-9,23.	However,	using	
CT	imaging	is	time	consuming	and	more	expensive	than	X-ray,	and	patient	transfer	to	the	CT	table	
and	back	to	the	bed	may	induce	catheter	displacement	by	itself.	In	our	method,	patients	remained	
in	bed	from	the	first	lateral	X-ray	until	the	last	fraction,	to	avoid	implant	displacements	as	much	as	
possible.	Pieters	et	al.	described	self-anchoring	catheters	that	reduced	the	mean	displacement	to	
1.2mm25,	which	is	less	than	the	3mm	limit	for	corrections	in	our	protocol.	However,	these	catheters	
have	a	larger	diameter	and	were	used	to	deliver	pulsed-dose-rate	BT.	An	option	to	compensate	for	
interfraction	catheter	displacement	and	ensure	PTV	coverage	could	be	to	add	margins	to	the	PTV	
in	cranio-caudal	direction.	However,	this	would	significantly	increase	OAR	dose,	possibly	resulting	in	
increased	toxicity	incidences.	Therefore,	this	option	is	not	preferred.
Recent	 developments	 towards	 HDR-BT	 monotherapy	 in	 a	 single	 dose-escalated	 fraction,	 as	
suggested	by	Hoskin	et	al.	and	Mavroidis	et	al.26,27,	might	avoid	the	need	for	checking	and	correcting	
implant	displacements	as	we	have	found	only	3	displacements	before	the	first	fraction	in	our	162	
patients.	However,	other	authors	have	shown	displacements	to	occur	in	almost	all	patients	in	HDR-
BT	boost	regimens	of	one	fraction28,29.	This	confirms	the	necessity	to	check	for	displacement	and	
correct	if	needed	before	each	fraction,	irrespective	of	the	used	regimen.
Processed on: 28-9-2016
505259-L-bw-Aluwini
99
6
Toxicity	 incidences	 of	 HDR-BT	 have	 been	 reported	 by	 several	 other	 authors.	 Depending	 on	 the	
inclusion	criteria	and	the	fractionation	schemes,	incidences	of	late	grade	≥2	toxicity	up	to	40%	for	GU	
and	10%	for	GI	were	reported5,30-32.	Our	late	GU	toxicity	incidences	were	slightly	higher	than	those	
reported	in	literature.	However,	most	reported	results	were	based	on	physicians	charts	only,	without	
the	use	of	questionnaires,	whereas	we	have	collected	toxicity	scores	prospectively	in	all	included	
patients	using	a	combination	of	both	questionnaires	and	physicians	charts.	Adding	questionnaires	
to	data	retrieved	from	physicians	charts	is	reported	to	increase	toxicity	incidences	17,33.	This	could	
explain	the	differences	in	incidences	between	our	results	and	the	incidences	in	literature.
Regarding	late	GU	toxicity,	we	found	a	borderline	significant	difference	between	NDC	and	DC.	The	
incidence	of	late	GU	grade	≥2	toxicity	in	the	DC	group	was	almost	half	of	that	in	the	NDC	group.	
However,	if	other	factors	were	also	taken	into	account	in	the	multivariable	regression,	the	difference	
was	clearly	non-significant	with	a	p-value	of	0.121.	This	indicates	that	the	differences	between	the	
two	groups	with	 regard	 to	other	 factors	have	a	 larger	effect	on	 the	 toxicity	 incidences	 than	 the	
displacement	correction.
There	are	some	 limitations	of	 this	 study.	Firstly,	 the	 two	groups	 (NDC	vs.	DC)	were	prospectively	
followed	but	not	randomized.	However,	as	other	studies	have	shown	previously	that	displacements	
>3mm	 result	 in	 underdosage	 of	 the	 tumor,	 it	 could	 not	 be	 ethically	 justified	 to	 study	 this	 in	 a	
randomized	setting.	Secondly,	in	the	DC	group	only	15	patients	(20%)	needed	displacement	correction	
before	more	than	1	fraction.	Even	though	the	differences	in	toxicity	between	the	groups	with	one	and	
more	than	one	displacement	corrections	(GU	35.2%	vs	20.1%;	GI	25.0%	vs	40.0%)	seemed	rather	large	
and	might	be	clinically	relevant,	the	relatively	limited	number	of	patients	in	the	second	group	was	
not	enough	to	detect	a	statistically	significant	difference.	However,	the	statistical	analysis	outcome	
(i.e.	the	high	p-values)	implies	that	there	is	no	different	outcome	to	be	expected	with	larger	groups.
Figure 6.2 | Incidences	of	late	GU	grade	≥2	toxicity	over	time.	NDC	=	no	displacement	correction,	 
DC	=	displacement	correction
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CONCLUSION
The	 occurrence	 and	 subsequent	 correction	 of	 catheter	 displacements	 exceeding	 3mm	 before	
each	fraction	in	HDR-BT	as	monotherapy	for	PCa	did	not	lead	to	increased	acute	or	late	GU	and	
GI	toxicity	incidences.	The	maximum	displacement	and	the	number	of	displacement	corrections	
had	no	 influence	on	 toxicity	 incidences.	This	 indicates	 that	our	clinical	protocol	 to	 correct	only	
displacements	over	3mm	results	in	safe	treatment.
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ABSTRACT 
Background and purpose
The	use	of	HDR	brachytherapy	 (HDR-BT)	as	monotherapy	 for	prostate	cancer	 (PC)	 is	 increasing	
worldwide	 with	 good	 tumour	 control	 rates	 and	 acceptable	 toxicity.	We	 report	 our	 results	 on	
toxicity	and	quality	of	life	(QoL)	after	HDR-BT	monotherapy	for	PC	patients.
Materials and methods
166	low-	and	intermediate-risk	localized	PC	patients	were	treated	with	HDR-BT	to	a	total	dose	of	
38	Gy	in	four	fractions.	Genitourinary	(GU)	and	gastrointestinal	(GI)	toxicities	were	prospectively	
assessed	using	EORTC-RTOG	questionnaires	and	physicians	charts.	QoL	was	evaluated	using	EORTC	
QLQ-PR25	questionnaires.	
Results 
Three	 months	 after	 treatment,	 acute	 GU	 and	 GI	 toxicities	 were	 reported	 in	 10.8%	 and	 7.2%.	
Acute	 toxicity	 resolved	within	 two	months	 in	 the	majority	of	patients	 (61%).	 Late	grade	≥2	GU	
and	GI	toxicity	were	reported	in	19.7%	and	3.3%	of	patients	12	months	after	HDR-BT.	Mean	QLQ-
PR25	scores	showed	clinically	 relevant	changes	 from	baseline	 for	urinary	symptoms	and	sexual	
functioning.	With	 a	mean	 follow-up	 of	 35	months,	 biochemical	 failure	 was	 observed	 in	 2.4%.	
Overall	survival	at	60	months	was	93.6%	and	cancer-specific	survival	was	100%.
Conclusions
HDR-BT	monotherapy	for	localized	PC	showed	excellent	clinical	outcome	and	acceptable	acute	and	
late	toxicity.	Urinary	symptoms	and	sexual	function	QoL	decreased	after	treatment.	
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INTRODUCTION
High-dose-rate	brachytherapy	(HDR-BT)	is	a	safe	and	effective	treatment	option	for	prostate	cancer	
(PC)	1-3.	There	is	accumulating	evidence	that	PC	cells	have	a	higher	sensitivity	to	fraction	dose,	which	
suggests	a	significant	therapeutic	benefit	of	hypofractionation4,5.	HDR-BT	is	the	ideal	technique	for	
extreme	hypofractionation	because	of	its	highly	conformal	dose	distribution	within	the	prostate	with	
a	rapid	dose	fall-off	outside,	sparing	the	organs	at	risk6.	The	biochemical	control	rate	in	favourable	
risk	 PC	 patients	 has	 been	 shown	 to	 be	 good	 for	 different	 radiotherapy	 treatment	 options1-3,7-9.	
Therefore,	toxicity	rates	and	health-related	quality	of	life	(QoL)	are	important	and	relevant	factors	for	
patients	to	choose	between	the	different	treatment	options.	The	literature	on	toxicity	and	clinical	
outcome	in	HDR-BT	using	a	scheme	of	four	fractions	of	9.5	Gy	is	scarce	10-13.	Prospective	validated	
questionnaires	to	monitor	long-term	toxicity	of	HDR-BT	are	hardly	used	and	data	on	QoL	for	this	
treatment	option	 is	 lacking	 in	 literature.	 In	 this	paper,	we	 report	 long-term	toxicity	and	QoL	of	
HDR-BT	as	monotherapy	for	patients	with	low-	and	intermediate-risk	PC.
METHODS AND MATERIALS
Patients
This	study	was	approved	by	our	institution’s	medical	ethics	committee	(MEC-2012-364).	Between	
September	2007	and	December	2013,	166	patients	with	histologically	confirmed	PC	clinical	stage	
T1b-T2b,	Nx-0,	Mx-0,	Gleason	score	(GS)	≤7,	PSA	≤	16	ng/ml	and	WHO	performance	status	of	0-2	
were	treated	with	HDR-BT	monotherapy.	TNM	scoring	was	according	to	the	AJCC	2003	guidelines14.	
Patients	with	clinical	stage	T1c-T2a,	GS	6	and	PSA	≤	10	ng/ml	were	defined	as	low-risk	PC	(67%),	
whereas	 patients	with	 PSA	 >10	 ng/ml,	 T2b	 and/or	 GS	 7,	 were	 defined	 as	 intermediate-risk	 PC	
(33%)15.	 The	 concomitant	 use	 of	 androgen	 deprivation	 therapy	 (ADT)	was	 not	 allowed.	 Patient	
characteristics	are	shown	in	Table	1.
Radiotherapy
HDR-BT	 was	 performed	 in	 one	 transperineal	 implant	 during	 a	 two-day	 admission1,16.	 Before	
implantation,	four	fiducials	were	inserted:	two	at	the	base	and	two	at	the	apex	of	the	prostate.	
Plastic	needles	were	inserted	using	transrectal	ultrasound	guidance	and	a	template.	Needle	depth	
was	controlled	by	cystoscopy	to	ensure	that	the	needle	tips	were	placed	just	beyond	the	prostate	
base	for	a	good	coverage	of	the	base.	After	implantation	a	planning	CT	scan	was	acquired,	in	which	
the	prostate,	rectum,	bladder	and	urethra	were	delineated.	The	Planning	Target	Volume	(PTV)	was	
the	prostate	without	margins.	Anatomy-based	inverse	planning	was	used	such	that	the	prescribed	
dose	(PD)	covered	≥95%	of	PTV.	The	doses	to	1cm3	of	the	rectum	and	the	bladder	were	limited	
to	80%	of	PD.	The	dose	to	1%	of	the	urethra	volume	was	limited	to	120%	of	PD.	The	total	dose	
administered	was	38	Gy	in	four	fractions	within	36	h	with	a	minimum	interval	between	fractions	
of	six	hours.	All	 fractions	were	delivered	according	to	one	treatment	plan.	Before	each	fraction	
a	lateral	X-ray	was	acquired	to	check	needle	positions	relative	to	the	implanted	markers.	Needle	
displacements	>3	mm	were	corrected	to	ensure	good	conformity	of	the	dose	distribution16.	
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Follow-up and questionnaires
All	patients	were	followed	up	prospectively	and	were	seen	every	three	months	in	the	first	year,	
and	twice	yearly	thereafter.	Toxicity	questionnaires	were	sent	to	all	patients	at	baseline	(before	
treatment),	at	1,	2,	3,	6,	12,	18,	24	months	after	treatment	and	yearly	thereafter.	QoL	questionnaires	
were	sent	following	the	same	scheme,	except	at	1	and	2	months.
The	European	Organization	for	Research	and	Treatment	of	Cancer	(EORTC)	and	Radiation	Therapy	
Oncology	Group	 (RTOG)	 toxicity	 score	based	questionnaires	were	used	 to	 assess	 genitourinary	
(GU)	and	gastrointestinal	(GI)	toxicities17,18.	The	International	Prostate	Symptom	Score	(IPSS)	was	
used	to	evaluate	the	urinary	function	after	treatment.	QoL	was	assessed	by	the	prostate-specific	
EORTC	QLQ-PR25	questionnaire19.	 The	QLQ-PR25	 is	a	validated	QoL	 instrument	and	consists	of	
four	domains:	urinary	symptoms,	bowel	symptoms,	hormonal	treatment	related	symptoms	and	
sexual	activity	and	functioning.	The	hormonal	domain	is	not	analysed	as	all	treated	patients	were	
hormone-naïve.
Table 7.1 | Patient	and	tumour	characteristics
n (%) Mean (min-max)
Patients 166
Age	(year) 68	(47-79)
Follow-up	(months) 35	(2-78)
Clinical stage T1c 112	(67%)
T2a 52	(31%)
T2b 2	(1%)
Gleason score 2+2 1	(1%)
2+3 1	(1%)
3+3 142	(86%)
3+4 21	(13%)
4+3 1	(1%)
PSA	(ng/ml) 8	(1-16)
Risk	group Low 112	(67%)
Intermediate 54	(33%)
Prostate	volume	(cm3) 34	(15-55)
IPSS baseline score 6	(0-24)
Urinary	flow	baseline	(Qmax;	ml/s) 16	(2-41)
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Oncologic outcome and PSA
Biochemical	 failure	 (BF)	was	determined	according	 to	 the	Phoenix	definition	 (every	 rise	of	PSA	
≥2ng/ml	above	nadir)20.	A	PSA	bounce	was	defined	as	a	≥0.4ng/ml	rise	in	PSA	level	with	subsequent	
normalization	of	PSA	values	21.	Freedom	from	BF	(FFBF)	was	defined	as	the	percentage	of	patients	
still	alive	without	evidence	of	BF.	Cancer-specific	survival	(CSS),	defined	as	mortality	due	to	PC,	and	
overall	survival	(OS)	were	also	analysed.	Patients	who	died	from	other	causes	than	PC	or	who	were	
lost	to	follow-up	were	censored	at	the	date	of	last	PSA	test	or	contact	for	the	survival	analysis.
Data analysis
The	date	of	the	implantation	was	considered	day	0.	GI	and	GU	toxicities	were	evaluated	according	
to	EORTC-RTOG	toxicity	scores,	using	a	combination	of	patient	questionnaires	and	physician	charts	
(as	was	also	used	in	other	multicentre	trials	before17,22).	The	highest	toxicity	score	of	the	two	was	
taken.	Toxicity	within	100	days	after	HDR-BT	was	considered	acute	toxicity,	and	toxicity	after	100	
days	as	late	toxicity.	IPSS	scores	were	assessed	and	compared	to	baseline	to	evaluate	the	effect	
of	 treatment	on	urinary	 function	and	symptoms.	 In	 the	 IPSS	analysis,	 the	question	on	QoL	was	
left	out,	resulting	in	scores	ranging	from	0	to	35.	QLQ-PR25	scores	were	analysed	to	obtain	the	
net	 effect	 on	 QoL	 compared	 to	 baseline.	 Raw	 QLQ-PR25	 scores	 were	 linearly	 transformed	 to	
values	between	0	and	100,	where	higher	scores	reflect	more	symptoms	in	the	urinary	and	bowel	
symptoms	domain	or	higher	levels	of	sexual	functioning19.	For	all	domains	changes	of	≥10	points	
were considered clinically relevant23.	Statistical	significance	was	tested	with	the	Wilcoxon	signed-
rank	test	for	differences	between	12,	24	and	36	months	versus	baseline.
Logistic	(univariate)	regression	was	applied	to	determine	the	effect	of	prognostic	factors	presented	
in	table	2	on	acute	toxicity,	while	Cox	regression	was	applied	for	the	effect	on	late	toxicity.	The	
cut-off	points	of	these	factors	were	based	on	mean	values	of	our	patient	population	in	general.	The	
Kaplan-Meier	method	was	applied	to	estimate	survival	probabilities.	Two-tailed	tests	were	used	
and	p-values	<0.05	were	considered	significant.	Statistical	analyses	were	performed	using	Stata® 
13.1	(StataCorp).
RESULTS
Mean	follow-up	(FU)	was	35	months	(2-78),	with	a	median	of	25	months.	The	overall	response	rate	
on	all	sent	questionnaires	was	90.3%.	For	the	toxicity	questionnaires	the	mean	response	rate	per	
patient	was	89.8%,	with	a	median	of	100%	(range	33.3-100).	The	QoL	questionnaires	had	a	mean	
response	 rate	of	90.9%	 (median	100%,	 range	14.3-100).	 From	3	months	after	 treatment	on,	all	
questionnaires	were	sent	together	to	the	patients.	Therefore,	return	rates	are	similar.
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Acute toxicity
The	 chronological	 incidences	 of	 grade	 ≥2	 GU	 and	 GI	 toxicities	 are	 depicted	 in	 Fig.	 1A	 and	 B,	
respectively.	The	incidence	of	grade	2	and	3	acute	GU	toxicity	was	19.3%	and	12.7%,	respectively.	
The	 incidence	 of	 grade	 2	 and	 3	 acute	 GI	 toxicity	 was	 21.7%	 and	 4.8%,	 respectively.	 Highest	
incidences	of	grade	2	and	3	acute	toxicity	were	reported	within	4	weeks	after	treatment.	Most	
patients	 (61%)	 had	 relief	 from	 their	 toxicity	within	 two	months	 after	 treatment.	 Eight	 patients	
(4.8%)	needed	an	indwelling	bladder	catheter	during	the	first	7	weeks	after	HDR-BT	for	at	least	3	
weeks	(0.75-14	months).	
Most	reported	acute	GU	complaints	were	increased	night	voiding	frequency	(20.9%;	5-7x/night	in	
17.3%	and	>7x/day	in	3.6%),	urinary	incontinence	with	use	of	pads	(17.9%;	daily	use	of	pads	in	9.8%	
and	>2x/week	use	in	8.1%)	and	increased	day	voiding	frequency	(14.9%;	12-16x/day	in	10.7%	and	
>16x/day	in	4.2%).	Increased	stool	frequency	of	≥	6x/day	was	the	main	GI	complaint	(10.8%).
Late toxicity
The	chronological	incidences	of	late	grade	2	and	grade	3	late	toxicities	is	shown	in	Fig.	1C	and	D.	
During	the	60	months	FU	grade	2	and	3	GU	toxicity	was	registered	in	20.3%	and	3.1%	of	patients,	
respectively.	The	highest	levels	of	GU	toxicities	were	reported	at	12	months,	with	19.7%	≥	grade	2.	
Grade	2	GI	toxicity	was	reported	in	8.6%	of	patients	and	no	grade	3	GI	toxicity	was	reported.
The	main	 causes	 of	 late	 GU	 toxicity	were	 increased	 day	 voiding	 frequency	 (16.6%;	 12-16x/day	
in	13.5%	and	>16x/day	in	3.1%),	incontinence	with	daily	use	of	pads	(14.8%)	and	increased	night	
voiding	frequency	(9.2%;	5-7x/night	in	7.7%	and	>7x/night	in	1.2%).	
Regarding	GI	toxicity,	increased	stool	frequency	of	≥6x/day	was	reported	by	8.0%	and	incontinence	
with	daily	use	of	pads	7.4%	of	patients.	
The	course	of	the	IPSS	score	over	time	is	shown	in	Fig.	2.	The	mean	IPSS	score	before	treatment	was	
Table 7.2 | Variables	tested	in	univariate	logistic	regression	for	the	effect	on	acute	and	late	GU	and	GI	toxicity
Lower limit Upper limit
Age	(year) ≤70 >70
IPSS	score	before	treatment ≤12 >12
Number	of	needles	used ≤17 >17
PTV	volume	(cm3) ≤40 >40
Urinary	flow	before	treatment	(Qmax;	ml/s) ≤15 >15
Urinary	residue	before	treatment	(ml) ≤30 >30
Prostate	volume	before	treatment	(cm3) ≤40 >40
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6/35.	After	treatment	the	mean	score	increased	to	11/35	at	3	months	to	a	maximum	of	12/35	at	36	
months.	After	that	the	mean	score	decreased	to	10/35	at	48	and	60	months.
Prognostic factors for toxicity
Baseline	urinary	flow	(Qmax)	>15ml/s	was	significantly	correlated	with	lower	incidence	of	acute	GU	
toxicity	(p=0.047)	with	an	odds	ratio	of	0.46	(95%	confidence	interval	(CI)	0.21-1.00)	compared	to	
Qmax	≤15ml/s.	Baseline	IPSS	score	>12	showed	a	tendency	to	correlate	with	higher	incidence	of	
late	GU	toxicity	(p=0.074)	with	a	relative	hazard	ratio	of	2.70	(95%	CI	1.01-7.22).	Other	evaluated	
factors	were	statistically	not	significant	for	GU	nor	GI	toxicity.
Quality of life assessment
Urinary	symptoms	score	of	 the	QLQ-PR25	 increased	>10	points	compared	to	baseline	 (clinically	
relevant)	during	the	first	three	years	after	treatment	(p<0.0001),	but	improved	thereafter.	Mean	
bowel	 symptoms	 score	 showed	 a	 slight	 increase	 compared	 to	 baseline.	 Although	 statistically	
significant	(p≤0.02),	the	mean	bowel	symptoms	QoL	score	increase	of	three	points	in	three	years	
was	not	clinically	relevant.	Mean	sexual	functioning	score	decreased	to	a	lowest	score	at	18	months	
FU	 and	 improved	 subsequently.	 Compared	 to	 baseline,	 the	 differences	 were	 both	 statistically	
significant	(p<0.0001)	and	clinically	relevant.	All	QLQ-PR25	scores	are	graphically	represented	in	
Fig.	3.	
Oncologic outcome and PSA
Five	patients	(3.0%)	died	after	a	mean	of	30.8	months	after	HDR-BT	(range	17.4-56.2	months).	None	
of	the	deaths	had	biochemical	progression.	The	3-	and	5-year	OS	were	95.8%	(95%	CI:	89.1-98.4)	
and	93.6%	(95%	CI:	84.3-97.5),	respectively,	and	the	5-year	CSS	was	100%.	Four	patients	developed	
BF	(2.4%).	Two	of	them	had	low-risk	PC	and	two	intermediate-risk	PC.	FFBF	was	99%	at	36	months	
FU	and	96%	at	60	months.
The	mean	PSA	nadir	was	0.74	ng/l	(0.01-6.90),	which	was	reached	after	a	mean	of	29	months	(1-72).	
A	nadir	<	1.0	ng/ml	was	registered	in	74.8%	of	our	patients.	
One	or	more	PSA	bounces	were	recorded	in	48	patients	(28.9%).	Of	these,	six	patients	had	two	
bounces	 and	 three	patients	 had	 three	bounces.	 The	mean	 interval	 from	 treatment	 to	 the	first	
bounce	was	10.8	months	(3-29	months).	None	of	the	patients	with	BF	showed	a	PSA	bounce.	
Discussion
We	report	on	the	toxicity	and	the	QoL	of	HDR-BT	as	monotherapy	in	low-	and	intermediate-risk	PC	
patients.	In	the	acute	phase	(up	to	100	days	after	treatment),	grade	≥2	GU	and/or	GI	toxicity	were	
seen	in	>25%	of	our	patients.	However,	at	three	months	after	treatment	toxicity	scores	had	almost	
returned	to	baseline	and	most	acute	toxicities	resolved	within	the	first	4-8	weeks,	a	time	period	that	
is	comparable	to	a	regular	EBRT	course.	In	the	late	phase,	the	highest	incidence	of	GU	toxicity	was	
seen	at	12	months	after	HDR-BT	which	decreased	thereafter.	Late	GI	toxicity	was	very	low	without	
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any	grade	3	toxicity.	Mean	IPSS	score	after	treatment	was	relatively	stable	with	a	very	acceptable	post	
treatment	mean	of	11/35,	which	reflects	a	fairly	satisfying	voiding	function.	QoL	score	for	urinary	
symptoms	showed	a	clinically	relevant	increase	in	the	first	three	years.	Sexual	functioning	reached	a	
minimum	at	18	months	after	treatment	and	improved	thereafter.
Toxicity
Acute	urinary	retention	for	which	an	indwelling	bladder	catheter	was	needed,	was	registered	in	
eight	patients	(4.8%).	This	percentage	was	high	compared	with	literature	and	made	us	change	our	
inclusion	policy	to	exclude	patients	with	IPSS	>18/35	during	the	remainder	of	the	study.	After	this	
Figure 7.1. | Acute	GU	(A),	acute	GI	(B),	late	GU	(C)	and	late	GI	toxicity	(D).
During	the	acute	phase	(A	and	B),	highest	incidences	of	grade	2	and	3	toxicity	are	seen	in	the	first	4	weeks,	
after	which	the	incidence	decreases	towards	baseline.	Highest	incidences	of	late	toxicities	(C	and	D)	are	seen	
up	to	18	months.
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7Figure 7.2. | Mean	 IPSS	 score	 showing	 an	 increase	 after	 treatment	 to	 a	 maximum	 at	 36	months	 after	
treatment	and	a	decrease	thereafter.
change	in	2011,	only	one	patient	needed	an	indwelling	bladder	catheter	due	to	urinary	retention.
The	mean	 IPSS	score	showed	minimal	changes	after	treatment,	which	may	be	explained	by	the	
good	tolerance	and	adaptation	of	patients	to	the	registered	GU	toxicity.	
Baseline	IPSS	score	>12	showed	a	tendency	to	correlate	with	late	GU	toxicity	with	a	nearly	three	times	
higher	risk.	This	finding	is	in	concordance	with	the	series	of	Pollack	et	al.	in	the	hypofractionated	
EBRT	arm	of	their	randomized	trial	24.	This	confirms	the	necessity	for	sharp	selection	criteria	for	
patients	 to	be	 treated	with	hypofractionated	 regimens.	Also,	 the	 found	 relation	between	good	
Qmax	of	>15	ml/s	with	the	lower	risk	of	acute	toxicity	is	important	for	patient	selection	to	limit	
acute	 toxicity.	 Incorporating	both	 these	 risk	 factors	 in	 the	 inclusion	criteria,	 could	 substantially	
reduce	 toxicity	 rates.	We	would	 therefore	 recommend	 to	 include	 baseline	 IPSS	 score	 ≤12	 and	
Qmax	>15	ml/s	in	the	selection	criteria	for	hypofractionated	brachytherapy	regimens.
GI	toxicity	was	very	low,	which	is	consistent	with	the	sharp	constraint	to	limit	rectal	wall	dose	to	
80%	of	PD	to	only	1	cm3 of	the	rectum.	The	monitoring	and	correction	of	implant	position	changes	
during	treatment	probably	contributed	to	the	low	GI	toxicity	too.	
Several	reports	have	shown	comparable	results	with	GU	grade	≥2	toxicities	of	13-18%,	and	<4%	for	
GI	toxicity2,25,26.	
In	most	of	these	series	toxicity	was	registered	only	by	the	physician	and	no	questionnaires	were	
used.	Our	results,	however,	were	based	on	both.	As	the	use	of	questionnaires	has	been	reported	to	
increase	the	incidence	of	reported	toxicity	compared	to	physician	charts	only22,27,	this	could	explain	
the	slightly	higher	toxicity	percentages	in	this	report	compared	to	literature.
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Quality of life assessment
We	 reported	 a	 clinically	 relevant	 increase	 in	 urinary	 symptoms	 scores	 and	 clinically	 relevant	
decrease	in	sexual	functioning.	This	 is	consistent	with	literature	on	other	PC	treatment	options.	
For	EBRT	with	BT	boost	QLQ-PR25	scores	have	been	described	by	Conaglen	et	al.	who	showed	
significant	changes	which	did	not	resolve	after	two	years,	especially	not	the	sexual	domain28.	Also	
after	both	IMRT	and	LDR-BT	clinically	relevant	decrease	of	sexual	functioning	was	described 29,30.	
However,	in	most	published	series	on	QoL	there	was	no	consistent	prospective	yearly	use	of	the	
questionnaires,	which	results	in	lack	of	information	on	the	intervening	time	points.	As	we	did	use	
Figure 7.3. | EORTC	QLQ-PR25	scores	on	urinary	symptoms	(A),	bowel	symptoms	(B)	and	sexual	functioning	
(C),	with	all	 scores	on	a	 scale	 from	0	 to	100.	For	urinary	 symptoms	 (A)	and	bowel	 symptoms	 (B),	higher	
scores	reflect	more	symptoms.	For	sexual	functioning	(C),	higher	scores	indicate	better	functioning.	In	all	
domains	changes	≥10	points	are	considered	clinically	relevant.	Statistically	significant	changes	from	baseline	
(0	months)	are	indicated	with	an	*	(*	=	p<0.0001;	**	=	p=0.0014;	***	=	p=0.02).	SD	=	standard	deviation.
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the	questionnaires	yearly,	the	course	of	QoL	scores	over	time	could	be	evaluated	and	the	results	
showed	an	improvement	in	QoL	after	three	years	FU.
For	both	urinary	symptoms	and	sexual	functioning,	age	has	been	described	to	be	associated	with	
changes	in	QoL	score	after	treatment.	Hampson	et	al.	showed	that	older	men	have	lower	baseline	
sexual	functioning	scores,	but	also	show	less	recovery	after	treatment31.	In	our	study,	85%	of	our	
patients	were	over	60	years	of	age	at	the	time	of	HDR-BT	and	40%	was	even	older	than	70	years.	
This	could	have	biased	the	sexual	functioning	scores	towards	less	favourable	results.
Sexual	 functioning	 can	 also	 be	 assessed	with	 the	 International	 Index	of	 Erectile	 Function	 (IIEF)	
questionnaire32,	which	will	provide	more	details	and	could	confirm	the	results	of	the	QLQ-PR25.
Oncologic outcome and PSA
Our	results	with	only	four	BF’s	are	comparable	to	those	reported	in	literature2,25,33,34.	However	most	
series	allowed	the	concomitant	use	of	ADT,	whereas	in	our	series	none	of	the	patients	used	ADT	
because	it	could	confuse	PSA	response	evaluation.	
Besides	 the	absence	of	ADT,	we	used	one	 fractionation	schedule	 for	all	patients,	while	 in	most	
publications	 on	 HDR-BT	 monotherapy	 different	 fractionation	 schedules	 were	 used.	 Demanes	
et	al.	described	HDR-BT	monotherapy	in	298	patients	with	localized	PC,	in	which	almost	50%	of	
the	patients	received	a	fractionation	schedule	 identical	to	ours.	The	8-year	biochemical	control	
rate	was	97%	2.	Other	series	reported	a	5-year	biochemical	control	rate	of	88-97%	using	different	
fractionation	schemes	25,35,36.	
PSA	bounce	 is	a	known	phenomenon	 in	PC	patients	treated	with	radiotherapy	and	observed	 in	
20-40%	of	patients1,21,37,38.	The	results	of	this	study	are	in	line	with	those	in	literature.	We	used	the	
definition	of	Horwitz	where	an	increase	of	≥0.4	ng/ml	followed	by	any	decrease	was	considered	
a bounce21.	 In	 his	multi-institutional	 pooled	 data	 of	 4839	 patients,	 20%	 experienced	 a	 bounce	
according	 to	 this	 definition.	Most	 reports	 on	 bounce	 are	 from	 series	 in	 which	 ADT	was	 used.	
Reports	on	PSA	bounce	after	HDR-BT	monotherapy	 in	hormone-naïve	patients	are	 scarce.	 In	a	
cohort	 that	used	HDR-BT	monotherapy	 in	five	fractions	of	7-7.25	Gy,	PSA	bounce	was	reported	
in	43%	of	patients	using	a	 lower	 threshold	of	0.2	ng/ml	and	 the	mean	time	to	bounce	was	1.3	
years37.	 In	a	previous	series	 in	hormone-naïve	patients	treated	with	a	combination	of	EBRT	and	
HDR-BT	boost,	we	observed	bounce	in	33%	of	patients	and	the	mean	interval	to	bounce	was	22	
months1.	Information	on	PSA	bounce	and	time	to	bounce	is	important	to	explain	PSA	results	after	
radiotherapy	and	to	guide	subsequent	management.
CONCLUSIONS
This	hypofractionated	regimen	using	HDR-BT	as	monotherapy	for	low-	and	intermediate-risk	PC	is	
feasible and well tolerated, providing high precision in delivery	of	radiation	dose	to	the	prostate.	
The	clinical	outcome	in	this	patient	population	is	excellent	and	toxicity	is	acceptable	with	very	low	
and	mild	GI	toxicity.	Overall,	the	toxicity	incidence	decreased	within	two	months	after	treatment.	
QoL	decreased	in	the	first	three	years	after	treatment	for	urinary	symptoms	and	sexual	functioning.	
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Sharper	selection	of	patients	to	these	extreme	hypofractionated	regimen	could	limit	toxicity	and	
improve	QoL.	 The	 rates	of	 acute	and	 late	 toxicity	 could	be	 limited	by	 sharpening	 the	 inclusion	
criteria	regarding	IPSS	score	and	Qmax	at	baseline.	
Conflicts of interest statement: 
None	of	the	authors	have	any	financial	disclosures	or	conflicts	of	interest	pertaining	to	this	research.
References
1.	 Aluwini,	 S,	 van	 Rooij,	 PH,	 Kirkels,	 WJ,	 et	 al.	 High-dose-rate	 brachytherapy	 and	 external-beam	
radiotherapy	for	hormone-naive	low-	and	intermediate-risk	prostate	cancer:	a	7-year	experience.	Int	J	
Radiat	Oncol	Biol	Phys	2012;83:1480-5.	
2.	 Demanes,	 DJ,	 Martinez,	 AA,	 Ghilezan,	 M,	 et	 al.	 High-dose-rate	 monotherapy:	 safe	 and	 effective	
brachytherapy	for	patients	with	localized	prostate	cancer.	Int	J	Radiat	Oncol	Biol	Phys	2011;81:1286-92.	
3.	 Demanes,	 DJ,	 Ghilezan,	 MI.	 High-dose-rate	 brachytherapy	 as	 monotherapy	 for	 prostate	 cancer.	
Brachytherapy	2014;13:529-41.	
4.	 Fowler,	JF.	The	radiobiology	of	prostate	cancer	including	new	aspECTS	of	fractionated	radiotherapy.	
Acta	Oncol	2005;44:265-76.	
5.	 Brenner,	DJ,	Martinez,	AA,	Edmundson,	GK,	Mitchell,	C,	Thames,	HD,	Armour,	EP.	Direct	evidence	that	
prostate	tumors	show	high	sensitivity	to	fractionation	(low	alpha/beta	ratio),	similar	to	late-responding	
normal	tissue.	Int	J	Radiat	Oncol	Biol	Phys	2002;52:6-13.	
6.	 Liao,	Y,	Joiner,	M,	Huang,	Y,	Burmeister,	J.	Hypofractionation:	what	does	it	mean	for	prostate	cancer	
treatment?	Int	J	Radiat	Oncol	Biol	Phys	2010;76:260-8.	
7.	 Hinnen,	KA,	Battermann,	 JJ,	 van	Roermund,	 JG,	et	al.	 Long-term	biochemical	and	survival	outcome	
of	921	patients	 treated	with	 I-125	permanent	prostate	brachytherapy.	 Int	 J	Radiat	Oncol	Biol	 Phys	
2010;76:1433-8.	
8.	 Peeters,	ST,	Heemsbergen,	WD,	Koper,	PC,	et	al.	Dose-response	in	radiotherapy	for	localized	prostate	
cancer:	results	of	the	Dutch	multicenter	randomized	phase	III	trial	comparing	68	Gy	of	radiotherapy	
with	78	Gy.	J	Clin	Oncol	2006;24:1990-6.	
9.	 Pollack,	A,	Zagars,	GK,	Starkschall,	G,	et	al.	Prostate	cancer	radiation	dose	response:	results	of	the	M.	
D.	Anderson	phase	III	randomized	trial.	Int	J	Radiat	Oncol	Biol	Phys	2002;53:1097-105.	
10.	 Hoskin,	P,	Rojas,	A,	Lowe,	G,	et	al.	High-dose-rate	brachytherapy	alone	for	localized	prostate	cancer	in	
patients	at	moderate	or	high	risk	of	biochemical	recurrence.	Int	J	Radiat	Oncol	Biol	Phys	2012;82:1376-
84.	
11.	 Ghadjar,	P,	Keller,	T,	Rentsch,	CA,	et	al.	Toxicity	and	early	treatment	outcomes	in	low-	and	intermediate-
risk	 prostate	 cancer	managed	 by	 high-dose-rate	 brachytherapy	 as	 a	monotherapy.	 Brachytherapy	
2009;8:45-51.	
12.	 Ghadjar,	P,	Oesch,	 SL,	Rentsch,	CA,	et	 al.	 Late	 toxicity	and	five	year	outcomes	after	high-dose-rate	
brachytherapy	as	a	monotherapy	for	localized	prostate	cancer.	Radiat	Oncol	2014;9:122.	
13.	 Zamboglou,	N,	Tselis,	N,	Baltas,	D,	et	al.	High-dose-rate	interstitial	brachytherapy	as	monotherapy	for	
clinically	 localized	prostate	 cancer:	 treatment	evolution	and	mature	 results.	 Int	 J	Radiat	Oncol	Biol	
Phys	2013;85:672-8.	
Processed on: 28-9-2016
505259-L-bw-Aluwini
115
7
14.	 Greene	F.L.,	PDL,	Fleming	I.D.,	Fritz	A.,	Balch	C.M.,	Haller	D.G.,	Morrow	M.	AJCC	Cancer	Staging	Manual,	
6th	edition.	New	York:	Springer.	2002.
15.	 Chism,	DB,	Hanlon,	AL,	Horwitz,	EM,	Feigenberg,	SJ,	Pollack,	A.	A	comparison	of	the	single	and	double	
factor	high-risk	models	for	risk	assignment	of	prostate	cancer	treated	with	3D	conformal	radiotherapy.	
Int	J	Radiat	Oncol	Biol	Phys	2004;59:380-5.	
16.	 Kolkman-Deurloo,	IK,	Roos,	MA,	Aluwini,	S.	HDR	monotherapy	for	prostate	cancer:	a	simulation	study	
to	determine	the	effect	of	catheter	displacement	on	target	coverage	and	normal	tissue	 irradiation.	
Radiother	Oncol	2011;98:192-7.	
17.	 Peeters,	ST,	Heemsbergen,	WD,	van	Putten,	WL,	et	al.	Acute	and	late	complications	after	radiotherapy	
for	prostate	cancer:	results	of	a	multicenter	randomized	trial	comparing	68	Gy	to	78	Gy.	Int	J	Radiat	
Oncol	Biol	Phys	2005;61:1019-34.	
18.	 Cox,	JD,	Stetz,	J,	Pajak,	TF.	Toxicity	criteria	of	the	Radiation	Therapy	Oncology	Group	(RTOG)	and	the	
European	Organization	 for	Research	and	Treatment	of	Cancer	 (EORTC).	 Int	 J	Radiat	Oncol	Biol	Phys	
1995;31:1341-6.	
19.	 van	Andel,	G,	Bottomley,	A,	Fossa,	SD,	et	al.	An	 international	field	study	of	the	EORTC	QLQ-PR25:	a	
questionnaire	 for	assessing	 the	health-related	quality	of	 life	of	patients	with	prostate	cancer.	Eur	 J	
Cancer	2008;44:2418-24.	
20.	 Roach,	M,	3rd,	Hanks,	G,	Thames,	H,	Jr.,	et	al.	Defining	biochemical	failure	following	radiotherapy	with	
or	without	hormonal	therapy	in	men	with	clinically	localized	prostate	cancer:	recommendations	of	the	
RTOG-ASTRO	Phoenix	Consensus	Conference.	Int	J	Radiat	Oncol	Biol	Phys	2006;65:965-74.	
21.	 Horwitz,	EM,	Levy,	LB,	Thames,	HD,	et	al.	Biochemical	and	clinical	significance	of	the	posttreatment	
prostate-specific	antigen	bounce	for	prostate	cancer	patients	treated	with	external	beam	radiation	
therapy	alone:	a	multiinstitutional	pooled	analysis.	Cancer	2006;107:1496-502.	
22.	 Aluwini,	S,	Pos,	F,	Schimmel,	E,	et	al.	Hypofractionated	versus	conventionally	fractionated	radiotherapy	
for	patients	with	prostate	cancer	 (HYPRO):	acute	toxicity	results	 from	a	randomised	non-inferiority	
phase	3	trial.	Lancet	Oncol	2015;16:274-83.	
23.	 Osoba,	D,	Bezjak,	A,	Brundage,	M,	et	al.	Analysis	and	interpretation	of	health-related	quality-of-life	
data	from	clinical	trials:	basic	approach	of	The	National	Cancer	Institute	of	Canada	Clinical	Trials	Group.	
Eur	J	Cancer	2005;41:280-7.	
24.	 Pollack,	 A,	 Walker,	 G,	 Horwitz,	 EM,	 et	 al.	 Randomized	 trial	 of	 hypofractionated	 external-beam	
radiotherapy	for	prostate	cancer.	J	Clin	Oncol	2013;31:3860-8.	
25.	 Barkati,	 M,	 Williams,	 SG,	 Foroudi,	 F,	 et	 al.	 High-dose-rate	 brachytherapy	 as	 a	 monotherapy	 for	
favorable-risk	prostate	cancer:	a	Phase	II	trial.	Int	J	Radiat	Oncol	Biol	Phys	2012;82:1889-96.	
26.	 Martinez,	AA,	Demanes,	J,	Vargas,	C,	Schour,	L,	Ghilezan,	M,	Gustafson,	GS.	High-dose-rate	prostate	
brachytherapy:	an	excellent	accelerated-hypofractionated	treatment	 for	 favorable	prostate	cancer.	
Am	J	Clin	Oncol	2010;33:481-8.	
27.	 Goldner,	G,	Wachter-Gerstner,	N,	Wachter,	S,	Dieckmann,	K,	 Janda,	M,	Potter,	R.	Acute	side	effects	
during	3-D-planned	conformal	 radiotherapy	of	prostate	cancer.	Differences	between	patient’s	 self-
reported	questionnaire	and	the	corresponding	doctor’s	report.	Strahlenther	Onkol	2003;179:320-7.	
28.	 Conaglen,	 HM,	 de	 Jong,	 D,	 Hartopeanu,	 C,	 Conaglen,	 JV,	 Tyrie,	 LK.	 The	 Effect	 of	 High	 Dose	 Rate	
Brachytherapy	 in	 Combination	 with	 External	 Beam	 Radiotherapy	 on	 Men’s	 Health-related	
Quality	 of	 Life	 and	 Sexual	 Function	 over	 a	 2	 Year	 Time	 Span.	 Clin	 Oncol-Uk	 2013;25:197-204.	 
Processed on: 28-9-2016
505259-L-bw-Aluwini
116
Chapter 7: QoL and toxicity in HDR brachytherapy as monotherapy for prostate cancer
29.	 Lips,	 IM,	 van	Gils,	 CH,	 van	der	Heide,	UA,	 Kruger,	AE,	 van	Vulpen,	M.	Health-related	quality	 of	 life	
3	 years	 after	 high-dose	 intensity-modulated	 radiotherapy	with	 gold	 fiducial	marker-based	 position	
verification.	BJU	Int	2009;103:762-7.	
30.	 Roeloffzen,	EMA,	Lips,	IM,	van	Gellekom,	MPR,	et	al.	Health-Related	Quality	of	Life	up	to	Six	Years	After	
125I	Brachytherapy	for	Early-Stage	Prostate	Cancer.	Int	J	Radiat	Oncol	Biol	Phys	2010;76:1054-60.	
31.	 Hampson,	LA,	Cowan,	JE,	Zhao,	S,	Carroll,	PR,	Cooperberg,	MR.	Impact	of	Age	on	Quality-of-life	Outcomes	
After	Treatment	for	Localized	Prostate	Cancer.	Eur	Urol	2015.	‘doi:’10.1016/j.eururo.2015.01.008.
32.	 Rosen,	RC,	Riley,	A,	Wagner,	G,	Osterloh,	IH,	Kirkpatrick,	J,	Mishra,	A.	The	international	index	of	erectile	
function	(IIEF):	a	multidimensional	scale	for	assessment	of	erectile	dysfunction.	Urology	1997;49:822-
30.	
33.	 Martinez,	AA,	Pataki,	I,	Edmundson,	G,	Sebastian,	E,	Brabbins,	D,	Gustafson,	G.	Phase	II	prospective	
study	of	 the	use	of	 conformal	 high-dose-rate	brachytherapy	 as	monotherapy	 for	 the	 treatment	of	
favorable	stage	prostate	cancer:	a	feasibility	report.	Int	J	Radiat	Oncol	Biol	Phys	2001;49:61-9.	
34.	 Yoshioka,	Y,	Konishi,	K,	Sumida,	I,	et	al.	Monotherapeutic	high-dose-rate	brachytherapy	for	prostate	
cancer:	five-year	results	of	an	extreme	hypofractionation	regimen	with	54	Gy	in	nine	fractions.	Int	J	
Radiat	Oncol	Biol	Phys	2011;80:469-75.	
35.	 Rogers,	CL,	Alder,	SC,	Rogers,	RL,	et	al.	High	dose	brachytherapy	as	monotherapy	for	intermediate	risk	
prostate	cancer.	J	Urol	2012;187:109-16.	
36.	 Schour,	 L,	 Demanes,	 J,	 Altieri,	 G,	 Brandt,	 D,	 Barnaba,	 M,	 Skoolisariyaporn,	 P.	 High	 Dose	 Rate	
Monotherapy	for	Prostate	Cancer.	Int	J	Radiat	Oncol	Biol	Phys	2005;63:S315.	
37.	 Mehta,	NH,	Kamrava,	M,	Wang,	PC,	Steinberg,	M,	Demanes,	J.	Prostate-specific	antigen	bounce	after	
high-dose-rate	monotherapy	for	prostate	cancer.	Int	J	Radiat	Oncol	Biol	Phys	2013;86:729-33.	
38.	 Rosser,	CJ,	Kuban,	DA,	Levy,	LB,	et	al.	Prostate	specific	antigen	bounce	phenomenon	after	external	
beam	radiation	for	clinically	localized	prostate	cancer.	J	Urol	2002;168:2001-5.	
Processed on: 28-9-2016
505259-L-bw-Aluwini
117
7
PART 3
Extreme hypofractionation  
with Stereotactic Body  
Radiation Therapy  
using the Cyberknife
Processed on: 28-9-2016
505259-L-bw-Aluwini
Processed on: 28-9-2016
505259-L-bw-Aluwini
119
8
Chapter 8
Cyberknife stereotactic radiotherapy as  
monotherapy for low to intermediate stage 
prostate cancer: Early experience,  
feasibility and tolerance.
Shafak Aluwini
Peter	van	Rooij
Mischa	Hoogeman
Chris	Bangma
Wim	J.	Kirkels
Luca Incrocci
Inger-Karine	Kolkman-Deurloo
Journal	of	Endourology	2010;	24:	865–869. 
Processed on: 28-9-2016
505259-L-bw-Aluwini
120
Chapter 8: Early experience with SBRT as monotherapy for prostate cancer
ABSTRACT
Purpose
The	 Cyberknife,	 a	 linear	 accelerator	 mounted	 on	 a	 robotic	 device,	 enables	 excellent	 dose	
conformation	to	the	target	and	minimizes	dose	to	surrounding	normal	tissue.	It	is	a	very	suitable	
device	 for	performing	hypofractionated	stereotactic	body	radiotherapy	 (SBRT)	as	monotherapy	
for	low-	to	intermediate-risk	prostate	cancer	patients.	We	report	our	early	experience	using	this	
technique.	
Material & Methods
Between	June	2008	and	June	2009	ten	patients	underwent	Cyberknife	monotherapy	as	treatment	
for	their	prostate	cancer	(stage	≤	T2b,	Gleason	score	(GS)	≤	7,	initial	PSA	(iPSA)	≤	15	ng/ml).	The	
prescribed	dose	(PD)	was	38	Gy	in	4	daily	fractions	of	9.5	Gy.	The	International	Prostate	Symptom	
Score	(IPSS),	and	Radiation	Therapy	Oncology	Group	(RTOG)	symptom	scale	were	prospectively	
administered	before	and	at	0.5,	1,	2,	3,	6	and	12	months.
Results
Median	age	of	the	patients	was	71	years	(range	66-76).	Three	patients	had	stage	T2a	and	7	a	T1c	
disease,	one	patient	had	GS	of	7,	and	all	others	had	GS	of	6.	Median	follow-up	was	5.1	months.	
Median	 iPSA	was	8.3	ng/ml	 (range	1.3-13.6	ng/ml).	Median	PTV	volume	delineated	on	CT	after	
matching	with	the	MRI	scan	was	107	cc	(range	42-158cc).	The	median	V100	of	the	prostate	was	
95.8%	(range	94.8-97.2).	The	D95	of	the	prostate	was	38.3	Gy	(range	38.1-38.8	Gy).	The	constraints	
for	the	bladder,	rectum	and	urethra	were	well	met.	The	IPSS-scores	after	3	months	were	stable	
compared	to	the	pre-treatment	scores.	Urinary	and	bowel	RTOG	symptoms	were	mild	and	within	
the	expected	levels.	
Conclusions
This	regimen	of	stereotactic	Cyberknife	monotherapy	for	low-	to	intermediate-risk	prostate	cancer	
with	excellent	dose	coverage	of	the	prostate	was	well	tolerated.	Ongoing	data	collection	is	being	
performed	for	further	assessment	of	toxicity	and	PSA	response.	
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INTRODUCTION
Prostate	cancer	is	the	most	common	cancer	in	men.	About	60%-70%	of	men	presenting	with	prostate	
cancer	have	an	organ-confined	disease1.	Treatment	options	for	this	group	include	surgery,	external	
beam	 radiation	 therapy,	 interstitial	 brachytherapy	 (Low-Dose-Rate	 with	 Iodine	 seeds	 or	 High-
Dose-Rate),	hormonal	therapy,	watchful	waiting	and	active	surveillance2.	Drawbacks	of	external	
beam	radiation	are	the	normal	tissue	toxicity	and	the	 long	treatment	course	(8	weeks).	Several	
publications	 suggested	 a	 radiobiological	 rationale	 for	 hypofractionated	 radiotherapy	 course	 in	
prostate	cancer,	due	to	a	low	α/β	ratio	(a	linear-quadratic	model	showing	the	dose	response	curve	
of	tumor	cells).	This	α/β	ratio	is	potentially	as	low	as	1.53-5.	This	suggests	that	prostate	cancer	cells	
are	more	sensitive	to	a	fraction	dose	>	3	Gy	than	the	conventional	daily	fraction	of	2	Gy.	This	was	
the	base	for	a	wide	use	of	hypofractionated	radiation	regimens	with	a	high	fraction	dose	for	early	
stage prostate cancer6-7.	These	radiation	regimens	used	stereotactic	body	radiation	therapy	(SBRT)	
or	High	dose	rate	(HDR)	brachytherapy.	SBRT	dose	level	treatments	(fraction	dose	higher	than	4	
Gy),	were	able	to	significantly	decrease	tumor	volume	and	PSA	level	in	mice8.	The	efficacy	of	the	
High	Dose	Rate	(HDR)	brachytherapy	as	monotherapy	was	established,	encouraging	the	wide	usage	
of	this	accurate	hypofractionated	radiation	delivery	mechanism	9-11.	Several	clinical	series	that	used	
hypofractionated	external	beam	regimens	have	also	shown	advantage	of	hypofractionation,	with	
doses	per	fraction	ranging	from	2.5	to	3.1	Gy	12-13.	Another	clinical	series	used	a	linac-based	SBRT	
technique	delivering	5	fractions	of	6.7	Gy	in	5	consecutive	days	with	promising	results14.
Cyberknife	is	an	excellent	treatment	device	for	performing	hypofractionated	accelerated	SBRT15 
[figure	1].	Due	to	its	submillimeter	accuracy	and	image	guided	tracking	technology,	an	optimal	dose	
distribution	to	the	target	is	possible,	creating	very	steep	dose	gradients	in	surrounding	normal	tissue.	
Fuller	et	al.	reported	the	opportunity	to	construct	Cyberknife	SBRT	plans	that	closely	resemble	HDR	
brachytherapy	dosimetry16.	In	our	preparing	phase	we	reached	the	same	conclusions	of	Fuller	after	
comparing	our	HDR	plans	with	virtual	CK	plans.
In	 this	 report,	we	present	our	preliminary	 results	 in	a	prospectively,	well	documented	ongoing	
clinical	 series	 using	 a	 Cyberknife	 SBRT	 for	 localized	 low	 to	 intermediate-risk	 prostate	 cancer	
patients,	delivering	38	Gy	in	4	daily	fractions	of	9.5	Gy.
METHODS AND MATERIALS
Patients
From	our	experience	with	HDR	brachytherapy	delivering	38	Gy	in	4	fractions	within	36	hours,	we	
started	a	planning	study	to	evaluate	the	possibility	to	give	an	optimal	HDR-like	dose	distribution	
with	the	Cyberknife	technique.	The	promising	results	of	this	study	have	lead	to	a	clinical	protocol	
for	a	pilot	study	to	treat	 low-	to	 intermediate-risk	prostate	cancer	patients	with	the	Cyberknife	
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Table 8.1. |	Inclusion	and	Exclusion	Criteria	
 Inclusion criteria Exclusion criteria
T1c-T2b Hormonal	therapy
GS	≤	7 Prostatectomy
PSA	≤	15 Previous	pelvic	irradiation
Tumor	load	>	50%	of	the	biopsy Prostate	volume	>	90	cc
International	Prostate	Symptom	Score	>	15 Other	malignancy
(except	well	treated	basal-cell	
carcinoma	of	the	skin)
WHO-score	≤	2 Clips	previous	operations	in	
prostate region
using	a	hypofractionated	regimen.	Inclusion	and	exclusion	criteria	were	equal	to	the	ones	we	have	
used	for	years	for	our	HDR-brachytherapy	regimen	(table	1),	because	of	our	wide	experience	in	this	
group	regarding	the	tolerance	to	the	dose	given,	and	the	excellent	PSA	response.	Our	choice	was	to	 
initiate	 an	 alternative	 treatment	 for	 this	 group	 of	 patients	 eligible	 for	 our	 HDR-brachytherapy	
protocol	who	do	not	want	an	invasive	treatment	or	were	not	eligible	for	surgery.	The	10	patients	
treated	were	well	informed	about	this	new	treatment.	All	other	options	for	the	treatment	of	their	
prostate	cancer	were	widely	discussed	with	them.	Our	aim	was	to	reach	the	same	PSA-response	
but	 with	 less	 toxicity	 (by	 avoiding	 the	 mechanical	 damage	 due	 to	 needle	 insertion	 in	 HDR-
brachytherapy).	From	June	2008	through	June	2009	10	patients	underwent	HDR-like	Cyberknife	
monotherapy	 as	 primary	 treatment	 for	 their	 biopsy	 proven	 early	 to	 moderate-risk	 prostate	
cancer,	receiving	38	Gy	in	4	daily	fractions	of	9.5	Gy.	All	patients	followed	a	low-fiber	diet	and	were	
given	laxatives	before	and	during	the	radiation	course	in	order	to	minimize	the	daily	variations	in	
intestine	filling	and	its	effect	on	the	prostate	movement.	Bladder	catheters	were	used	to	keep	a	
constant	bladder	filling	of	100	cc	during	the	computed	tomography	(CT)	and	magnetic	resonance	
imaging	(MRI)	scans	(which	could	also	be	used	as	an	extra	reference	for	matching	these	2	scans),	
and	during	the	radiation	course	for	the	first	8	patients.	Ultrasound	measurements	of	bladder	filling	
were	registered	before,	during	and	after	the	radiation	session,	 to	check	the	changes	 in	bladder	
filling	during	the	fraction	and	to	be	able	to	correct	it	if	necessary.	The	last	2	patients	were	irradiated	
without	catheter	(a	catheter	was	only	used	during	the	CT-	and	MRI-scans).	The	bladder	catheters	
were	not	used	in	these	2	patients	after	the	evaluation	of	the	data	of	the	first	8	patients	showing	
that	ultrasound	measurement	of	the	bladder	filling	before	and	during	the	radiation	was	sufficient	
to	keep	a	constant	filling	during	the	radiation	fraction	making	insertion	of	a	catheter	not	necessary.	
Four	golden	fiducials	were	implanted	into	the	prostate	before	the	treatment	for	target	tracking	
during	irradiation.	All	patients	received	a	questionnaire	at	the	end	of	the	treatment	to	evaluate	
their	satisfaction	about	all	steps	of	this	regimen.	
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Treatment planning
For	each	patient	a	CT	and	MRI-scan	of	the	prostate	region	was	made.	Prostate	delineation	occurs	
on	 the	 prostate	 MRI,	 three-	 dimensionally	 co-registered	 with	 the	 prostate	 MRI	 imaging,	 plus	
a	3	mm	volume	expansion	 in	all	directions	for	the	planning	target	volume	(PTV).	Both	MRI	and	 
CT-scans	were	made	on	the	same	day	in	the	same	position;	a	second	CT-scan	was	made	several	
days	afterwards	to	evaluate	the	variations	in	rectum	filling.	The	urethra	was	identified	by	insertion	
of	a	Foley	catheter,	which	was	also	used	as	an	extra	reference	point	to	match	MRI-	and	CT	images.	
Table 8.2. |	Dosimetric	Constrains	and	Objectives
Targets or OAR Doses(Gy) Reference dose (%)
Planning	target	volume:	Reference	dose 38 100
Anterior	rectal	wall:	Dmax 38 100
Rectal	mucosa:	Dmax 28.5 75
Rectum:	Dose	to	1	cc 32.3 85
Bladder: Dose to 1 cc 38 100
Bladder:	Dmax 41.8 110
Urethra:	Dose	to	5%	of	the	volume 45.5 119.7
Urethra:	Dose	to	10%	of	the	volume 42 110.5
Urethra:	Dose	to	50%	of	the	volume 40 105.3
Sigmoid	/	intestine 28.5 75.0
Femur	head 24 63.2
Figure 8.1. | CyberKnife	accelerator.
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Our	set	of	constraints	and	objectives	for	each	CK	SBRT	include	the	following	(table	2):	minimal	dose	
coverage	of	the	planning’s	target	volume	(PTV)	of	95%	(at	least	95%	of	the	PTV	volume	has	to	receive	
100%	of	the	PD)	with	a	maximum	dose	of	<150%	of	the	prescribed	dose	(PD)	(57	Gy)	allowed.	The	
maximum	rectal	wall	dose	(Dmax	rectal	wall)	should	be	less	than	100%	of	the	prescribed	dose	(38	
Gy)	and	the	Dmax	rectal	mucosa	(a	solid	structure	obtained	by	3	mm	contraction	of	the	rectal	wall)	
has	to	be	less	than	75%	of	the	prescribed	dose	(28.5	Gy).	The	highest	dose	to	1	cc	of	the	rectum	
must	be	limited	to	85%	of	the	prescribed	dose	(32.5	Gy).	A	maximum	bladder	dose	of	110%	of	the	
prescribed	dose	(41.8	Gy)	is	allowed,	and	the	highest	dose	to	1	cc	of	the	bladder	has	to	be	limited	to	
100%	of	the	prescribed	dose.	The	urethral	dose	is	limited	to	120%	of	the	prescribed	dose	(45.6	Gy).	
These	constraints	are	the	same	as	used	in	our	HDR	brachytherapy	protocol11.
Patient reported Quality of life assessments
The	primary	outcome	of	this	report	is	the	early	and	intermediate	toxicity	score	and	the	early	PSA	
response.	Validated	quality	of	life	(QoL)	questionnaires	were	prospectively	administered	before,	at	
baseline,	and	at	0.5,	1,	2,	3	and	6	months	post	radiation.	PSA	analyses	were	made	before	treatment,	
at	baseline,	and	every	3	months	post	radiation.	Functions	and	complaints	were	measured	using	the	
questionnaires	of	the	International	Prostate	Symptom	Score	(IPSS),	and	Radiation	Therapy	Oncology	
Group	(RTOG),	and	European	Organization	for	Research	and	Treatment	of	Cancer	Prostate	Module	
(EORTC	QLQ-PR25):	 the	EORTC	QLQ-PR25	data	are	not	 reported	here.	 The	 IPSS	 17, 18 for benign 
prostate	hypertrophy	calculates	the	amount	of	voiding	symptom	severity:	(urinary	QoL	scale),	and	
urinary	bother	scale	(UB).	The	urinary	QoL	is	calculated	by	a	summation	of	7	items	scores	(range	
0-35),	and	the	UB	is	a	single	 item	scale	(range	0-6).	Gastrointestinal	(GI)	and	genitourinary	(GU)	
toxicity	were	 graded	 using	 the	 RTOG	 scales19-20;	 both	 scales	 are	 summarized	multi-item	 scales.	
Computation	of	 the	QoL	scales	of	 the	questionnaires	 is	made	according	to	 the	 instructions;	 for	
missing	data	the	rule	of	half	is	used:	imputation	of	the	missing	items	with	the	mean	scale	score	is	
accepted	if	less	than	half	of	the	items	of	a	scale	are	missing.	
Figure 8.2. | Prostate-specific	antigen	response.
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Table 8.3. |	Radiation	Therapy	Oncology	Group	Toxicity
No. of patients (%)
 Radiation Therapy Oncology Group defecation symptoms
2 weeks 1	months 2	months 3	months 6	months
Mild 2/10	(20) 1/10	(10) 1/10	(10) 1/9	(11) 0/8	(0)
Moderate 1/10	(10) 0/10	(0) 0/10	(0) 0/9	(0) 0/8	(0)
Severe 0/10	(0) 0/10	(0) 0/10	(0) 0/9	(0) 0/8	(0)
 Radiation Therapy Oncology Group urinary symptoms
Mild 5/10	(50) 4/10	(40) 2/10	(20) 3/9	(33) 2/8	(25)
Moderate 2/10	(20) 2/10	(20) 2/10	(20) 1/9	(11) 1/8	(12)
Severe 0/10	(0) 0/10	(0) 0/10	(0) 0/9	(0) 0/8	(0)
	0=	no	toxicity	reported	at	that	moment.
RESULTS
Median	age	of	patients	was	71	years	(range	66-76),	3	patients	had	stage	T2a	and	7	T1c	diseases,	
one	patient	had	GS	of	7,	and	all	others	had	GS	of	6.	Median	iPSA	was	8.3	ng/ml	(range	1.3-13.6	ng/
ml).	Median	PTV	volume	delineated	on	CT	after	matching	with	the	MRI	scan	was	107	cc	 (range	
42-158cc).	The	median	follow	up	was	5.1	months	(range	2-13	months).	Figure	2	shows	the	patterns	
of	PSA	response.	There	is	a	decline	of	the	mean	PSA	to	3.8	(SD	2),	and	1.6	(SD	2),	at	three	and	6	
months	follow	up	respectively.	This	means	a	decline	of	53%	after	3	months	and	81%	after	6	months.
Acute toxicity
The	median	IPSS-score	increased	from	a	baseline	of	7	to	10	and	11	after	3	and	6	months	respectively.	
The	satisfaction-scores	did	not	change	due	to	this	increase	and	remained	stable	after	3	and	6	months.	
Three	 out	 of	 10	 patients	 treated,	 are	 still	 using	 alpha–blockers	 after	 2	months	 follow	 up,	which	
were	usually	prescribed	during	the	first	4	weeks	after	the	radiation	course.	One	patient	started	the	
treatment	with	a	baseline	IPSS	of	24/35	and	needed	a	bladder	catheter	2	weeks	after	completion	of	
the	radiation	course	(4	months	till	now).	(This	was	the	second	patient	that	we	treated;	due	to	this	
experience	we	changed	the	protocol:	IPSS	should	be	<	15).	The	RTOG	rectal	toxicity	shows	a	mild	
toxicity	(grade	1-2)	in	2/10	patients	after	2	weeks,	returning	to	normal	after	4	weeks	except	for	one	
patient	where	the	symptoms	were	relieved	after	3	months.	Rectal	bleeding	was	registered	in	one	
patient,	which	was	transient,	started	after	2	weeks	and	relieving	4	weeks	after	radiation.	The	RTOG	
urinary	toxicity	shows	mild	symptoms	in	5/10	patients	after	2	weeks,	and	in	2/10	after	2	months,	with	
another	peak	after	3	months	(3/9).	Table	3	shows	the	RTOG	toxicity-scores.
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Patients Satisfaction
After	 the	 treatment	 each	 patient	 received	 a	 questionnaire	 about	 all	 steps	 of	 preparation	 and	
treatment.	 The	 response	 rate	was	 100%:	 80%	was	 very	 satisfied	 about	 the	 procedures	 of	 this	
treatment	regimen,	20%	was	neutral.	The	only	point	that	patients	were	not	satisfied	about,	was	
the	Foley	catheter	during	the	irradiation	(4/8	50%).	The	use	of	catheter	was	replaced	by	ultrasound	
measurements	in	the	protocol.
DISCUSSION
Acute toxicity
In	this	pilot	study,	our	data	using	the	Cyberknife	for	early	to	intermediate	stage	prostate	cancer	
demonstrate	that	this	course	is	well	tolerated	with	an	acceptable	expected	percentage	of	acute	
urinary,	bowel	and	rectum	symptoms.	The	percentages	of	urinary	and	rectal	acute	toxicities	were	
similar	to	those	reported	by	patients	treated	with	conventionally	fractionated	courses26.	Also	from	
our	 experience	with	 the	 same	hypofractionated	 course	 (4	 x	 9.5	Gy)	 in	 the	HDR-brachytherapy	
setting,	we	noticed	that	the	Cyberknife	hypofractioanted	stereotactic	radiotherapy	course	caused	
even	 less	acute	urinary	toxicity	 21-23.	The	mechanical	 trauma	due	to	needle	 insertion	during	the	
HDR-brachythyerapy	may	well	explain	 the	difference	between	these	2	modalities	 (our	data	will	
be	 reported	 in	 the	 future).	Until	now	we	have	not	observed	any	severe	acute	urinary	or	 rectal	
toxicity	and	the	only	patient	that	needed	a	catheter	2	weeks	after	his	Cyberknife	treatment	was	
the	 one	with	 the	worst	 IPSS-score	 (24/35)	 before	 treatment.	 He	 described	 his	 urinary	QOL	 as	
“mostly	dissatisfied”.	This	patient	also	had	a	prostate	volume	of	97	cc.	Such	a	huge	prostate	volume	
can	be	a	predisposing	factor	for	acute	toxicities.24, 25	These	observations	led	to	a	modification	of	
our	protocol:	the	prostate	volume	should	be	smaller	than	90	cc	and	patients	with	an	IPSS-score	
>15	were	excluded.	Fuller	et	al.	 reported	an	acceptable	acute	urinary	and	rectal	 toxicity	 for	his	
first	 10	 patients	 treated	with	 the	 Cyberknife	 following	 the	 same	 regimen	we	used	 (4	 fractions	
of	 9.5	 Gy)16.	 King	 et	 al.	 reported	 that	 patients	 treated	 with	 a	 hypofractionated	 stereotactic	
course	of	 radiotherapy	 for	 localized	prostate	 cancer	using	5	 fractions	of	7.25	Gy	had	 the	 same	
urinary	 and	 rectal	 toxicities	 as	 experienced	 with	 conventionally	 fractionated	 courses	 with	 an	
excellent	PSA	 response26.	 In	 their	data,	no	biochemical	 failure	was	 reported	after	a	median	FU	
of	33	months.	We	are	aware	 that	10	patients	 is	 a	 too	 small	population	and	 that	our	 follow-up	
is	 too	 short	 to	draw	conclusions.	 That’s	why	we	have	 to	be	 cautious	about	any	 interpretation;	
however	it	is	very	encouraging	to	reproduce	similar	results	to	the	few	data	published	about	the	
use	of	hypofractionated	stereotactic	radiotherapy	for	early-	to	intermediate-stage	prostate	cancer	
using	the	Cyberknife.	The	results	of	our	treatment	evaluating	questionnaire	suggest	that	this	new	
method	of	hypofractionated	radiosurgery	giving	a	non-invasive	treatment	for	low	to	intermediate	
risk	prostate	cancer	was	appreciated	by	our	entire	patients	because	of	the	short	treatment	course	
and	the	limited	acute	toxicity.	This	has	yet	to	be	confirmed	by	long-term	results.	
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PSA response
Our	patients	show	a	good	and	more	rapid	PSA	decline	compared	to	literature	regarding	conventional	
external	 beam	 radiotherapy27, 28.	 The	 same	 response	 after	 hypofractionated	 regimen	 using	 the	
Cyberknife	 for	 SBRT	 has	 been	 reported	 before16, 26.	 A	 PSA	 bounce	 effect	 and	 other	 recurrence	
phenomena	were	not	experienced	in	this	study,	possibly	because	of	the	short	follow-up	period.	
This	encouraging	PSA	response	may	support	the	radiobiologic	assumption	of	a	 low	α/β	ratio	of	
prostate	cancer.	A	longer	follow-up	is	needed	to	confirm	this.
CONCLUSIONS
This	regimen	was	well	tolerated	in	our	pilot	group,	with	a	very	acceptable	acute	toxicity.	Expanding	
our	data	with	more	patients	and	longer	follow-up	is	needed	to	further	evaluate	this	new	method.
CONFLICT OF INTEREST STATEMENT
None	of	the	authors	have	a	conflict	of	interest	in	connection	with	this	article	and	they	disclose	any	
financial	and	personal	relationships	with	other	people	or	organizations	that	could	inappropriately	
influence	(bias)	their	work.	
ACKNOWLEDGMENTS 
The	 authors	 acknowledge	 and	 thank	 sincerely	 the	 following	 persons	 from	 the	 department	 of	
Radiation	Oncology	of	the	Erasmus	MC	in	Rotterdam	for	their	help	with	data	collection:	Erik	de	
Klerck,	Connie	de	Pan	and	Steffanie	Klosinski.	
References
1.	 Jemal	A,	Tiwari	RC,	Murray	T	et	al.	Cancer	statistics,	2004.	CA Cancer J Clin.	2004;	54:	8-29.
2.	 Thompson	I,	Thrasher	JB,	Aus	G	et	al.	Guideline	for	the	management	of	clinically	 localized	prostate	
cancer:	2007	update.	J Urol.	2007;	177:	2106-31.
3.	 Brenner	DJ,	Hall	EJ.	Fractionation	and	Protraction	for	Radiotherapy	of	Prostate	carcinoma.	Int J Radiat 
Oncol Biol Phys.	1999;	43:	1095-101.
4.	 D’Souza	WD,	Thames	HD.	Is	the	alpha/beta	ratio	for	prostate	cancer	low?	Int J Radiat Oncol Biol Phys.	
2001; 51:	1-3.
5.	 King	CR,	Fowler	JF.	A	simple	analytic	derivation	suggests	that	prostate	cancer	alpha/beta	ratio	is	low.	
Int J Radiat Oncol Biol Phys.	2001;	51:	213-4.
6.	 Martinez	 AA,	 Gustafson	 G,	 Gonzalez	 J	 et	 al.	 Dose	 Escalation	 Using	 Conformal	 High-Dose-Rate	
Brachytherapy	Improves	Outcome	in	Unfavorable	Prostate	Cancer.	Int J Radiat Oncol Biol Phys.	2002;	
53:	316-27.
Processed on: 28-9-2016
505259-L-bw-Aluwini
128
Chapter 8: Early experience with SBRT as monotherapy for prostate cancer
7.	 Yoshioka	 Y,	 Nishimura	 T,	 Kamata	 M	 et	 al.	 High-dose-rate	 interstitial	 brachytherapy	 using	 inverse	
planning	for	locally	advanced	cervical	cancer.	Nippon Igaku Hoshasen Gakkai Zasshi.	2003;	63:	171-6.
8.	 Lotan	Y,	Stanfield	 J,	Cho	C	et	al.	Efficacy	of	High	Dose	per	Fraction	Radiation	 for	 Implanted	Human	
Prostate	Cancer	in	a	Nude	Mouse	Model.	J Urol. 2006;	175:	1932-1936.
9.	 Bentzen	SM,	Wasserman	TH.	Balancing	on	a	Knife’s	Edge:	Evidence-Based	Medicine	and	the	Marketing	
of	Health	Technology.	Int J Radiat Oncol Biol Phys.	2008;	72:	12-4;	discussion	4-8.
10.	 Lyons	JA	KP,	Mohan	DS,	Reddy	CA,	Klein	EA.	Importance	of	High	Radiation	Doses	(72	Gy	or	greater)	in	
the	Treatment	of	Stage	T1-T3	Adenocarcinoma	of	the	Prostate.	Urology.	2000;	55:	85-90.
11.	 Martinz	AA,	Pataki	 I,	Edmundson	G,	et	al.	Phase	II	Prospective	Study	of	the	Use	of	Conformal	High-
Dose-Rate	Brachytherapy	as	Monotherapy	for	the	Treatment	of	Favorable	Stage	Prostate	Cancer:	A	
Feasibility	Report.	Int J Radiat Oncol Biol Phys.	2001;	49:	61-69.
12.	 Lukka	H,	Hayter	C,	Julian	JA	et	al.	Randomized	Trial	Comparing	two	Fractionation	Schedules	for	Patients	
with	Localized	Prostate	Cancer.	J Clin Oncol.	2005;	23:	6132-8.
13.	 Yeoh	EE,	Holloway	RH,	Fraser	RJ	et	al.	Hypofractionated	versus	Conventionally	Fractionated	Radiation	
Therapy	for	Prostate	Carcinoma:	Updated	Results	of	a	Phase	III	Randomized	Trial.	Int J Radiat Oncol 
Biol Phys.	2006;	66:	1072-83.
14.	 Madsen	BL,	Hsi	RA,	Pham	HT,	Fowler	JF,	Esagui	L,	Corman	J.	Stereotactic	Hypofractionated	Accurate	
Radiotherapy	of	the	Prostate	(SHARP),	33.5	Gy	in	five	fractions	for	Localized	Disease:	First	Clinical	Trial	
Results.	Int J Radiat Oncol Biol Phys.	2007;	67:	1099-105.
15.	 King	CR,	Lehmann	J,	Adler	JR,	et	al.	Cyberknife	Radiotherapy	for	Localized	Prostate	Cancer:	Rationale	
and	Technical	Feasibility.	Technol Cancer Res Treat. 2003;	2:	25-30.
16.	 Fuller	DB,	Naitoh	J,	Charles	L,	et	al.	Virtual	HDR	Cyberknife	Treatment	for	Localized	Prostatic	Carcinoma:	
Dosimetry	Comparison	with	HDR	Brachytherapy	and	Preliminary	Clinical	Observations.	J	Radiat	Oncol	
Biol	Phys	2008;	70:	1588-1597.
17.	 Barry	MJ,	Fowler	FJ,	 Jr.,	O’Leary	MP	et	al.	The	American	Urological	Association	Symptom	 Index	 for	
Benign	Prostatic	Hyperplasia.	The	Measurement	Committee	of	the	American	Urological	Association.	J 
Urol.	1992;	148:	1549-57;	discussion	64.
18.	 Keyes	 M,	 Miller	 S,	 Moravan	 V	 et	 al.	 Predictive	 Factors	 for	 Acute	 and	 Late	 Urinary	 Toxicity	 after	
Permanent	 Prostate	 Brachytherapy:	 Long-Term	Outcome	 in	 712	 Consecutive	 Patients.	 Int J Radiat 
Oncol Biol Phys.	2009;	73:	1023-32.
19.	 Cox	JD,	Stetz	 J,	Pajak	TF.	Toxicity	Criteria	of	 the	Radiation	Therapy	Oncology	Group	(RTOG)	and	the	
European	Organization	for	Research	and	Treatment	of	Cancer	(EORTC).	 Int J Radiat Oncol Biol Phys.	
1995; 31:	1341-6.
20.	 Lawton	CA,	Won	M,	Pilepich	MV	et	al.	Long-term	Treatment	Sequel	following	External	Beam	Irradiation	
for	Adenocarcinoma	of	the	Prostate:	Analysis	of	RTOG	Studies	7506	and	7706.	Int J Radiat Oncol Biol 
Phys.	1991;	21:	935-9.
21.	 Corner	C,	Rojas	AM,	Bryant	L	et	al.	A	phase	 II	 Study	of	High-Dose-Rate	afterloading	Brachytherapy	
as	Monotherapy	 for	 the	Treatment	of	 Localized	Prostate	 cancer.	 Int J Radiat Oncol Biol Phys.2008; 
72:441-446.
22.	 Yoshioka	Y,	Nose	T,	Yoshida	K	et	al.	High-Dose-Rate	Interstitial	Brachytherapy	as	a	Monotherapy	for	
Localized	Prostate	Cancer:	Treatment	Description	and	Preliminary	Results	of	a	Phase	I/II	Clinical	Trial.	
Int J Radiat Oncol Biol Phys.	2000;	48:675-681.
Processed on: 28-9-2016
505259-L-bw-Aluwini
129
8
23.	 Aluwini	S,	Kirkels	W,	Hofstra	S	et	al.	Early	Experience	in	CT-planned	HDR	Brachytherapy	of	Early	Stage	
Prostate	Cancer	as	Monotherapy.	Radioth	Oncol.	2008;	88:	s323.
24.	 Pinkawa	M,	fischedick	K,	Asadpour	B	et	al.	Toxicity	profile	with	a	large	Prostate	Volume	after	external	
Beam	Radiotherapy	for	Localized	Prostate	Cancer.	Int J Radiat Oncol Biol Phys.	2008;	70:	83-89.
25.	 Peeters	S,	Hoogeman	M,	Heemsbergen	W	et	al.	Volume	and	Hormonal	effects	for	Acute	Side	effects	
of	Rectum	and	Bladder	During	Conformal	Radiotherapy	 for	Prostate	Cancer.	 Int J Radiat Oncol Biol 
Phys.2005;	63:	1142-1152.
26.	 King	CR,	Brooks	JD,	Gill	H	et	al.	Stereotactic	Body	radiotherapy	for	Localized	prostate	Cancer:	Interim	
Results	of	a	prospective	Phase	II	clinical	Trial.	Int J Radiat Oncol Biol Phys.	2009;	73:	1043-1048.
27.	 Leborgne	 F,	 and	 Fowler	 J.	 Late	 Outcomes	 following	 Hypofractionated	 Conformal	 Radiotherapy	 vs.	
Standard	Fractionation	for	Localized	Prostate	Cancer:	A	Nonrandomized	Contemporary	Comparison.	
Int J Radiat Oncol Biol Phys.	2009	(article	in	press).
28.	 Yeoh	 E,	Holloway	R,	 Faster	 R	 et	 al.	Hypofractionated	 versus	 Conventionally	 Fractionated	Radiation	
Therapy	for	Prostate	Carcinoma:	Updated	of	A	phase	III	Randomized	Trial. Int J Radiat Oncol Biol Phys. 
2006;	66:	1072-1083.
Processed on: 28-9-2016
505259-L-bw-Aluwini
Processed on: 28-9-2016
505259-L-bw-Aluwini
131
9
Chapter 9
Stereotactic body radiotherapy with a  
focal boost to the MRI-visible tumor as  
monotherapy for low- and intermediate-risk 
prostate cancer: early results.
Shafak Aluwini
Peter	van	Rooij
Mischa	Hoogeman
Wim	Kirkels
Inger-Karine	Kolkman-Deurloo,
Chris	Bangma
Radiation	Oncology	2013;	8(1):	84.
Processed on: 28-9-2016
505259-L-bw-Aluwini
132
Chapter 9: SBRT with focal boost to visible tumor for prostate cancer
ABSTRACT 
Background
There	 is	 growing	 evidence	 that	 prostate	 cancer	 (PC)	 cells	 are	 more	 sensitive	 to	 high	 fraction	
dose	 in	 hypofractionation	 schemes.	 High-dose-rate	 (HDR)	 brachytherapy	 as	 monotherapy	 is	
established	 to	 be	 a	 good	 treatment	 option	 for	 PC	 using	 extremely	 hypofractionated	 schemes.	
This	 hypofractionation	 can	 also	 be	 achieved	 with	 stereotactic	 body	 radiotherapy	 (SBRT).	 We	
report	results	on	toxicity,	PSA	response	and	quality	of	life	(QoL)	in	patients	treated	with	SBRT	for	
favorable-risk	PC.
Methods
Over	the	last	4	years,	50	hormone-naïve	patients	with	low-	and	intermediate-risk	PC	were	treated	
with	SBRT	to	a	total	dose	of	38	Gy	delivered	in	four	daily	fractions	of	9.5	Gy.	An	integrated	boost	
to	11	Gy	per	fraction	was	applied	to	the	dominant	lesion	if	visible	on	MRI.	Toxicity	and	QoL	were	
assessed	prospectively	using	validated	questionnaires.
Results
Median	follow-up	was	23	months.	The	2-year	actuarial	biochemical	control	rate	was	100%.	Median	
PSA	nadir	was	0.6	ng/ml.	Median	International	Prostate	Symptoms	Score	(IPSS)	was	9/35	before	
treatment,	with	a	median	increase	of	4	at	3	months	and	remaining	stable	at	13/35	thereafter.	The	
EORTC/RTOG	toxicity	scales	showed	grade	2	and	3	gastrointestinal	(GI)	acute	toxicity	in	12%	and	
2%,	 respectively.	The	 late	grade	2	GI	 toxicity	was	3%	during	24	months	FU.	Genitourinary	 (GU)	
grade	2,	3	toxicity	was	seen	in	15%,	8%	in	the	acute	phase	and	10%,	6%	at	24	months,	respectively.	
The	urinary,	bowel	and	sexual	domains	of	the	EORTC-PR25	scales	recovered	over	time,	showing	no	
significant	changes	at	24	months	post-treatment.	
Conclusions
SBRT	to	38	Gy	in	4	daily	fractions	for	low-	and	intermediate-risk	PC	patients	is	feasible	with	low	
acute	 and	 late	 genitourinary	 and	 gastrointestinal	 toxicity.	 Longer	 follow-up	 preferably	 within	
randomized	studies,	is	required	to	compare	these	results	with	standard	fractionation	schemes.
Keywords
Clinical	outcome;	Low-	and	 intermediate-risk;	Radiotherapy;	Prostate	cancer;	Stereotactic	Body	
radiation.
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BACKGROUND 
Although	external	beam	radiotherapy	(EBRT)	 is	a	highly	effective	treatment	for	prostate	cancer	
(PC),	 the	 long	 course	 of	 7-9	weeks	 can	 have	 a	 negative	 impact	 on	 the	 patients’	 quality	 of	 life	
(QoL)	and	hospital	 resources.	Hypofractionated	radiotherapy	 is	used	 increasingly	because	of	 its	
radiobiological	benefits,	acceptable	toxicity,	economic	and	social	advantages.	
Several	publications	suggest	a	radiobiological	rationale	for	hypofractionated	radiotherapy	in	PC1,2.	
This	 indicates	a	high	sensitivity	of	PC	to	 fraction	dose	but	not	to	the	total	dose,	suggesting	the	
possibility	of	significant	therapeutic	benefit	from	hypofractionation	in	terms	of	local	control	and	
reduction	of	normal	tissue	complication	probability	for	bladder	and	rectum1-3.	
Brachytherapy	is	commonly	used	as	treatment	for	PC	because	of	the	possibility	to	deliver	a	high	
dose	to	the	prostate	while	sparing	the	surrounding	organs	at	risk	(OARs).	The	use	of	high-dose-rate	
brachytherapy	(HDR-BT)	is	proven	to	be	safe	and	effective	and	this	technique	is	increasingly	used	
either	as	a	boost	after	EBRT	or	as	monotherapy.4, 5	Fuller	et	al.6	demonstrated	that	it	is	possible	to	
achieve	the	same	dose	distributions	with	SBRT	as	with	HDR-BT.	Based	on	these	findings	and	our	
HDR-BT	experience,	we	initiated	an	SBRT	protocol	to	treat	low-	and	intermediate-risk	PC	patients.	
This	protocol	was	used	for	patients	who	were	not	eligible	for	HDR	brachytherapy. 
METHODS
Patients and planning
Between	 June	 2008	 and	November	 2011,	 50	 hormone-naïve	 patients	with	 biopsy-proven	 low-	
to	 intermediate-risk	 PC	 underwent	 SBRT	 treatment	 of	 PC,	 using	 the	 Cyberknife®, in four daily 
fractions	of	9.5	Gy	 to	a	 total	dose	of	38	Gy.	The	first	10	patients	were	 treated	 in	a	pilot	 study	
with the results reported in 20107.	The	inclusion	criteria	can	be	found	in	this	report	as	well.	These	
patients	were	not	eligible	for	HDR	brachytherapy	because	of	a	large	volume	of	the	prostate	(>	50	
cc),	or	a	combination	of	limited	urine	flow/second	(Q-max	<	10	ml/sec.)	and	a	significant	residual	
volume	 in	 the	 bladder	 (>100	 cc)	 (37/50,	 74%).	 Other	 reasons	 were:	 transurethral	 resection	 of	
the	prostate	in	the	medical	history	in	six	patients	(12%),	pelvic	surgery	in	two	(4%)	and	hip	joint	
prostheses	in	five	(10%).	Patients	with	clinical	stages	T1c-T2a,	Gleason-score	6	and	PSA	≤10	ng/ml	
were	defined	as	low-risk	PC.	Patients	with	PSA	10-20	ng/ml	and/or	T2b-T3a	and/or	Gleason-score	
7,	were	defined	as	intermediate-risk	PC	8.	In	all	patients,	four	gold	fiducial	seeds	were	implanted	
in	 the	 prostate	 through	 ultrasound-guided	 trans-perineal	 pre-loaded	 needles.	 One	 week	 after	
fiducial	implantation,	computed	tomography	(CT)	and	magnetic	resonance	image-scan	(MRI)	were	
acquired.	T1-	and	T2-weighted	sequences	were	performed	(1.5	Tessla	without	endorectal	coil)	to	
elaborate	the	treatment	plan	after	placement	of	a	Foley	catheter.	The	Foley	catheter	was	delineated	
as	the	urethra.	The	CT	and	MRI	images	were	matched	on	the	markers	and	the	Foley	catheter.	All	
patients	followed	a	low	fiber	dietary	protocol	to	minimize	intestinal	activity.	The	MultiPlan	(version	
2.1.5,	Accuray)	treatment	planning	system	was	employed.	If	the	dominant	tumor	was	visible	on	
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the	MRI,	an	integrated	boost	to	the	visible	tumor	was	planned	up	to	11	Gy/fraction	which	is	120%	
of	the	prescribed	dose	(PD).	The	planning	target	volume	(PTV)	included	the	prostate	expanded	by	
3	mm	in	all	directions	and	had	to	receive	≥	95%	of	the	PD.	Minor	violation	of	the	constraints	up	to	
110%	of	the	constraint	dose	were	accepted.	Details	on	treatment	planning	and	applied	constraints	
can be found in an earlier report7.
PSA measurement, toxicity, and QoL
All	patients	were	 followed	prospectively.	Biochemical	 failure	 (BF)	was	determined	according	 to	
the	Phoenix	definition	(nadir	PSA	+	2	ng/ml)9.	A	PSA	bounce	is	defined	as	a	transient	rise	in	the	
PSA	level	with	a	subsequent	normalization	of	the	PSA	values10.	GI	and	GU	toxicity	was	defined	and	
reported	using	the	Radiation	Therapy	Oncology	Group	and	European	Organization	for	Research	
and	 Treatment	 of	 Cancer	 (RTOG-EORTC)	 scoring	 criteria11.	 RTOG-EORTC	 toxicity	 and	 the	 IPSS	
questionnaires	were	sent	to	the	patients	at	the	following	time	points:	baseline,	at	1,	2,	3,	6,	12	
months	after	treatment,	and	twice	yearly	thereafter.	International	Index	of	Erectile	Function	(IIEF)	
and	the	EORTC	QLQ-PR25	questionnaires	were	sent	at	baseline,	6	and	12	months	after	treatment,	
and	yearly	afterward.	All	patients	were	seen	every	3	months	 in	the	first	year	and	subsequently	
twice	yearly.
Statistical analysis
The	 GI	 and	 GU	 toxicity	 were	 evaluated	 according	 to	 the	 EORTC-RTOG	 toxicity	 scores,	 using	 a	
combination	of	the	patients’	questionnaires	and	physicians’	charts.	The	highest-score	of	toxicity	
was	recorded.	Toxicity	within	90	days	after	radiotherapy	was	considered	acute	toxicity,	and	toxicity	
after	90	days	was	considered	late	toxicity.	The	IPSS,	the	PR-25	and	the	IIEF	questionnaires	were	
used	to	asses	the	GU,	GI	functional	QoL	and	erectile	function.	These	questionnaires	were	analyzed	
to	obtain	the	net	effect	on	function	compared	to	baseline. 
RESULTS 
Table	1	shows	patient	characteristics.	The	MRI	staging	was:	T1c	(9,	18%),	T2a	(22,	44%),	T2b	(4,	8%),	
T2c	(2,	4%),	T3a	(13,	26%).	The	mean	dosimetric	constraints	were	mostly	met	but	in	30%	a	minor	
violation	was	accepted.
In	14	patients	(28%),	a	visible	dominant	tumor	was	detected	on	the	contrast-enhanced	MRI	with	
a	mean	tumor	volume	of	1.2	cc	(range,	0.46-4.1	cc).	In	three	patients	more	than	one	lesion	was	
detected.	The	mean	dose	to	this	visible	dominant	tumor	area	defined	as	gross	target	volume	(GTV)	
was	47.8	Gy	(40.3-	53.8	Gy)	which	is	120-150%	higher	than	the	PD.	Capsule	invasion	on	T2-weighted	
MRI	was	registered	in	13	(26%)	patients.	The	area	of	invasion	was	included	in	the	high	dose	area	 
(>	100	PD)	without	changing	the	margin	used.
The	treatment	time	was	between	60-130	minutes	per	fraction.	There	was	no	difference	between	
patients	with	or	without	boost.
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All	patients	were	alive	without	biochemical	failure	at	the	end	of	follow-up.
 
Acute Toxicity
The	mean	IPSS	before	treatment	was	9/35	and	did	not	increase	in	the	acute	phase.	The	percentages	
of	grade	2	and	3	acute	GI	toxicity	were	12%	and	2%,	respectively.	The	incidence	of	grade	2	and	3	
acute	GU	toxicity	was	15%	and	8%,	respectively.	
The	most	common	GU	complaints	during	this	phase	were	urinary	urge	and	increased	night	voiding	
frequency.	Increased	stool	frequency	was	the	main	GI	complaint.	One	out	of	the	first	10	patients	
needed	an	indwelling	bladder	catheter	because	of	urinary	retention	1	week	after	completion	of	
the	radiation	course.	This	patient	had	a	baseline	prostate	volume	of	110	cc;	the	maximum	prostate	
volume	allowed	was	lowered	to	90	cc	in	our	protocol	following	this	incident.
n n% Mean (min.-max.)
  Age 68	(48-80)
  Fup (months) 23	(9-47)
TNM T1cN0 30 60%
T2aN0 17 34%
T2bN0 1 4%
T2cN0 1 2%
Gleason 3+3 41 82%
3+4 9 18%
IPSA 8.2	(1.3-16)
Prostate	volume 48	(22-110)
Q-max 13	(4-33)
Residual 87	(0-300)
Risk	Group Low risk 30 60%
Intermediate	risk 20 40%
Position	positive	biopsy Single sided 31 62%
Double sided 19 38%
Count	positive	biopsy 1 12 24%
2 14 28%
3 9 18%
4 8 16%
5 5 10%
7 2 4%
Table 9.1. |	Patient,	tumor	and	treatment	characteristics.
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Late toxicity 
The	chronologic	 incidence	of	grade	≥	2	GI	and	GU	toxicity	 is	shown	 in	Figure	1.	The	mean	 IPSS	
increased	to	13/35	at	12	months	after	treatment,	resolved	to	10/35	at	24	months	(figure	2).	The	
main	cause	of	grade	2	GU	toxicity	was	increased	night	voiding	frequency	(>	4x/night).	This	reached	
a	peak	at	12	months	in	20%	of	patients	resolving	to	10%	at	24	months.	Other	complaints	were	urge	
and	radiation	prostatitis	in	two	patients	which	were	treated	by	NSAID.	The	GI	toxicity	was	limited	
to	increased	stool	frequency	and	necessity	of	using	adult	diapers	which	resolved	in	all	(2)	patients	
within	6	months.
There	were	no	differences	in	toxicity	between	the	group	patients	with	MRI-visible	tumor	receiving	
a	boost	in	comparison	to	the	others	without	MRI-visible	tumor.	
PSA nadir and bounce
The	median	PSA	nadir	for	patients	with	a	follow-up	≥	24	months	was	0.6	ng/ml	(range,	0.1-2	ng/
ml)	and	1.1	ng/ml	for	patients	with	a	FU	≥	12	months	(Figure	3).	Nadir	PSA	<	1	was	reported	in	27	
patients	(59%).	PSA	bounce	was	recorded	in	seven	patients	(14%),	and	the	mean	interval	to	the	
bounce	episode	was	12	months	(range,	4.0-22	months).
QoL
The	mean	 changes	 in	 the	 EORTC-QLQ	PR25	 score	 for	 each	domain	 are	 shown	 in	 Figure	 4.	 The	
median	PR-25	GU	score	was	increased	from	13	before	the	treatment	to	25	at	12	months	returning	
to	21	after	2	years	(p=0.264).	The	median	bowel	symptoms	did	not	change	after	the	treatment.	
The	sexual	function	was	decreased	from	75	at	the	baseline	to	66.76	after	2	years	(p=0.145).	The	
incontinence	 and	bother	 score	was	 slightly	 and	 insignificantly	 increased	 in	 the	 first	 12	months	 
post-treatment,	returning	to	normal	afterward.	The	IIEF	results	with	only	24	months	FU	are	not	yet	
mature	for	publication12.
DISCUSSION 
SBRT	is	increasingly	used	because	of	the	possibility	of	this	image-guided	technique	to	minimize	the	
margins	needed	for	treatment,	reducing	normal	tissue	dose	and	resulting	in	a	lower	percentage	
of	toxicity.	This,	in	combination	with	the	possibility	of	SBRT	to	deliver	a	high	radiobiological	dose	
in	 few	 fractions	makes	 this	 technique	 ideal	 for	 the	 treatment	of	 PC.	Our	 fractionation	 scheme	
was	used	in	HDR-brachytherapy	series	with	excellent	10-year	results5.	Despite	such	good	results,	
the	invasive	character	and	the	need	of	hospitalization	and	anesthesia	makes	brachytherapy	less	
convenient	and	a	labor	intensive	method.
PSA response
In	our	patients,	an	excellent	early	PSA	nadir	was	achieved.	This	is	comparable	to	HDR	and	EBRT	
series	with	longer	FU5, 13.	This	is	important	because	the	PSA	nadir	could	predict	long-term	BF	and	
distant	metastases-free	survival5, 13, 14.	Because	of	our	short	FU,	the	final	nadir	may	not	yet	have	
been	reached.	Other	SBRT	series	have	reported	lower	PSA	nadirs	after	longer	follow-up15, 16.	The	
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Figure 9.1. |	GU	and	GI
Genitourinary	and	Gastrointestinal	toxicity	(%)
Figure 9.2. | IPSS
International	Prostate	Symptoms	Score	(IPSS)	
changes	(mean)	
Figure 9.3. | PSA
PSA	response	(outsides	not	shown)
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Table 9.2. |	Toxicity	SBRT	published	series
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percentage	of	patients	with	bounce	phenomena	was	lower	than	the	percentage	in	brachytherapy	
and	EBRT	series4, 10;	the	short	FU	may	explain	this. 
Toxicity
The	toxicity	percentage	was	conform	literature.	Although	this	group	had	more	GU	complaints	because	
of	their	predisposing	factors	(large	volume,	bad	flow,	high	IPSS,	TURP	or	abdominal	surgery)	before	
the	treatment,	they	did	not	show	more	toxicity	in	the	acute	neither	in	the	late	phase.	This	suggests	
that	our	treatment	could	reach	 lower	toxicity	percentages	 in	patients	without	these	predisposing	
factors	as	confirmed	in	other	SBRT	series;	e.g.	Freeman	et	al15	reported	7%	and	2.5%	grade	2	and	3	
GU	toxicity,	respectively	with	2.5%,	0%	grade	2,	3	GI	toxicity,	respectively.	King	et	al	used	the	same	
fractionation	scheme	(5	fractions)	as	Freeman16	and	reported	5%	and	3.5%	for	grade	2	and	3	GU	late	
toxicity,	respectively.	The	grade	2	GI	toxicity	was	reported	in	only	2%	of	the	patients.	Several	series	
reported	toxicities	between	3%	and	20%17-19.	The	treatment	time	was	relatively	high	comparing	with	
conventional	series	(	>	60	minutes).	Fowler	et	al.20	mentioned	the	influence	of	treatment	time	for	
high	fraction	dose	on	the	log	cell	kill	(BED)	suggested	a	decrease	in	the	BED	for	fraction	duration	
of	more	 than	30	minutes.	Although	 this	 subject	 requires	more	discussion	 it	may	play	 a	 role	 in	
decreasing	late	toxicity	for	this	regimen.	Using	our	fractionation	scheme	Jabbari	et	al.21 reported a 
higher	grade	2	late	toxicity,	but	a	lower	grade	3	late	toxicity.	The	number	of	patients	treated	with	
monotherapy	was	only	20	patients	with	a	shorter	follow-up.	To	date	Jabbari	published	the	only	
series	using	our	HDR	like	4x9.5	Gy	scheme.	The	relative	higher	grade	3	GU	toxicity	in	our	series	
compared	to	other	SBRT	series	could	be	explained	by	patient	selection;	we	treated	patients	with	
more	complaints	and	predisposing	factors.	We	also	used	the	combination	of	questionnaires	and	
physician’s	charts	reporting	the	highest	score	from	both,	which	could	result	in	higher	scores.	The	
difference	 in	measurement	 instrument	using	 the	EORTC/RTOG	criteria7, 15-17 in our group where 
some	other	 series	 used	 the	Common	 terminology	Criteria	 for	 adverse	 events	 (CTCAE)18, 19, 21, 22, 
makes	a	comparison	between	series	difficult.	The	different	dose	levels	and	fractionation	schemes	
between	series	could	also	be	a	reason	for	differences	in	toxicity	records.	Table	2	shows	toxicity	of	
published	SBRT	series.	
QoL
The	 EORTC-QLQ	 PR-25	 questionnaire	 is	 a	 validated	 25-item	 instrument	 with	 four	 domains	
(urinary,	 bowel,	 sexual,	 and	 hormonal),	 as	 well	 as	 two	 urinary	 subscales	 of	 incontinence	 and	
irritative/bother23.	Responses	are	 transformed	 to	a	 scale	of	0-100.	For	 functional	 scales,	higher	
scores	 represent	 better	 QoL.	 For	 symptom	 scales,	 higher	 scores	 indicate	 more	 symptoms	 or	
more	problems. In	our	 cohort,	 there	was	a	 significant	 increase	 in	 the	urinary	 symptoms	 in	 the	
first	year	which	was	reversed	at	24	months.	The	bowel	symptoms	did	not	increase	and	remained	
stable	during	the	24	months	after	treatment,	which	 indicates	 limited	bowel	 toxicity.	The	sexual	
function	changes	were	more	obvious	at	12	months	but	not	significant	after	24	months.	This	has	
to	be	confirmed	with	the	results	of	the	IIEF-questionnaires.	There	is	very	limited	data	published	
regarding	sexual	function	after	SBRT	for	PC.	The	group	of	King	et	al.12	reported	the	sexual	function	
during	3	years	FU	of	32	PC	patients	having	undergone	SBRT	with	5	fractions	of	7.25	Gy.	They	used	the	
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Expanded	Prostate	Cancer	Index	Composite	(EPIC)12,	unfortunately	with	the	same	limitations	as	the	
PR-25	questionnaires	to	give	a	detailed	analysis	about	the	effect	of	treatment	on	the	sexual	function.	
SBRT
Published	 results	of	SBRT	as	monotherapy	 reported	a	short	FU	and	many	variations	 in	 fraction	
size,	total	dose,	and	technique	used.	Also,	the	toxicity	was	measured	with	different	tools	making	
comparison	difficult.	The	group	of	Freeman	and	King	used	five	fractions	of	7-7.25	Gy	first	in	daily	
fractions	 but	 later	 in	 every-other-day	 fractions15, 16.	 They	 planned	 a	 more	 homogeneous	 dose	
distribution	and	used	less	strict	constraints.	This	is	 in	contrast	to	our	technique,	which	was	also	
used	by	Jabbari	21	administering	four	daily	fractions	of	9.5	Gy,	where	the	dose	distribution	inside	the	
prostate	is	heterogeneous	up	to	40%	above	the	PD. This heterogeneity contributes to a higher dose 
in	the	entire	prostate	which,	in	the	light	of	the	low	alpha/beta	of	the	prostate,	may	contribute	to	the	
excellent	HDR	brachytherapy	results.	Furthermore,	this	gives	us	the	opportunity	to	shape	the	dose	
distribution	in	the	critical	area	of	the	prostate	to	give	higher	dose	in	the	entire	peripheral	zone	of	
the	prostate	where	almost	65%	of	prostate	tumors	were	found	in	prostatectomy	specimens24.	Our	
constraints	for	bladder	and	rectum	were	the	same	as	that	of	our	HDR	brachytherapy,	restricting	the	
volumes	receiving	80%	of	the	PD	to	<1.5	cc.	Minor	violations	for	the	rectum	and	bladder	constraints	
were	accepted	(80%	PD	to	1.5-2	cc)	in	30%	of	the	patients,	according	to	the	position	of	the	tumor	
and	the	patient’s	anatomical	variation,	as	more	than	50%	of	this	group	had	a	prostate	volume	>50	
cc	with	a	prominent	transient	zone.
King	et	al.	reported	more	rectal	toxicity	in	the	daily	treated	group	versus	the	every-other-day	treated	
group16.	In	our	current	cohort,	10	patients	were	treated	with	a	weekend	rest	of	2	days	between	the	
four	fractions	due	to	logistic	reasons.	These	10	patients	did	not	show	a	lower	rectal	or	bladder	toxicity.	
We	are	aware	that	the	limited	number	of	patients	and	the	relatively	short	FU	make	it	hard	to	reach	a	
conclusion	about	this	point.	The	number	of	patients	with	a	visible	tumor	on	the	MRI	was	low	(28%),	
this	could	be	explained	because	of	the	inclusion	of	more	low-risk	patients	with	a	Gleason-score	of	6	
which	is	not	always	visible	on	the	MRI.	SBRT	is	an	emerging	treatment	approach	for	PC	and	so	far	has	
been	safe	and	effective	as	monotherapy.	However	trials	are	warranted	addressing	many	of	the	raising	
questions	about	the	optimal	fraction	dose,	total	dose,	safety	constraints	and	the	optimal	technique	
to	be	used.	Recently,	the	results	of	a	phase	1	study	concerning	dose	escalation	and	toxicity	has	been	
published25.	Next	year	we	will	start	a	phase	III	trial	to	compare	this	SBRT	schemes	with	the	standard	
EBRT	of	39x2	Gy	to	address	outcomes,	toxicity	and	QoL.
CONCLUSIONS 
In	this	cohort	where	many	patients	were	not	suitable	for	HDR	brachytherapy,	an	SBRT	regimen	
of	four	daily	fractions	of	9.5	Gy	shows	low	toxicity	in	line	with	the	published	literature.	The	PSA	
response	to	date	is	good	without	any	BF.	More	patients	and	longer	FU	is	needed	to	confirm	this	
conclusion.
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INTRODUCTION 
Prostate	cancer	is	the	second	most	common	cause	of	cancer	and	the	sixth	leading	cause	of	cancer	
death	among	men	worldwide.	Details	on	epidemiology	are	provided	in	Chapter	1	of	this	thesis.	There	
are	various	treatment	options	for	men	with	organ-confined	prostate	cancer.	Surgery,	fractionated	
EBRT,	brachytherapy	(HDR	or	LDR)	and,	for	selected	patients,	active	surveillance	are	all	considered	
to	be	effective	methods	 for	 treating	prostate	cancer5,27,31,48-60.	So	 far,	none	of	 these	options	has	
been	proven	to	be	superior.	In	clinical	practice	all	suitable	options	are	discussed	with	the	patient	to	
enable	treatment	to	be	tailored	to	his	stage,	circumstances	and	preferences.	Physicians	wish	to	give	
patients	the	best	advice.	This	is	not	possible	without	the	support	of	scientific	evidence	on	efficacy,	
toxicity	 and	 quality	 of	 life,	 preferably	 obtained	 from	 randomized	 trials.	 In	 recent	 radiotherapy	
literature,	there	are	radiobiological,	technological,	economical	and	practical	arguments	in	favor	of	
hypofractionated	treatment.	In	this	thesis,	studies	are	reported	that	investigate	the	clinical	impact	
of	both	moderate	and	extreme	hypofractionation	schedules.
MODERATE HYPOFRACTIONATION: WHAT TO DO IN DAILY PRACTICE? 
Summary of published randomized phase III trials
Studies on the α/β	ratio	for	prostate	cancer,	based	on	different	radiotherapy	treatment	options,	
have	suggested	that	it	may	be	as	low	as	1.5	Gy8,10-13,15,18-20,22.	If	correct,	this	would	predict	an	enhanced	
therapeutic	 ratio	 for	 hypofractionated	 schedules	 compared	 to	 the	 currently	 applied	 standard	
schedules	using	1.8-2.0	Gy	daily	fractions.	To	date,	reports	are	available	of	six	phase	III	randomized	
studies	that	have	investigated	moderate	hypofractionation59,61-64.	Two	trials	were	executed	prior	
to the era of dose escalated radiotherapy29,30.	Lukka	et	al.64	reported	results	of	936	patients	with	
low-	and	 intermediate-risk	prostate	cancer	 in	a	non-inferiority	phase	 III	hypofractionation	 trial,	
comparing	 delivery	 of	 33x2	 Gy	 in	 45	 days	with	 20x2.625	 Gy	 in	 28	 days.	 The	 use	 of	 hormonal	
therapy	(HT)	was	an	exclusion	criterion.	The	study	failed	to	confirm	the	non-inferiority	endpoint	
for	hypofractionation,	with	a	5-year	biochemical	relapse	free	survival	(bRFS)	of	52.95%	for	standard	
fractionation	versus	59.95%	for	the	hypofractionation	arm.	Grade	3	and	4	acute	toxicity	was	higher	
in	the	hypofractionation	arm	(11.4%	versus	7%	for	standard	fractionation),	while	late	toxicity	was	
3.2%	in	both	arms.	Yeoh	et	al.63	reported	on	217	low-	and	intermediate-risk	prostate	cancer	patients,	
randomized	in	a	phase	III	trial.	Standard	fractionation	with	32x2	Gy	(6.5	weeks)	was	compared	with	
hypofractionation,	delivering	55	Gy	in	20	fractions	in	4	weeks.	The	trial	was	designed	to	show	a	
decrease	in	rectum	toxicity	for	hypofractionation,	based	on	an	assumed	rectum	α/β	ratio	of	4	Gy.	
Low-	and	intermediate-risk	patients	were	included.	The	use	of	HT	was	an	exclusion	criterion.	At	90	
months,	a	significantly	higher	level	of	bRFS	was	observed	for	hypofractionation:	53%	vs	34%	for	
standard	fractionation	(p<0.05).	The	study	failed	to	demonstrate	the	hypothesized	reduction	 in	
rectum	toxicity.	
Arcangeli	et	al.61	published	 results	of	a	phase	 III	 study	 (180	high	 risk	patients),	 comparing	40x2	
Gy	(5	fractions/week)	with	20x3.1	Gy	(4	fractions/week)	with	the	use	of	 (neo)adjuvant	HT	for	9	
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months.	The	hypotheses	of	this	study	were	a	reduction	of	late	rectal	toxicity	from	29%	for	standard	
fractionation	to	12%	for	hypofractionation,	and	iso-effectivity	with	regard	to	bRFS.	However,	at	3	
years,	differences	in	GI	and	GU	toxicity	were	statistically	not	significant;	GI	and	GU	toxicity	rates	
were	17%	and	14%	for	hypofractionation	vs.	16%	and	14%	for	standard	fractionation,	respectively.	
The	 observed	 3-year	 bRFS	 for	 hypofractionation	 was	 superior	 to	 standard	 fractionation	 (87%	
compared	to	79%,	p=0.035).	This	is	to	date	the	only	randomized	study	with	a	high	dose	standard	
fractionation	arm	that	shows	statistically	superior	bRFS	for	the	hypofractionation	arm.	However,	
the	study	was	not	powered	for	this	endpoint	and	failed	to	show	a	reduction	in	rectum	toxicity	as	a	
planned	endpoint.	
Pollack	et	al.59	reported	on	a	phase	III	trial	(303	intermediate	and	high	risk	patients),	comparing	
delivery	of	26	fractions	of	2.7	Gy	in	5.2	weeks	(EQD2Gy=	84.4	Gy	for	an	assumed	α/β	ratio	of	1.5	Gy)	
with	the	conventional	treatment	(38x2	Gy	delivered	in	8	weeks).	The	study	aimed	to	demonstrate	a	
reduction	in	4-year	biochemical	relapse	with	hypofractionation	from	30%	to	15%.	The	use	of	short	
(4	months)	and	long	term	HT	(24	months)	was	allowed	according	to	risk	group	and	the	institution’s	
policy.	 The	 hypothesized	 increase	 in	 bRFS	 was	 not	 observed:	 76.7%	 vs.	 78.6%	 for	 standard	
fractionation	(p=0.74).	There	were	no	differences	in	late	toxicity.
The CHHiP trial62	 is	the	 largest	randomized	controlled	trial	to	date,	comparing	hypofractionated	
schedules	of	60	Gy	in	20	fractions	(4	weeks)	and	57	Gy	in	19	fractions	(3.8	weeks)	with	standard	
fractionation	delivering	74	Gy	in	37	fractions	(7.5	weeks).	Based	on	assumed	α/β	ratios	of	2.5	Gy	
and	1.5	Gy	for	the	tumor,	non-inferiority	in	5-year	bRFS	was	hypothesized	for	the	hypofractionated	
60	Gy	and	57	Gy	arms,	 respectively,	without	 increase	 in	 toxicity	 rates.	 The	 trial	 recruited	3216	
patients	(in	all	risk	groups	excluding	patients	with	T3b	or	those	with	PSA	>	30	ng/l),	and	closed	in	
June	2011.	All	patients	received	short	course	HT	for	3-6	months.	Early	data	from	the	trial	suggested	
that	moderate	hypofractionation	is	safe	and	well	tolerated62.	The	2-year	patient-reported	quality	
of	 life	outcome	was	 similar	 in	all	 arms65.	Recently,	 the	5-year	efficacy	and	 toxicity	 results	were	
presented,	showing	non-inferiority	of	60	Gy	regimens,	with	comparable	late	toxicity	rates66.
In	 the	 Dutch	 HYPRO	 trial,	 820	 intermediate	 and	 high	 risk	 patients	 were	 randomized	 to	 a	
hypofractionated	treatment	with	19	fractions	of	3.4	Gy	delivered	in	6.5	weeks	(EQD2Gy=90.4	Gy	for	
an	assumed	α/β	ratio	of	1.5	Gy)	or	a	standard	fractionation	with	39	x	2Gy	in	8	weeks26.	Both	short	
term	and	long	term	HT	was	allowed.	Primary	endpoints	were	superiority	of	hypofractionation	in	
outcome	(10%	increase	in	5-year	bRFS)	and	non-inferiority	of	the	hypofractionation	arm	in	acute	
and	late	cumulative	grade	≥2	GU	and	GI	toxicity67.	Superiority	in	5-year	bRFS	for	hypofractionation	
was	not	observed	(80%	vs.	77%	for	standard	fractionation,	p=0.36)68.	For	both	acute67 and late69 
GU	and	GI	toxicity,	non-inferiority	of	hypofractionation	could	also	not	be	confirmed.	Instead,	we	
observed	a	significant	increase	in	the	cumulative	incidence	of	grade	≥	2	acute	GI	toxicity	in	the	HF	
arm	(42%	vs.	31%	for	SF,	p=0.0015).	Moreover,	the	cumulative	incidence	of	grade	≥3	late	GU	toxicity	
was	significantly	higher	 in	the	hypofractionation	arm	(19%)	compared	to	standard	fractionation	
(13%)	(p=0.021).	For	both	acute	and	late	toxicity,	several	rates	of	specific	toxicity	symptoms	were	
significantly	increased	for	the	hypofractionation	arm.
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Given	the	summary	above,	it	can	be	concluded	that	the	only	randomized	study	to	date	that	met	its	
endpoint(s)	is	the	CHHiP	trial.	In	the	other	trials,	the	hypotheses	were	not	confirmed.	
Published	hypofractionation	series	used	different	fraction	doses,	different	total	doses,	different	overall	
treatment	 times,	 and	 different	 toxicity	 scores.	 It	 also	 included	 different	 numbers	 of	 patients	 and	
reported	different	follow-up	(FU)	periods.	The	policy	on	the	use	of	HT	was	always	different.	All	these	
factors	should	be	carefully	taken	into	consideration	when	comparing	results	from	various	series59,67,70,71.	
Evidence for increased treatment efficacy with hypofractionation
So	far,	only	the	randomized	trials	by	Yeoh	et	al.63	and	Arcangeli	et	al.61 have shown an increase in 
bRFS	using	hypofractionation.	However,	none	of	the	two	was	powered	to	demonstrate	an	efficacy	
increase.	Both	studies	aimed	at	a	decrease	in	rectum	toxicity	with	hypofractionation	and	included	
a	low	number	of	patients.	Even	when	assuming	an	α/β	ratio	as	low	as	1.5	Gy,	the	prostate	EQD2Gy 
values	 for	 the	hypofractionation	arms	 in	 the	studies	by	Yeoh	et	al.72	and	Arcangeli	et	al.70 were 
only	2.8	Gy	and	1.5	Gy	higher	than	for	the	corresponding	standard	fractionation	schedules.	In	the	
trials	by	Lukka	et	al.64	and	Yeoh	et	al.63,	 low	total	dose	EBRT	 in	the	standard	arm	was	used	and	
treatment	was	delivered	with	2D	and	3D	techniques.	Therefore,	the	results	are	not	representative	
for	the	current	practice.	The	increase	in	bRFS	in	the	trial	by	Yeoh	et	al.	was	only	observed	after	90	
months	and	was	not	seen	five	years	after	treatment72.	Apart	from	the	low	number	of	patients	in	the	
study	by	Arcangeli	et	al.61,	the	reported	enhanced	bRFS	for	hypofractionation	was	based	on	a	FU	
of	only	three	years,	despite	the	fact	that	all	patients	were	included	with	a	high-risk	profile	and	they	
received	9	months	of	(neo)adjuvant	HT.
Only	 the	 randomized	 trial	 by	 Pollack	 et	 al.59	 and	 the	 HYPRO	 trial26 hypothesized superiority 
of	hypofractionation	 in	 treatment	outcome,	and	 they	both	 failed	 to	meet	 this	endpoint.	 In	 the	
study	by	Pollack	et	al.,	the	assumed	enhancement	in	EQD2Gy	of	8.4	Gy	resulted	in	a	non-significant	
reduction	in	bRFS	by	0.9%,	instead	of	the	hypothesized	15%	improvement.59	In	the	HYPRO	trial,	the	
assumed	increase	in	EQD2Gy	by	12.4	Gy	only	resulted	in	a	non-significant	increase	in	5-year	bRFS	of	
3%	instead	of	the	hypothesized	10%.26
The	reported	limited	gain	in	the	5-year	bRFS	for	hypofractionation	in	the	HYPRO	trial	could	point	
at an α/β	ratio	that	is	higher	than	the	assumed	1.5	Gy.	However,	there	was	a	substantial	number	
of	patients	with	long-term	use	of	HT	in	the	trial,	which	could	delay	the	biochemical	recurrences.	
Therefore,	with	longer	FU,	a	bRFS	advantage	for	hypofractionation	might	still	be	observed.68
In the CHHiP trial62,	hypofractionation	was	non-inferior	in	bRFS,	as	hypothesized.	For	an	α/β	ratio	
of	1.5	Gy,	the	differences	in	EQD2Gy	compared	to	standard	fractionation	were	-0.8	Gy	and	+3.1	Gy	
for	the	19x3	Gy	and	20x3	Gy	schedules,	respectively.	However,	clinical	T3b	patients	(seminal	vesicle	
invasion)	and	patients	with	PSA	levels	>	30	ng/l	were	excluded	and	3-6	months	(neo)adjuvant	HT	
was	used	for	all	patients.	In	case	the	α/β	ratio	for	prostate	cancer	is	2.5	Gy	or	higher,	the	delivered	
EQD2Gy	for	the	two	hypofractionation	arms	in	the	CHHiP	trial	have	total	doses	that	are	lower	than	
73	Gy.	Given	these	conditions,	it	is	questionable	whether	the	CHHiP	hypofractionation	protocols	
are	suited	for	high-risk	patients	as	included	in	the	HYPRO	trial	and	in	the	study	by	Pollack	et	al.	59
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Recently,	 an	 enhanced	 biological	 efficacy	 of	 delivered	 radiation	 dose	 with	 reduced	 overall	
treatment	 time	 (OTT)	 of	 0.3	 Gy/day	 of	 treatment	 time	 reduction	 was	 reported	 for	 prostate	
cancer73.	 In	 the	 randomized	 trials	 by	 Arcangeli	 et	 al.70,	 Pollack	 et	 al.59,	 and	 Dearnaley	 et	 al.62, 
OTT	was	2.8-4	weeks	 shorter	 in	 the	hypofractionation	arm,	which	would	 suggest	an	enhanced	
advantage	for	hypofractionation	by	decreasing	the	OTT.	In	the	study	by	Arcangeli	et	al.61 this could 
have	contributed	to	the	observed	gain	in	bRFS	in	the	hypofractionation	arm.	However,	Pollack	et	
al.	did	not	observe	 the	expected	superiority	of	hypofractionation.	Also	 in	 the	HYPRO	trial,	OTT	
for	 hypofractionation	was	 shorter	 than	 for	 standard	 fractionation	 (6.5	 vs.	 8	 weeks).	 However,	
superiority	of	hypofractionation	was	not	observed.68	In	the	CHHiP	trial,	OTT	for	hypofractionation	
was	3.5	weeks	shorter	than	for	the	standard	arm.	Nevertheless,	bRFS	was	similar,	in	line	with	the	
presumed	α/β	ratio	of	2.5	Gy	for	both	arms.
To	date,	the	above	mentioned	trials	did	not	show	enhanced	efficacy	with	hypofractionation.	This	
indicates	 the	need	 for	 caution	when	applying	 these	 schedules	 to	avoid	enhanced	 complication	
rates	for	patients.
Late toxicity and the α/β ratio: is 5 Gy low enough?  
When	the	HYPRO	trial	was	designed,	the	assumed	α/β	ratio	for	late	toxicity	was	5-6	Gy26,69, based 
on	published	papers	at	that	time8,9. Here	we	will	discuss	this	choice	 in	the	context	of	data	from	
recently	published	clinical	trials,	including	the	HYPRO	trial.
When	assuming	an	α/β	ratio	of	5	Gy	for	late	toxicity,	the	rectum	EQD2Gy	for	hypofractionation	in	the	
study	by	Lukka	et	al.64	would	be	57.2	Gy	compared	to	66	Gy	for	the	standard	arm,	i.e.	a	reduction	of	
almost	9	Gy	for	hypofractionation.	However,	no	reduction	in	late	toxicity	in	the	hypofractionation	
arm	was	observed.	In	the	study	by	Yeoh	et	al.63,72	an	assumed	α/β	ratio	for	late	rectal	toxicity	of	5	
Gy	results	in	a	rectum	EQD2Gy	of	60.9	Gy	for	the	hypofractionation	schedule	vs.	64	Gy	for	standard	
fractionation.	 The	 hypothesized	 reduced	 late	 rectal	 toxicity	 was	 not	 observed.	 In	 the	 study	 by	
Arcangeli	 et	al.70	 the	 rectal	EQD2Gy	 for	hypofractionation	was	8.3	Gy	 lower	 than	 the	80	Gy	 in	 the	
standard	arm,	when	assuming	an	α/β	ratio	of	5	Gy.	Nevertheless,	also	in	this	study,	no	reduction	
in	late	rectal	toxicity	in	the	hypofractionation	arm	was	observed.	For	an	assumed	α/β	ratio	of	5	Gy,	
the	rectum	EQD2Gy	for	hypofractionation	in	the	study	by	Pollack	et	al.
59	was	0.8	Gy	lower	than	for	
standard	fractionation.	As	expected,	no	difference	in	late	rectal	toxicity	was	observed.	For	an	α/β 
ratio	of	5	Gy,	the	rectal	EQD2Gy for	the	20	and	19	fraction	regimens	in	the	CHiPP	trial	are	68.6	and	65.1	
Gy,	respectively,	compared	to	74	Gy	for	the	standard	arm.	Notwithstanding	the	calculated	reduced	
rectal	dose	for	hypofractionation,	observed	toxicity	was	not	different	from	standard	fractionation.	In	
the	HYPRO	trial,	the	assumed	α/β	ratio	of	4-6	Gy	resulted	in	highly	similar	EQD2Gy values in the two 
treatment	arms.	However,	the	hypothesized	non-inferiority	of	hypofractionated	treatment	regarding	
cumulative	grade	≥	2	late	GI	and	GU	toxicity	could	not	be	confirmed.	Moreover,	cumulative	grade	≥3	
late	GU	toxicity	was	significantly	enhanced	in	the	hypofractionation	arm.	The	above	analyses	seem	
to point at an α/β	ratio	for	late	toxicity	substantially	lower	than	5	Gy,	assuming	that	occurrence	of	
late	toxicity	is	indeed	mostly	correlated	with	delivery	of	high	doses,	more	specifically	the	maximum	
tumor	dose.	Inter-observer	variability	in	rectum	delineation	is	well	described74-76.	There	is	however	
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no	 indication	 that	 the	 variability	would	be	different	 for	hypofractionation	 compared	 to	 standard	
deviation.	Therefore,	it	is	to	be	expected	that	delineation	uncertainty	will	not	impact	the	conclusion	
that	the	rectum	α/β	ratio	is	probably	considerably	lower	than	5	Gy.
Toxicity scoring by physicians and patients
The	way	of	scoring	acute	and	late	toxicity	and	the	system	used	for	toxicity	registration	are	important	
to	interpret	the	toxicity	results	and	to	compare	results	of	various	trials.	 In	the	HYPRO	trial,	scoring	
was	based	on	both	clinical	record	forms	(CRFs)	filled	in	by	physicians	and	patient’s	self-assessment	
questionnaires	(PSAQ).	It	was	demonstrated	that	adding	the	PSAQ	to	the	analyses	resulted	in	significant	
increases	in	reported	incidences	of	toxicity.	Underestimation	of	toxicity	by	use	of	CRFs	only	has	been	
reported previously77.	Adding	PSAQ	to	the	CRFs	in	reporting	toxicity	results	 in	more	robust	toxicity	
scores	and	may	seriously	impact	conclusions	drawn	from	studies.	In	most	published	hypofractionation	
trials	the	source	of	the	toxicity	report	(only	CRFs	or	both	CRFs	and	PSAQ)	is	not	clearly	mentioned.	The	
reported	relatively	low	2-year	late	toxicity	rates	in	the	CHHiP	trial	of	4.3%	(74	Gy	arm),	3.6%	(60	Gy	
arm),	1.4%	(57	Gy	arm)	for	GI,	and	for	GU	2.2%	in	both	the	74	Gy	and	60	Gy	arms	and	no	patients	with	
reported	late	GU	toxicity	in	the	57	Gy	arm,	compared	to	results	observed	in	the	HYPRO	trial,	are	most	
certainly	(partially)	related	to	the	use	of	physician	scoring	only	in	the	former	trial.
EXTREME HYPOFRACTIONATION WITH HDR BRACHYTHERAPY
HDR-BT	is	widely	used	as	boost	after	EBRT	with	excellent	bRFS	and	acceptable	late	toxicity27,32,78.	
Our	long	term	results79	for	an	HDR-BT	boost	of	3	fractions	of	6	Gy	followed	by	EBRT	(25x1.8	Gy)	
confirmed	the	efficacy	of	 this	concept	 (Chapter	4).	The	prospective	character	of	collecting	data	
and	the	use	of	patients’	self	assessment	questionaires,	besides	the	 long	FU	period,	make	these	
results	 robust.	The	reported	7-years	bRFS	of	97%	is	excellent	even	for	 low-	and	 intermediate-risk	
patients,	especially	in	the	light	of	low	rates	of	late	GI	and	GU	toxicity.	Martinez	et	al.27 published their 
data	on	HDR-BT	boost	dose	escalation	after	EBRT,	delivering	3	fractions	of	6.5	Gy	and	2	fractions	of	
11.5	Gy	for	intermediate-	and	high-risk	patients80.	The	higher	total	HDR-BT	boost	dose,	delivered	in	2	
fractions	significantly	increased	bRFS	without	increasing	toxicity,	which	in	itself	supports	the	theory	
that	the	α/β	ratio	for	prostate	cancer	is	lower	than	that	of	the	surrounding	normal	structures.	These	
data	motivated	us	making	a	switch	 from	our	regimen	of	HDR-BT	boost	dose	of	3x6	Gy	on	top	of	
25x1.8	Gy	EBRT38	to	a	boost	of	1x13	Gy,	combined	with	20x2.2	Gy	EBRT	for	intermediate-	and	high-risk	
patients	in	2007.	This	regimen	is	being	compared	with	EBRT,	delivering	35x2.2	Gy	in	a	National	phase	
III	randomized	study.	
Increasing	 belief	 in	 a	 low	 α/β	 ratio	 for	 prostate	 cancer	 encouraged	 the	 use	 of	 HDR-BT	 as	
monotherapy.	 The	 rapid	 fall-off	 of	 the	 dose	 towards	 the	 rectum	 and	 bladder	may	 explain	 the	
low	 toxicity	 reported	 after	 HDR-BT.	 Compared	 to	 EBRT	 series,	 our	 5	 year	 report	 on	 HDR-BT	
monotherapy	 showed	 relatively	 low	 toxicity,	 despite	 toxicity	 registration	 using	 both	 physician	
reports	 and	 PSAQ77,81.	 The	 investigated	 QoL	 using	 the	 EORTC-QLQ	 PR25	 questionaires42 gave 
important	 additional	 information	 besides	 the	 toxicity	 and	 outcome	 results.	 The	 QoL	 studies	
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showed	the	advantage	of	HDR-BT	monotherapy	in	keeping	QoL	in	the	bowel	domain	stable	without	
deterioration	after	treatment,	and	showing	the	possibility	of	improvement	in	sexual	function	after	
a	decrease	in	the	first	year	of	FU,	even	in	this	group	of	patients	with	a	median	age	of	70	years.	
In	 our	 report,	 several	 factors	were	 associated	with	 acute	 and	 late	GU	 toxicity,	 as	 the	 baseline	
International	Prostate	Symptoms	scores	(IPSS)	(with	acute	GU)	and	the	maximum	urininary	flow	
(Qmax)	(with	late	toxicity).	Other	factors	have	been	reported	to	be	associated	with	toxicity	too;	
Hoskin	et	al.82	reported	in	2014	on	the	correlation	of	the	mean	PTV	with	stricture	formation	after	
HDR-BT	monotherapy	and	the	important	correlation	of	IPSS	≥	20	with	higher	incidence	of	acute	GU	
toxicity.	In	our	study	we	observed	a	correlation	of	acute	GU	toxicity	with	an	IPSS	of	≥	13.	Ghilezan	et	
al.83	reported	the	importance	of	limiting	the	rectum	volume	receiving	100%	of	the	prescribed	dose	
because	of	its	correlation	with	increased	incidence	of	acute	and	late	GI	toxicity.	
Because	HDR-BT	monotherapy	is	mostly	given	in	several	fractions	using	the	same	plan,	the	safety	
of	the	treatment	and	the	long	term	biochemical	control	probabilty	is	dependent	on	the	accuracy	
of	the	dwell	positions	in	all	fractions.	In	our	study	on	the	influence	of	catheter	corrections	(Chapter	
6),	we	observed	no	difference	 in	 toxicity	 between	patients	with	 displaced	 catheters	 that	were	
corrected	and	the	patients	where	no	displacements	were	registered.	This	could	reflect	the	safety	
of	our	correction	protocol.	On	the	other	hand,	the	need	for	corrections	points	to	the	importance	of	
decreasing	the	number	of	fractions	(preferably	1)	and	the	overall	treatment	time	to	limit	the	hazard	
of	displacement.	Other	advantages	of	an	HDR-BT	regimen	of	1-2	fractions	delivered	in	one	day	are	
improvements	in	logistics,	patient	comfort,	shorter/fewer	hospital	visits	and	saving	resources.
Few	authors	reported	their	clinical	experiences	with	1-2	fraction	regimens.	Hoskin	et	al.84 reported 
that	“Reduction	in	number	of	fractions	(3	to	2)	has	not	been	associated	with	any	reduction	in	efficacy	
or	increase	in	toxicity”.	Ghilezan	et	al.83	reported	on	a	dose	escalation	study	with	2	fractions	HDR-BT	
monotherapy	in	one	day.	They	used	2x12	Gy	for	50	patients	and	2x13.5	Gy	for	another	44	patients	
with	 low	 and	 intermediate	 risk	 prostate	 cancer.	 No	 differences	 between	 the	 two	 schemes	were	
observed	in	reported	toxicity,	but	the	FU	was	short	(17	months	for	2x12	Gy	and	9	months	for	2x13.5	
Gy).	Prada	et	al.85	reported	results	of	a	one	fraction	HDR-BT	regimen	of	19	Gy	in	40	patients	with	low-	
and	intermediate-risk	prostate	cancer	and	reported	after	a	relatively	short	FU	(range	8-32	months)	
no	acute	and	late	GU	≥	2	toxicity.	In	5	patients	grade	1	anal	mucositis	was	reported.	Hoskin	et	al.84 
published	in	2014	the	results	of	3	regimens	(2x13	Gy/115	patients,	1x19	Gy/24	patients,	1x20	Gy/26	
patients)	HDR-BT	monotherapy	for	intermediate-	and	high-risk	prostate	cancer	patients.	Except	for	
the	higher	percentage	urinary	retention	with	the	need	for	a	temporarily	Foley	catheter	in	the	one	
fraction	regimens	(7%	with	2	fractions	vs.	20-33%	with	a	single	fraction),	he	reported	no	differences	
between	the	groups.
At	this	moment,	several	trials	are	open	in	different	institutions	investigating	HDR-BT	monotherapy	
in	1	or	2	fractions86.	In	general,	reported	results	of	HDR-BT	monotherapy	are	excellent	compared	
to	 EBRT	 results.	 However,	 as	 reported	 in	 the	 review	 paper	 by	 Demanes	 et	 al.87:	 “There	 is	 no	
consensus	on	the	optimal	dose	and	fractionation	for	HDR-BT	as	monotherapy”.	There	is	still	a	need	
to	determine	the	optimal	dose	and	number	of	fractions	in	randomized	trials.
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EXTREME HYPOFRACTIONATION WITH STEREOTACTIC BODY 
RADIOTHERAPY (SBRT).
In	this	section,	the	literature	on	prostate	SBRT	is	discussed,	including	our	contribution	(Chapters	8	
and	9).	
Reported toxicity for prostate SBRT 
Freeman	et	al.	reported	their	5-year	experience	of	treating	41	low-risk	prostate	cancer	patients	
with	35-36.25	Gy	in	5	fractions88.	None	received	hormonal	therapy.	One	patient	experienced	acute	
grade	3	GU	toxicity,	but	there	was	no	acute	grade	3	or	higher	GI	toxicity.	No	grade	2	or	higher	GI	
toxicity	was	reported,	while	late	grade	2	and	3	GU	toxicity	was	observed	in	7%	and	2.5%	of	cases,	
respectively.	Katz	et	al.	reported	the	results	of	304	men	with	low-risk	prostate	cancer	treated	in	
5	fractions	of	7-7.25	Gy	with	the	Cyberknife89.	Acute	grade	2	GU	and	GI	toxicity	rates	were	4.7%	
and	3.6%,	respectively.	Late	GU	and	GI	toxicity	was	experienced	by	3%	of	patients.	Neither	acute	
nor	late	grade	3	GI	toxicity	was	reported.	In	patients	with	more	than	12	months	FU,	there	was	1	
patient	with	grade	3	GU	toxicity.	Friedland	et	al.	 treated	112	prostate	cancer	patients	with	 the	
CyberKnife	in	5	fractions	of	7	Gy90.	Patients’	GI	and	GU	symptom	scores	had	returned	to	baseline	at	
4	months	after	treatment,	only	1	patient	developed	a	rectal	bleeding	(grade	3).	King	et	al.91 treated 
67	low-risk	prostate	cancer	patients	in	5	fractions	of	7.25	Gy	using	CyberKnife.	Late	grade	2	and	3	
GU	toxicity	was	reported	in	5%	and	3.5%	of	patients,	respectively.	Late	GI	toxicity	occurred	in	2%	
of	cases	with	no	grade	3	GI	toxicity.	Importantly,	King	et	al.	92reported	lower	toxicity	rates	for	those	
patients	receiving	alternate	day	treatment	compared	with	an	uninterrupted	daily	regimen,	but	the	
number	of	patients	was	too	small	to	draw	definitive	conclusions.
Several	papers	have	reported	on	profound	hypofractionation	treatment	with	a	conventional	linac.	
Madsen	et	al.	used	5	fractions	of	6.7	Gy	to	treat	40	patients93.	With	a	median	FU	of	42	months,	
the	incidences	of	acute	grade	≥	2	GU	and	GI	toxicity	were	23%	and	13%,	respectively.	Late	grade	
2	GU	toxicity	was	observed	in	20%	of	patients	and	late	grade	2	GI	toxicity	in	7.5%.	No	late	grade	
3	toxicity	was	reported.	Tang	et	al.	reported	on	30	low-risk	prostate	cancer	patients	treated	on	a	
conventional	linac,	receiving	5	fractions	of	7	Gy	over	29	days94.	With	a	FU	of	only	6	months,	the	
acute	toxicity	was	not	higher	than	for	standard	fractionation.
All	the	above	mentioned	studies	were	performed	with	conventional	SBRT	dose	distributions,	i.e.	
no	attempt	to	mimic	HDR-BT.	Jabbari	et	al.	9	reported	results	of	only	20	patients	treated	with	a	
HDR-like	regimen	using	a	fractionation	schedule	of	4x9.5	Gy.	They	observed	grade	2	acute	GU	and	
GI	toxicity	rates	of	45%	and	5%,	respectively.	With	a	FU	of	only	18	months,	the	incidences	of	late	
GU	and	GI	toxicity	were	5%	and	3%,	respectively.	The	very	limited	number	of	patients	and	short	FU	
make	it	difficult	to	compare	these	results	with	other	data.
We	published	our	2-year	toxicity	results	for	50	low-	and	intermediate-risk	prostate	cancer	patients,	
treated	with	HDR-like	dose	distributions	delivering	38	Gy	in	4	fractions	using	the	CyberKnife.	(Chapter	
9)96.	Observed	acute	grade	2-3	GU	and	GI	toxicity	rates	were	23%	and	14%,	respectively.	The	late	grade	
2	and	3	GU	toxicity	rates	were	10%	and	6%,	respectively,	while	only	3%	of	our	patients	experienced	
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a	grade	2	late	GI	toxicity	(no	grade	3	late	GI	toxicity	was	reported).	Despite	the	use	in	our	study	of	
PSAQ	for	toxicity	reporting	on	top	of	physician	scoring	and	the	delivery	of	HDR-like	dose	distributions,	
toxicity	 rates	were	 very	 acceptable	 and	 comparable	with	 other	 series.	 However,	 the	 number	 of	
patients	in	all	above	mentioned	single	institutional	series	was	small	with	relatively	short	FU.
Reported outcome for prostate SBRT
Published	series	for	prostate	SBRT	report	excellent	bRFS,	but	with	relatively	short	FU	periods88,89,92.	
Data	on	bRFS	of	patients	treated	with	SBRT	in	8	institutions	were	published	in	201397.	For	the	1100	
patients	(58%	low-risk,	30%	intermediate-risk	and	11%	high-risk),	the	5-year	bRFS	was	93%,	but	
only	135	had	a	follow-up	of	5	years	or	more.	Katz	et	al.89	reported	outcome	for	304	patients	(70%	
low-risk,	26%	intermediate-risk	and	4%	high-risk)	with	a	failure	rate	of	1.3%.	The	follow	up	was	
short	(range	17-30	months).	Other	series	used	the	same	fractionation	schedule	as	Katz	et	al.	and	
reported	93-94%	4-year	bRFS	for	low-risk	patients88,97.	Madson	et	al.93	reported	a	90%	4-year	bRFS	
for	low-risk	patients	for	a	relatively	low	total	dose	of	33.5	Gy	in	5	fractions.	For	our	series	(60%	low-
risk,	and	40%	intermediate-risk	patients),	we	have	reported	an	encouraging	100%	bRFS.	However,	
the	median	FU	was	only	2	years	(Chapter	9),	and	longer	FU	is	needed	for	definitive	conclusions.
Quality of Life studies
As	the	majority	of	patients	treated	with	SBRT	is	low-risk	with	an	excellent	bRFS	and	long	survival,	it	
is	particularly	important	to	also	investigate	quality	of	life	(QoL).	Unfortunately	QoL	data	for	prostate	
SBRT	are	 scarce.	A	pooled	QoL	analysis98	was	performed	 for	 treatments	with	4-5	 fractions	and	a	
median	total	dose	of	36.25	Gy,	including	data	of	864	prostate	cancer	patients	(14%	received	hormonal	
therapy).	The	mean	FU	was	3	years.	Modest	declines	in	the	urinary	and	bowel	domains	of	the	used	
Expanded	Prostate	Cancer	Index	Composite	(EPIC)	were	reported	that	were	followed	by	a	recovery	
after	around	6	months.	The	sexual	 function	declined	 in	the	first	9	months	after	treatment.	 In	our	
QoL	 report	 (Chapter	 9)	 the	QLQ-PR25	 questionnaires	were	 used,	which	were	 comparable	 to	 the	
above	mentioned	EPIC	scores.	The	patterns	of	recovery	were	comparable	to	the	results	of	the	pooled	
analysis,	with	a	 significant	decline	 in	 the	GU	domain	at	9-12	months	and	 recovery	at	24	months.	
Changes	in	the	bowel	domain	were	minimal	and	showed	no	deterioration	in	bowel	symptoms	during	
the	first	2	years	after	treatment.	The	sexual	function	part	of	our	QoL	analyses	shows	the	same	pattern	
as	the	pooled	data	results.
Although	 thousands	 of	 prostate	 cancer	 patients	 have	 been	 treated	 with	 profound	 SBRT	
hypofractionation,	there	are	as	yet	no	randomized	studies	that	have	compared	this	approach	with	
standard	fractionation.	In	the	UK,	an	on-going	randomized	trial	is	investigating	this	approach99.
GENERAL CONCLUSIONS AND FUTURE DIRECTIONS
Interpretation	of	study	results	and	comparison	of	studies	on	moderate	hypofractionation	with	EBRT	
need	great	caution	because	of	differences	in	inclusion	criteria,	delivered	total	and	fraction	dose,	
overall	treatment	time,	FU	period,	system	for	toxicity	registration,	and	the	use	of	HT.	Nonetheless,	
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the	current	literature	appears	inconclusive	on	the	added	value	of	moderate	hypofractionation	with	
EBRT.	In	the	study	by	Pollack	et	al.59	and	the	HYPRO	trial26,68,69,	hypothesized	large	increases	in	bRFS	
were	not	observed,	posing	questions	on	 the	widely	assumed	 low	α/β-ratio	 for	prostate	cancer.	
In the CHHiP trial66,	the	expected	non-inferiority	of	hypofractionation	was	indeed	demonstrated,	
however,	 applied	 tumor	 doses	were	 possibly	 on	 the	 low	 side,	 especially	 for	 high-risk	 patients.	
Compared	 to	 the	 study	 by	 Pollack	 et	 al.59	 and	 the	 CHHiP	 trial,	 the	 fraction	dose	 in	 the	HYPRO	
trial	was	0.7-0.4	Gy	higher.	This	may	have	contributed	 to	 the	 failure	 to	prove	 the	hypothesized	
non-inferiority	regarding	acute	and	late	GU	and	GI	toxicity	in	the	latter	trial.	On	the	other	hand,	
multivariate	analyses	hinted	at	a	possibility	of	selecting	patients	for	the	hypofractionated	regimen.	
Clearly,	there	is	a	need	for	future	studies	on	the	optimal	fractionation	regimen	for	prostate	cancer	
treatment	with	moderate	hypofractionation.
The	use	of	HDR-BT	as	boost	in	combination	with	EBRT	is	proven	to	be	effective,	but	the	impact	of	
this	regimen	on	toxicity	warrants	further	investigation	in	randomized	trials.
HDR-BT	(monotherapy)	and	SBRT	are	promising,	both	regarding	reported	outcome	and	toxicity.	
However,	 the	 series	are	often	 small,	 FU	 is	 short,	 and	evaluation	 in	 randomized	 studies	has	not	
yet	been	performed.	There	is	a	clear	need	for	more	data	to	fully	appreciate	the	value	of	extreme	
fractionated	regimens.	In	the	clinical	studies	described	in	this	thesis,	toxicity	reporting	was	based	
both	on	scoring	by	physicians	and	by	the	use	of	PSAQ.	It	was	demonstrated	that	the	addition	of	
PSAQ	can	have	a	dramatic	impact	on	reported	toxicity.	For	future	trials	the	use	of	PSAQ	is	highly	
recommended,	as	it	gives	a	more	complete	picture	of	experienced	toxicity.	Addition	of	QoL	studies	
can	further	enrich	our	knowledge	on	treatment	related	morbidity	as	experienced	by	patients.
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Summary
SUMMARY
With	an	 incidence	of	11.000	new	patients,	prostate	cancer	 is	responsible	for	more	than	2500	
deaths	each	year	in	the	Netherlands.	External-beam	radiotherapy	(EBRT),	High-Dose-Rate	(HDR)	
and	Low-Dose-Rate	(LDR)	brachytherapy	(BT)	are	common	treatment	options	for	organ	confined	
prostate	 cancer.	 In	 recent	 years	 there	has	been	a	 lot	of	 attention	 for	hypofractionated	 (daily	
dose	>	 2	Gy)	 radiotherapy	 in	prostate	 cancer,	mainly	due	 to	 the	 assumed	 low	α/β	 ratio	 that	
determines	the	sensitivity	of	prostate	cancer	cells	for	hypofractionated	radiotherapy.	
The	 purpose	 of	 this	 thesis	 was	 to	 investigate	 the	 feasibility	 of	 moderate	 and	 extreme	
hypofractionated	 radiotherapy	 for	 prostate	 cancer	 with	 emphasis	 on	 treatment	 induced	
morbidity,	 scored	 by	 both	 treating	 physicians	 and	 patients	 using	 patient	 self-assessment	
questionnaires	 (PSAQ).	 Moderately	 hypofractionated	 treatments	 were	 delivered	 with	 a	
conventional	linac	(results	reported	in	Chapters	2	and	3),	while	extreme	hypofractionation	was	
delivered	with	HDR	brachytherapy	(results	reported	in	Chapters	4-7)	or	a	robotic	Cyberknife	unit	
(results	reported	in	Chapters	8	and	9).	
In	Chapters	2	and	3,	results	on	acute	and	late	toxicity	are	reported	as	observed	in	the	national	
HYPRO	randomized	phase	III	trial	in	which	patients	with	intermediate-	or	high-risk	prostate	cancer	
were	randomly	assigned	to	standard	fractionation	(SF)	given	39	fractions	of	2	Gy	in	eight	weeks	
or	hypofractionation	(HF)	given	in	19	fractions	of	3.4	Gy	in	6.5	weeks.	Patients	were	stratified	to	
center	and	risk	group.	Per	protocol,	non-inferiority	of	HF	for	cumulative	grade	≥	2	acute	and	late	
GU	and	GI	toxicity	were	primary	endpoints	of	the	trial.	
In	Chapter	2,	we	 report	on	 the	acute	 toxicity	 in	 the	HYPRO	 trial	with	391	and	403	evaluable	
patients	in	the	SF	and	HF	arm,	respectively.	The	analyses	were	based	on	4	measurements	per	
patient;	at	baseline,	twice	during	EBRT,	and	3	months	after	completion	of	EBRT.	The	hypothesized	
non-inferiority	for	acute	GU	and	acute	GI	toxicity	could	not	be	demonstrated.	The	cumulative	
incidence	 of	 grade	 ≥2	 acute	 GI	 toxicity	 was	 higher	 for	 HF	 (42%	 vs.	 31.2%,	 p=0·0015).	 Three	
months	after	completion	of	 treatment,	 there	was	no	difference	between	the	arms	 in	grade	≥	
2	acute	GI	toxicity.	The	use	of	the	PSAQ	on	top	of	physician	scoring	largely	increased	reported	
toxicity	incidences.
In	 Chapter	 3,	we	 report	 on	 the	 late	 toxicity	 in	 the	HYPRO	 trial,	 including	 387	 SF	 and	 395	HF	
evaluable	 patients	 with	 a	 median	 follow	 up	 of	 60	 months.	 Five	 years	 after	 treatment,	 non-
inferiority	of	HF	for	late	GU	and	GI	toxicity	was	not	demonstrated.	Grade	≥3	late	GU	toxicity	was	
significantly	higher	for	HF	(19%	vs.	13%	SF,	p=0·021).	The	presence	of	acute	GU	toxicity,	age	>	70	
years	and	use	of	hormonal	therapy	were	associated	with	an	increased	rate	of	late	GU	toxicity,	
while	acute	GI	toxicity	and	treatment	of	seminal	vesicles	resulted	in	increased	late	GI	toxicity.	
Again,	addition	of	PSAQ	resulted	in	substantial	increases	in	reported	toxicity.
Chapter	4	 reports	on	 the	 toxicity	 and	 long-term	outcome	of	 264	 low-	 and	 intermediate-	 risk	
prostate	cancer	patients	treated	with	a	hypofractionated	HDR-BT	boost	of	3x6	Gy	+	EBRT	in	25	
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fractions	of	1.8	Gy.	Even	with	toxicity	scoring	by	both	physicians	and	patients,	the	late	toxicity	
rates	were	lower	than	published	for	EBRT	only;	especially	the	late	grade	≥2	GI	with	an	average	
of	3%	was	very	low.	With	a	7-year	bRFS	of	97%	this	regimen	demonstrated	an	excellent	outcome.
Chapter	 5	 reports	 on	 the	 influence	 of	 in-between-fraction	 catheter	 displacement	 in	 HDR	
brachytherapy	monotherapy,	delivering	4	fractions	of	9.5	Gy,	on	target	coverage	and	organ	at	risk	
doses.	This	study	confirmed	the	need	to	check	the	catheter	positioning	at	the	start	of	each	fraction.	
Corrections	were	found	necessary	when	displacements	exceeded	3	mm.
In	 Chapter	 6,	we	 reported	 on	 the	 consequences	 of	 performing	 corrections	 in	 case	 of	 catheter	
displacements	 for	 reported	 acute	 and	 late	 toxicity	 in	 the	 HDR-BT	 monotherapy	 regimen	 of	 4	
fractions	of	9.5	Gy.	No	differences	in	toxicity	were	found	between	the	group	of	patients	that	needed	
corrections	for	proper	treatment	and	the	group	of	patients	that	did	not	need	corrections.	Neither	
the	extent	of	displacements,	or	the	number	of	displacements	had	an	influence	on	acute	and	late	
toxicity.	The	applied	protocol	for	corrections	may	have	prevented	occurrence	of	excessive	toxicity.	
Chapter	7	reports	the	long-term	outcome,	toxicity	and	QoL	for	an	HDR-BT	monotherapy	regimen	
of	4x9.5	Gy	in	166	patients.	Acute	toxicity	was	comparable	with	other	series	and	most	toxicity	was	
resolved	within	2	months.	Late	toxicity	rates	(GU	grade	≥2	of	20%,	GI	grade	≥2	of	3%)	were	low	
and	comparable	to	other	radiotherapy	treatment	options.	QoL	scores,	using	the	EORTC-QLQ	PR25	
questionnaires,	showed	no	changes	for	GI	symptoms,	and	no	relevant	clinical	changes	(>10	points)	
for	urinary	symptoms	and	sexual	function.	With	a	value	of	97%,	the	5-year	bRFS	was	excellent.	
In	Chapter	8	we	describe	the	clinical	feasibility	of	an	HDR-like	SBRT	regimen,	consisting	of	4	daily	
fractions	of	9.5	Gy	delivered	with	the	robotic	Cyberknife	treatment	unit.	Low-	and	intermediate-
risk	patients	were	 included	 in	 the	 study.	The	 imposed	constraints	 for	PTV	and	OARs	were	all	
feasible	in	the	first	10	patients	investigated.	The	acute	toxicity	was	acceptable	(3/10	presented	
with	grade	2	GU	acute	toxicity	and	2/10	grade	1-2	acute	GI	toxicity)	and	comparable	to	other	
radiotherapy	options.
Chapter	9	reports	on	the	toxicity	and	QoL	in	50	low-	and	intermediate-risk	prostate	cancer	patients	
treated	with	the	Cyberknife	using	4	daily	fractions	of	9.5	Gy.	With	a	median	follow-up	of	2	years,	
the	bRFS	was	100%.	The	IPSS	score	for	GU	toxicity	showed	a	temporary	light	increase	from	9/35	to	
13/35	in	the	2	years	follow-up	period.	Acute	grade	≥	2	toxicity	rates	(14%	GI	acute	toxicity	and	23%	
acute	GU	toxicity)	were	comparable	to	those	of	HDR-BT	monotherapy,	and	grade	2	late	GI	toxicity	
was	low	(3%)	with	no	grade	3	registered	in	the	2	years	after	treatment.	Late	grade	≥	2	GU	toxicity	
(16%)	was	acceptable	and	comparable	to	other	series.
Summary
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Met	een	incidentie	van	11.000	nieuwe	patiënten	in	Nederland	is	prostaatkanker	verantwoordelijk	
voor	meer	dan	2500	doden	per	jaar.	Als	de	kanker	nog	tot	de	prostaat	beperkt	is,	is	radiotherapie	
een	 belangrijke	 behandeloptie.	 De	 mogelijkheden	 zijn:	 uitwendige	 bestraling	 (‘external	 beam	
radiotherapy’,	EBRT)	en	inwendige	bestraling	(brachytherapie),	waarbij	zowel	een	laag	dosistempo	
(‘low	dose	rate’,	 LDR)	als	een	hoog	dosistempo	 (‘high	dose	rate’,	HDR)	gebruikt	kan	worden.	 In	
de	afgelopen	jaren	is	er	veel	aandacht	geweest	voor	het	hypofractioneren	van	de	bestraling	van	
prostaatkanker,	wat	voornamelijk	samenhangt	met	de	veronderstelde	lage	α/β	ratio.
Het	doel	 van	dit	 proefschrift	was	het	onderzoeken	van	de	haalbaarheid	 van	matig	en	extreem	
hypogefractioneerde	 radiotherapie	 voor	 prostaatkanker.	 Hierbij	 werd	 vooral	 gekeken	 naar	 de	
bijwerkingen	 (toxiciteit)	 van	 de	 behandeling,	 zoals	 die	werden	 gescoord	 door	 de	 behandelend	
artsen	 en	 door	 de	 patiënten	 zelf,	 middels	 gevalideerde	 vragenlijsten	 (‘patient	 self-assessment	
quesionnaires’,	 PSAQ).	 Matig	 hypogefractioneerde	 bestralingen	 werden	 uitgevoerd	 met	 een	
conventionele	versneller	(Hoofdstukken	2	en	3),	terwijl	extreem	hypogefractioneerde	bestralingen	
werden	 uitgevoerd	 met	 HDR	 brachytherapie	 (Hoofdstukken	 4-7),	 of	 een	 robotversneller,	 de	
Cyberknife	(Hoofdstukken	8	en	9).
In	de	hoofdstukken	2	en	3	worden	de	acute	en	 late	urogenitale	 en	 gastro-intestinale	 toxiciteit	
van	 de	 bestraling	 gerapporteerd,	 zoals	 waargenomen	 in	 de	 nationale	 HYPRO	 studie.	 In	 deze	
gerandomiseerde	 fase	 III	 studie	 werden	 patiënten	 met	 matig-	 of	 hoog-risico	 prostaatkanker	
willekeurig	 ingedeeld	voor	behandeling	met	de	standaard	 fractionering	 (SF)	van	39	 fracties	van	
2	Gy	 in	8	weken	of	de	hypogefractioneerde	 (HF)	behandeling	van	19	 fracties	van	3.4	Gy	 in	6½ 
week.	 Patiënten	werden	 gestratificeerd	naar	 deelnemend	 centrum	en	 risicogroep.	 Ten	 aanzien	
van	toxiciteit	waren	de	primaire	eindpunten	van	deze	studie	de	non-inferioriteit	van	HF	voor	de	
cumulatieve	incidentie	van	graad	≥	2	acute	en	late	urogenitale	en	gastro-intestinale	bijwerkingen.
In	 hoofdstuk	 2	 wordt	 gerapporteerd	 over	 de	 acute	 toxiciteit	 in	 de	 HYPRO	 studie	 voor	 391	 en	
403	patiënten	die	respectievelijk	behandeld	zijn	met	SF	en	HF.	De	analyses	zijn	gebaseerd	op	4	
meetmomenten	per	patiënt:	voorafgaand	aan	de	behandeling,	twee	keer	tijdens	de	behandeling	
en	 3	maanden	 na	 afronding	 van	 de	 bestraling.	 De	 hypothese	 van	 non-inferioriteit	 voor	 acute	
urogenitale	en	gastro-intestinale	toxiciteit	kon	niet	worden	bevestigd.	De	cumulatieve	incidentie	
van	graad	≥	2	acute	gastro-intestinale	toxiciteit	was	hoger	voor	HF	(42%	vs.	31.2%,	p=0.0015).	Drie	
maanden	na	afronding	van	de	behandeling	was	er	geen	verschil	in	graad	≥	2	acute	gastro-intestinale	
toxiciteit.	Het	gebruik	van	PSAQ	in	aanvulling	op	de	scores	van	de	behandelend	artsen	zorgde	voor	
een	sterke	verhoging	van	de	gerapporteerde	toxiciteit	incidentie.
In	hoofdstuk	3	wordt	de	late	toxiciteit	 in	de	HYPRO	studie	gerapporteerd	voor	387	patiënten	in	
de	SF	arm	en	395	patiënten	in	de	HF	arm.	De	mediane	‘follow-up’	was	60	maanden.	Vijf	jaar	na	de	
behandeling	kon	de	non-inferioriteit	van	HF	voor	late	urogenitale	en	gastro-intestinale	toxiciteit	
niet	worden	aangetoond.	Incidentie	van	graad	≥	3	urogenitale	toxiciteit	was	significant	hoger	in	
de	HF	arm	(19%	vs.	13%,	p=0.021).	De	aanwezigheid	van	acute	urogenitale	toxiciteit,	leeftijd	>	70	
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jaar	en	het	gebruik	van	hormonale	therapie	waren	gerelateerd	aan	een	verhoogde	kans	op	late	
urogenitale	toxiciteit.	De	kans	op	late	gastro-intestinale	toxiciteit	was	verhoogd	bij	het	optreden	
van	acute	gastro-intestinale	toxiciteit	en	bij	behandeling	van	de	zaadblaasjes.	Ook	voor	late	schade	
resulteerde	 het	 toevoegen	 van	 de	 PSAQ	 in	 substantiële	 verhogingen	 van	 de	 gerapporteerde	
toxiciteit	incidenties.
In	hoofdstuk	4	worden	de	 toxiciteit	en	 lange-termijn	uitkomsten	beschreven	voor	264	 laag-	en	 
matig-risico	 prostaatkankerpatiënten	 die	 behandeld	 zijn	 met	 een	 HDR	 boost	 van	 3x6	 Gy,	
gecombineerd	met	25	fracties	EBRT	van	1.8	Gy.	Zelfs	met	de	gecombineerde	toxiciteitsscore	van	
zowel	arts	als	patiënt	was	de	 incidentie	van	 late	toxiciteit	 lager	dan	voor	gepubliceerde	studies	
met	EBRT	alleen.	Vooral	de	graad	≥	2	 late	gastro-intestinale	toxiciteit	was	met	een	gemiddelde	
incidentie	van	3%	erg	laag.	Met	een	7-jaar	recidiefvrije	overleving	van	97%	is	aangetoond	dat	dit	
behandelschema	een	uitstekende	tumorcontrole	geeft.
In	hoofdstuk	5	wordt	de	invloed	onderzocht	van	katheterverschuivingen	tussen	de	fracties	op	de	
dosisverdeling	in	de	prostaat	en	de	dosis	in	de	risico-organen	in	HDR	brachytherapie.	Dit	onderzoek	
bevestigde	dat	het	noodzakelijk	is	om	de	katheterpositionering	te	controleren	vóór	de	start	van	
elke	fractie.	Correctie	van	verschuivingen	>	3mm	wordt	noodzakelijk	geacht.
Het	 effect	 van	 het	 corrigeren	 van	 katheterverschuivingen	 >	 3mm	op	 acute	 en	 late	 toxiciteit	 in	
HDR	brachytherapie	als	monotherapie	met	4	fracties	van	9.5	Gy	wordt	beschreven	in	Hoofdstuk	
6.	Er	werden	geen	verschillen	gevonden	tussen	de	groep	patiënten	bij	wie	correcties	nodig	waren	
en	de	groep	waarbij	dit	niet	nodig	was.	Noch	de	grootte	van	de	verschuivingscorrectie	noch	het	
aantal	correcties	hadden	invloed	op	de	acute	en	late	toxiciteit.	Het	toegepaste	protocol	voor	het	
corrigeren	van	katheterverschuivingen	heeft	waarschijnlijk	bijgedragen	aan	het	voorkomen	van	
ernstige	toxiciteit.
In	hoofdstuk	7	wordt	gerapporteerd	over	de	lange-termijn	uitkomsten,	toxiciteit	en	kwaliteit	van	
leven	(QoL)	van	166	patiënten	die	behandeld	zijn	met	HDR	brachytherapie	als	monotherapie	met	
4x9.5	Gy.	De	acute	toxiciteit	was	vergelijkbaar	met	andere	studies	en	het	merendeel	van	de	toxiciteit	
verdween	weer	binnen	2	maanden.	Late	toxiciteit	incidenties	(20%	graad	≥	2	urogenitaal,	3%	graad	
≥2	 gastro-intestinaal)	 waren	 laag	 en	 vergelijkbaar	 met	 andere	 bestralingsopties.	 QoL	 scores,	
verkregen	met	de	EORTC-QLQ	PR25	vragenlijst,	toonden	voor	gastro-intestinale	symptomen	geen	
veranderingen	ten	opzichte	van	vóór	de	behandeling	en	voor	urogenitale	symptomen	en	seksueel	
functioneren	geen	klinisch	relevante	veranderingen	(>	10	punten).	De	5-jaar	recidiefvrije	overleving	
was	met	96%	uitstekend.
In	hoofdstuk	8	wordt	een	onderzoek	beschreven	naar	de	klinische	uitvoerbaarheid	van	extreem	
hypogefractioneerde	 bestralingen	 met	 de	 Cyberknife	 robotversneller.	 Uitgangspunt	 was	 een	
bestraling	 met	 4	 dagelijkse	 fracties	 van	 9.5	 Gy,	 afgegeven	 met	 een	 dosisverdeling	 die	 HDR	
brachtherapie	 behandeling	 nabootst.	 Laag-	 en	 matig-risico	 patiënten	 werden	 in	 deze	 studie	
geïncludeerd.	De	opgelegde	dosisbeperkingen	(‘constraints’)	voor	de	tumor	en	de	risico-organen	
werden	allemaal	gehaald	in	de	eerste	10	onderzochte	patiënten.	De	acute	toxiciteit	was	acceptabel	
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(3	 patiënten	 hadden	 graad	 2	 urogenitale	 toxiciteit	 en	 2	 hadden	 graad	 1-2	 gastro-intestinale	
toxiciteit)	en	vergelijkbaar	met	andere	bestralingsopties.
In	 hoofdstuk	 9	 worden	 de	 toxiciteit	 en	 QoL	 beschreven	 voor	 50	 laag-	 en	 matig-risico	
prostaatkankerpatiënten	die	behandeld	werden	met	de	Cyberknife	met	4	dagelijkse	fracties	van	
9.5	Gy.	Met	een	mediane	follow-up	van	2	jaar	was	de	recidiefvrije	overleving	100%.	De	IPSS	score	
voor	urogenitale	toxiciteit	 liet	een	tijdelijke,	 lichte	stijging	zien	van	9/35	naar	13/35	 in	de	2	 jaar	 
‘follow-up’	periode.	Acute	graad	≥	2	toxiciteit	incidenties	(14%	gastro-intestinaal	en	23%	urogenitaal)	
waren	vergelijkbaar	met	die	van	HDR	brachytherapie.	In	de	eerste	2	jaar	na	behandeling	was	de	
incidentie	van	graad	2	late	gastro-intestinale	toxiciteit	laag	(3%),	terwijl	er	geen	graad	3	toxiciteit	
werd	geregistreerd.	Late	graad	≥	2	urogenitale	toxiciteit	(16%)	was	acceptabel	en	vergelijkbaar	met	
andere	studies.
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stonden	jullie	namen	op	de	voorpagina	onder	de	titel	van	dit	boek.	Jullie	onvoorwaardelijke	steun	
met	alles,	en	dan	ook	echt	alles,	is	niet	in	woorden	te	beschrijven.	Het	was	altijd	een	feest	om	met	
jullie	te	praten	en	zaken	te	regelen.	Jullie	zijn	vrienden	voor	het	leven.
Prof.	Bangma,	beste	Chris,	vanaf	mijn	start	in	het	Erasmus	MC	in	2007	heb	je	me	veel	vertrouwen	
en	steun	gegeven	bij	alles	wat	 ik	heb	opgezet.	Hiervoor	veel	dank	en	waardering.	Dat	 je	straks	
moeilijke	vragen	gaat	stellen	bij	de	verdediging	heb	ik	je	al	vergeven.
Brachytherapie-collegae,	 dr.	 Praag	 en	 dr.	 Jansen.	 Beste	 John	 en	 Peter,	 hartelijk	 dank	 voor	 de	
enorme	inzet	van	jullie	voor	de	brachytherapie;	patiënten	includeren,	 lang	in	de	FU	houden,	en	
uitgebreid	overleggen	en	feedback	geven	over	wat	in	dit	boek	is	beschreven	over	brachytherapie.
Dr.	 Kolkman-Deurloo	 en	 mw.	 de	 Pan.	 Beste	 Inger-Karine	 en	 Connie,	 hartelijk	 dank	 voor	 jullie	
bijdrage,	steun	en	de	zeer	aangename	en	intensieve	samenwerking	in	vele	jaren.
Speciaal	dank	ook	aan	drs.	Busser.	Beste	Wendy,	je	bent	een	aanwinst	voor	ons	en	je	hebt	me	veel	
geholpen	met	het	afronden	van	de	laatste	2	papers,	waarvoor	mijn	hartelijke	dank.
Mijn	collega-urologen,	Dr.	Kirkels	en	Dr.	Boormans.	Beste	Wim	en	Joost,	ook	voor	jullie	veel	dank	
voor	de	steun	en	de	zeer	prettige	samenwerking	in	de	afgelopen	10	jaar.
Speciaal	dank	aan	mijn	lieve	secretaresse	Corina	Douwes-van	Duijn	voor	haar	inzet,	hulp	en	vooral	
de	zeer	prettige	samenwerking.
Dank	aan	Natasha	Witvliet-Smalheer,	Marion	van	der	Staaij-Moret,	Carolien	Baijards	en	Ilse	Post	
voor	hun	steun	en	de	fijne	samenwerking.
Collega-laboranten	van	de	brachytherapie	en	de	Cyberknife,	Dick	Sipkema,	Martin	Roos,	Marjan	de	
Ruijter,	Wilhelm	den	Toorn,	Amarseo	Tahapary,	Anton	Rink,	Renee	Rijnsdorp,	Martin	Otto,	Lorne	
Luthart,	 Jan	 Koffijberg,	Marianne	 van	 der	 Knaap-Kalkman,	 Lisette	 Klop,	 Erik	 de	 Klerck,	Michele	
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Huge,	Marjan	Faase.	Heel	veel	dank	voor	het	enorme	enthousiasme	dat	jullie	hebben	getoond	voor	
alle	vernieuwing	op	de	brachytherapie	en	de	Cyberknife.	Het	was	altijd	een	belangrijke	stimulans	
voor	mij	om	nog	meer	te	gaan	doen.	Zonder	jullie	bijzondere	bijdragen	was	een	hoop	van	wat	we	
nu	bereikt	hebben	onmogelijk	geweest.	Hartelijk	dank	en	ga	zo	door.
Veel	dank	ook	aan	de	poli-dames,	Erna	Maan,	Christine	Somowidjojo	en	Wilma	Rintjema,	voor	hun	
steun	en	het	geduld	om	mijn	uitgebreide	en	ingewikkelde	FU	schema’s	te	handhaven.	
speciaal	dank	aan	de	dames	van	de	PPR:	Yvonne	Anomtaroeno,	Sarieta	Bhoewar,	Ellen	van	Dam,	
Nelly	 Dos	 Santos,	 Nazima	 Fatemahomed,	Monique	 van	Marlen,	 Esther	 Schoenmaker,	 Caroline	
Tertoole,	Josine	Verboom.
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PhD	portfolio
PhD PORTFOLIO
Summary of PhD training and teaching 
Name	PhD	student:	Shafak	Aluwini
Erasmus	MC	Department:	Radiotherapy
Research	School:	Molecular	Medicine
PhD period: 2009-2016
Promotor(s):	Prof.	dr.	L.	Incrocci
	Prof.	dr.	B.J.M.	Heijmen
1. PhD training
Year Workload
(Hours/ECTS)
-BROK	course	(basis	cursus	regelgeving	klinisch	onderzoek)
-Good	clinical	practice	
-Course survival analysis
-Course	writing	a	successful	grant	proposal	
-Course research integrity 
-Course	research	management	for	PhD	students
2013
2013
2015
2015
2016
2016
40/1.5	ECTS
16/0.5	ECTS
30/1.0	ECTS
30/1.0	ECTS
16/0.5	ECTS
16/0.5	ECTS
Specific courses (e.g. Research school, Medical Training)
-ESTRO	course;	rectum	carcinoma,	Roma,	Italy
-Delineation	course,	Barcelona,	Spain
2011
2015
10/0.5	ECTS
30/1.0	ECTS
Seminars and workshops
-Refereeravond	department	of	Radiation	Oncology
-Research	rounds	department	of	Radiation	Oncology
2010-2016
2015-2016
2.0	ECTS
1.0	ECTS
Presentations
-ESTRO	31,	Barcelona	Spain
-2nd	ESTRO	forum	April	2013,	Geneva,	Switzerland
-ASTRO’s	55th	annual	meeting,	Atlanta,	USA
-ESTRO	33,	Vienna,	Austria
-3rd	ESTRO	forum,	Barcelona,	Spain
-ESTRO	35,	Turin,	Italy
-Presentations	Nederlandse	Vereniging	voor	Radiotherapie	en	
Oncologie
-Presentations	Nederlandse	Vereniging	voor	Urologie
-Presentations	Integraal	kankercentrum	Nederland
2012
2013
2013
2014
2015
2016
2013
2013-2015
2013-2016
40/2.0	ECTS
40/2.0	ECTS
40/2.0	ECTS
40/2.0	ECTS
40/2.0	ECTS
40/2.0	ECTS
16/1.0	ECTS
2.0	ECTS
2.0	ECTS
(Inter)national conferences
-European	Multidisciplinary	Cancer	Conference	(ECCO,	ESMO,	
ESTRO),	Stockholm,	Sweden
-4th	European	Multidisciplinary	meeting	on	Urological	Cancers	
(EMUC),	Barcelona,	Spain
-ASTRO’s	57th	Annual	meeting,	San	Antonio,	USA
-American	Brachytherapy	Congress	(ABS)/GEC/ESTRO,	San	
Francisco,	USA
2011
2012
2015
2016
30/1.0	ECTS
30/1.0	ECTS
30/1.0	ECTS
30/1.0	ECTS
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Year Workload
(Hours/ECTS)
Other
-Supervising	research	activities	AIOS	radiation	oncology	and	urology
-PI	phase	3	multicenter	phase	3	randomized	trial	(PROBACH	Trial)
-PI	phase	I/II	trial	on	single	fraction	HDR	brachytherapy	
2011-2016
2013-2016
2.0	ECTS
2.0	ECTS
2. Teaching
Year Workload  
(Hours/ECTS)
Lecturing
-Postgraduate lectures 
-Education	AIOS	radiation	oncology,	Erasmus	MC
-OMBO	workshops	Erasmus	MC	
2010-2016
2010-2016
2010-2016
1.0	ECTS	
3.0	ECTS
4.0	ECTS
Supervising practicals and excursions, Tutoring
-Supervising	post	doc	MRI	guided	brachytherapy 2014-2016 2.0	ECTS
Supervising Master’s theses
-Prostate	brachytherapy	master	theses 2015-2016 1.0	ECTS
Other
14 peer reviewed papers in 4 journals 2012-2016
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